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Abstract 
The Janus kinase (Jak)/Signal transducer and activator of transcription (Stat) signaling pathway 
regulates fundamental cellular functions, such as proliferation, survival, and differentiation as well as 
developmental processes. Importantly, it is one of the core pathways which is frequently deregulated 
in primary tumors. Stat5 transcription factors have a key role in hematopoiesis, lipid metabolism, 
reproduction, and the immune response. Aberrant Stat5 activation has been shown to contribute to a 
wide range of diseases, such as immunodeficiency and autoimmune disease, chronic inflammation, 
and cellular transformation in hematopoietic and epithelial cells. The biology of Stat5 function and its 
potential cooperation with other signaling pathways has therefore become a growing area of research.  
In our study on leukemogenesis, persistent Stat5 activity in hematopoietic cells was modeled by using 
an oncogenic Stat5a variant (cS5), harboring the point mutation S710F. To analyze the hitherto 
unrecognized role of Stat5a serine phosphorylation in this context, we generated cS5 constructs with 
mutated C-terminal serines 725 and 779, either alone or in combination. We found no evidence for a 
key role of Stat5a serine phosphorylation in normal hematopoietic cell types. Yet, our data suggest 
that Stat5a serine phosphorylation is a prerequisite for cS5-mediated myeloid transformation. 
Moreover, activation of the PI3K/Akt/mTOR pathway through protein-protein interaction with the 
Gab2 scaffold protein was found to be another mechanism by which constitutively activated Stat5a 
contributes to multi-lineage leukemia and myeloproliferative disorders.  
In addition to its well-known functions in the hematopoietic system, Stat5 also has a crucial role in 
epithelial cells. In hepatocytes, Stat5 regulates postnatal body growth by transcription of growth-
mediating target genes like IGF-1. Transcription of growth hormone (GH)-stimulated target genes is 
mediated by Stat5 together with the glucocorticoid receptor (GR), which is its most important 
cofactor. Both hyperactivation and deletion of Stat5 in hepatocytes have been implicated in the 
development of hepatocellular carcinoma (HCC). Using GH transgenic (GHtg) and conditional 
knockout mice lacking hepatic Stat5a/b (Stat5Δhep, AlfpCre), we analyzed the role of Stat5 in the 
development of inflammatory liver cancer resulting from hyperactivated GH signaling. 
Histopathologic analyses of the liver revealed that Stat5 is essential for postnatal body growth and that 
the polymorphic nuclear shape and increased size of GHtg hepatocytes is clearly dependent on Stat5b. 
Surprisingly, the tumor phenotype seen in GHtg mice was aggravated upon deletion of Stat5 and was 
accompanied by increased hepatic fat deposition (hepatosteatosis), which was also observed as a result 
of double knock-out of Stat5 and the GR in the liver. Our results suggest that in GHtg mice deletion of 
hepatic Stat5 proteins leads to enhanced tumor formation secondary to increased lipid synthesis, loss 
of hepatoprotective mediators, and compensatory Stat3 activation. 
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Zusammenfassung 
Der Jak (Janus Kinase)/Stat (signal transducers and activators of transcription) 
Signaltransduktionsweg ist für die Regulation von grundlegenden Zellfunktionen, wie Wachstum, 
Überleben, Differenzierung sowie Entwicklungsprozessen von großer Bedeutung und ist einer der 
wenigen zentralen Signalwege, die in Tumoren dereguliert sind. Stat5 Transkriptionsfaktoren 
regulieren wichtige Zellfunktionen in Hämatopoese, Immunantwort, Reproduktion und 
Fettstoffwechsel. Veränderte Stat5 Aktivierung wurde mit einer Reihe von verschiedenen 
Krankheitsbildern in Verbindung gebracht, wie zum Beispiel Immundefekten, 
Autoimmunerkrankungen, chronischer Entzündung, metabolischen Störungen oder maligner 
Entartung von hämatopoetischen und epithelialen Zellen. Aus diesen Gründen rückten die 
Funktionsweise von Stat5 und andere potentiell interagierende Signalwege ins Zentrum des Interesses. 
In einem Modell wurde die konstitutive Aktivierung von Stat5 in hämatopoetischen Zellen durch eine 
punktmutierte onkogene Variante von Stat5a (cS5) künstlich verursacht. Um die noch unbekannte 
Rolle der Serin-Phosphorylierung von Stat5 Molekülen im hämatopoetischen System zu untersuchen, 
wurden cS5 Moleküle mit zusätzlichen Mutationen von den C-terminalen Serinen 725 und 779 
verwendet. In dieser Studie konnte der Stat5a Serin-Phosphorylierung keine wesentliche Rolle in 
normalen hämatopoetischen Funktionen zugeordnet werden. Für die Transformation von myeloiden 
Zellen durch die konstitutive Aktivierung von Stat5a  ist die Phosphorylierung der beiden Serine 
jedoch von unerwarteter, zentraler Wichtigkeit. Als weiterer Mechanismus für die onkogene 
Wirkungsweise von konstitutiv aktivem Stat5a in hämatopoetischen Tumoren wurde die Aktivierung 
des PI3K/Akt/mTOR Signalwegs durch Interaktion von Stat5a und Gab2 identifiziert.  
Neben den wohlbekannten Funktionen im hämatopoietischen System spielt Stat5 auch in epithelialen 
Zellen eine wesentliche Rolle. In Hepatozyten reguliert Stat5b longitudinales Wachstum durch die 
Transkription von Wachstumshormon (GH)-stimulierten Genen (z.B. IGF-1) gemeinsam mit dem 
Kofaktor GR (Glucocorticoidrezeptor). Sowohl die Hyperaktivierung als auch der Verlust von Stat5 
sind im Zusammenhang mit der Entstehung von hepatozellulären Karzinomen beschrieben. Anhand 
von GH-transgenen (GHtg) und Stat5-defizienten Mäusen (Stat5Δhep, AlfpCre) wurde die Rolle von 
Stat5 bei der Entstehung von entzündlichen hepatozellulären Karzinomen, ausgelöst durch 
hyperaktivierten Jak-Stat Signaltransduktionsweg, untersucht. Die Analysen ergaben, dass Stat5 
essentiell für Größenwachstum ist und die polymorphen Kernstrukturen und die Größe der 
Hepatozyten in GHtg Mäusen eindeutig von Stat5 bestimmt werden. Erstaunlicherweise wurde der 
Tumorphänotyp durch Deletion von Stat5 verstärkt. Dies war mit massiver Fetteinlagerung in der 
Leber (Hepatosteatose) verbunden, wie sie in Stat5/GR Knock-out Mäusen zu sehen ist. Die 
Ergebnisse dieser Studie deuten darauf hin, dass es in der Leber von GHtg Mäusen bei Verlust von 
Stat5 Proteinen zu einer beschleunigten Tumorentwicklung kommt, die durch erhöhte Lipidsynthese, 
den Verlust von hepatoprotektiven Faktoren und ausgleichende Stat3 Aktivierung ausgelöst wird. 
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1. Introduction 
 
1.1  Hallmarks of cancer 
Cancer is a class of diverse diseases which differ widely in their etiology and biology. 
Cancer is expected to overtake heart disease and become the leading cause of death 
worldwide in 2010 (World Cancer Report 2008, International Agency for Research on 
Cancer, World Health Organization). There are more than 150 different types of cancers 
broadly classified as liquid or solid. They can be subdivided on the basis of phenotypes and 
genetic abnormalities. Many of the thousands of genetic alterations found in individual 
tumors by systematically sequencing their genomes may be important for tumor initiation or 
progression, but most of these are likely to be ‘passenger mutations’ without functional effect. 
To date, only a small fraction of the genetic changes in a tumor are thought to be ‘driver 
mutations’ that provide cells with a selective advantage and are thus able to promote 
tumorigenesis 1,2. Essentially, human cancer development is a multi-step process that requires 
the accumulation of genetic alterations or protein expression changes, each of which has a 
limited transformation potential. Mammalian cells have multiple safety mechanisms to protect 
them against potentially lethal effects of cancer gene mutations, i.e. cancer can develop only if 
several genes are defective 3. 
Alterations in three types of genes contribute to tumorigenesis: oncogenes, tumor suppressor 
and stability genes 2. Mutations in oncogenes render them active either in a constitutive 
manner or under conditions in which the respective wild-type gene does not show activity. 
Oncogene activation may occur as a result of chromosomal translocation, gene amplification 
or intragenic mutations in residues that regulate the activity of the gene product 4. Mutations 
in tumor suppressor genes, which mediate transcription or operate in signal transduction 
pathways involved in regulating processes of cell division, differentiation, and apoptosis, 
generally inactivate the gene product or reduce its activity. Silencing of tumor suppressor 
genes is mainly due to missense mutations at residues that are essential for their activity, to 
mutations that result in truncated proteins, or to epigenetic silencing 5. Overall genetic 
integrity is compromised by mutations in stability genes, which are responsible for repairing 
subtle mistakes occurring during normal DNA replication, mitotic recombination, and 
chromosomal segregation as well as for correcting genetic changes induced by exposure to 
mutagens (e.g. BRCA1, BLM and ATM) 6. Although the resulting increase in the mutation 
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rate has an impact on all genes, a selective growth advantage can only be conferred to the 
mutant cell by mutations in oncogenes and tumor suppressor genes 2. 
Mutations contributing to tumor development can be induced by chemical carcinogens, 
ionizing radiation, infection, immune system dysfunction, hormonal imbalances, or hereditary 
genetic changes (e.g. predisposition to breast cancer due to loss of BRCA1 or a mutation in 
p53; familiar predisposition to colon cancer resulting from mutations in DNA mismatch repair 
genes or mutations of APC) 7,8. Furthermore, processes such as chronic tissue damage have 
been found to accelerate cancerogenesis 9. Tissue damage can be caused by chronic 
inflammation and infection as well as toxic substances and leads to genetic or epigenetic 
changes, which are frequently mediated by DNA damage responses 10. Risk factors also 
include tobacco smoke, overweight and obesity, low fruit and vegetable intake, physical 
inactivity, alcohol, sexually transmitted infections, and air pollution 11. 
Until today many genetic alterations predisposing to various types of cancer have been 
identified and the pathways through which they act have been characterized. The importance 
and the dynamics of the cascades of events contributing to the development of cancer, 
however, are still poorly understood mainly because of the lack of suitable in vivo models. 
 
1.2  Deregulated signaling pathways in human cancer 
Cancer has been shown to be a genetic disease of somatic cells 12. The first somatic 
mutation in an oncogene or tumor-suppressor gene causes clonal expansion by stimulating 
cell division or inhibiting cell death or cell-cycle arrest and thereby initiates the neoplastic 
process 13. Subsequent somatic mutations result in additional rounds of clonal expansion and 
thus in tumor 14. 
From the analysis of known mutations, it has become obvious that of the great multitude of 
genetic alterations many result in similar phenotypes 15. This is due to the fact that the number 
of signaling pathways which have been implicated in tumorigenesis is comparatively low. 
Apart from the Rb and p53 pathways—the two most frequently mutated ones—there are only 
few other pathways and signaling molecules for which a role in tumor development has been 
described. These include Ras/Raf signaling, adenomatous polyposis coli (APC), glioma-
associated oncogene (GLI), hypoxia-inducible transcription factor (HIF)-1, phosphoinositide 
3-kinase (PI3K), Notch, SMADs, and receptor tyrosine kinases (RTKs). Mutations in the 
above mentioned core pathways provide selective growth advantages for the cell 16. 
Interestingly, only a few of all mutated genes are oncogenes or DNA repair genes, while the 
vast majority (more than 90%) has been identified to be tumor suppressor genes 12,17. Specific 
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targeting of a particular gene product is feasible only for the limited number of oncogenes but 
not for tumor suppressor genes. Yet, it should be possible to treat several different tumor 
types by targeting their common oncogenic pathway addiction, since the tumorigenic 
alterations are restricted to a relatively small number of pathways. Thus, the concept of a 
limited number of cancer pathways might provide a powerful stimulus for the development of 
new approaches to the treatment and prevention of cancer. However, it may take another 
decade or more to explore the feasibility of this concept.  
 
 
1.3 Overview of the Jak-Stat pathway 
One of the key pathways frequently deregulated in primary tumors is the Janus kinase 
(Jak)/signal transducer and activator of transcription (Stat) signaling pathway 18. Jaks and 
Stats constitute a rapid two-component signal transduction unit for communicating 
extracellular signals to the respective target genes (Figure 1). This pathway is utilized by a 
broad spectrum of receptors. Jak/Stat signal transduction is conserved in evolution from slime 
molds and worms to mammals (not including fungi and plants), which indicates that it has 
important functions in multicellular organisms. In mammals, four Jak kinases (Jak1/2/3 and 
Tyk2) and seven Stat proteins (Stat1/2/3/4/5a/5b and Stat6) regulate fundamental cellular 
functions such as proliferation, survival, and differentiation of different cell types as well as 
developmental processes 19-22. 
Stat proteins are cytoplasmic transcription factors that contribute to signal transduction of 
cytokines, hormones, and growth factors. Their activity requires phosphorylation of 
positionally conserved tyrosine residues by protein tyrosine kinases of the Jak family upon 
binding of ligands to the cognate receptors. Phosphorylation, which is normally a transient 
and precisely regulated process, results in dimerization, efficient nuclear translocation, 
binding of Stats to specific consensus DNA-recognition motifs in the promoter sequences of 
their respective target genes, and subsequent gene transcription 23. Stats may also be directly 
tyrosine-phosphorylated either by receptor tyrosine kinases such as the epidermal growth 
factor receptor (EGFR) or by non-receptor tyrosine kinases such as c-src. The pathway is 
negatively regulated on multiple levels. Protein tyrosine phosphatases such as SHP-1/2 
remove phosphates from cytokine receptors as well as activated Stats 24. Additionally, 
Suppressors of Cytokine Signaling (SOCS) inhibit Stat phosphorylation by inhibiting Jaks or 
targeting cytokine receptors for proteolysis 25-28. Stats are also negatively regulated by Protein 
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Inhibitors of Activated Stats (PIAS), which act via several mechanisms in the nucleus such as 
binding and blocking DNA consensus sequences 29. 
 
plasma 
membrane
Stat 
phosphorylation
cytokine
cytokine receptor
JakJak
nuclear 
translocation
gene transcription
nucleus
DNA
Stat
Y
Stat
Y Y
DNA binding
Y
Y
Y
Y
Y
Y
Y
Stat Stat
Stat
Y
Stat
Y
Y
Y
Y
Y
 
 
 
 
Figure 1. Key steps of the Jak/Stat pathway.  
Ligand-induced receptor oligomerization activates Jak kinases by bringing them into close proximity. 
Jak kinases subsequently phosphorylate tyrosine residues (Y) on the cytoplasmic portion of the 
receptor. Stat dimers are then recruited to the activated receptor complex via their N-terminal domains 
and are phosphorylated by Jaks on a conserved tyrosine residue in the C-terminal domain. This 
mediates efficient translocation into the nucleus where they bind to specific response elements to 
regulate transcription of their target genes. 
 
 
Structurally, Stat molecules are very similar 30. They consist of a flexible amino-terminal 
domain, their oligomerization domain, an alpha-helical coiled-coil domain (CCD), a DNA-
binding domain (DBD), and a src homology 2 (SH2) domain. The CCD binds co-regulators 
and interacts with chaperons; the DBD allows binding of Stat proteins to their respective 
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response elements. Their DNA-binding is stabilized by the linker domain. The SH2 domain is 
responsible for (1) efficient recruitment of Stat proteins to the cytokine receptor through 
recognition of specific receptor phosphotyrosine motifs, (2) the association with activating 
Jak kinases, and (3) Stat homo- or heterodimerization 18. The SH2 domain is the most highly 
conserved sequence in Stat proteins and is located in close vicinity to the tyrosine residue, 
which is essential for protein activity. Conversely, the carboxy-terminal transactivation 
domain (TAD) is the least conserved region 18. It is the site of interaction with cofactors 
(activators and repressors) that are required for transcriptional regulation 31 and with tyrosine 
phosphatases which recycle phosphorylated Stat proteins 32. 
 
1.4  The biology of Stat5 function 
Signal transducer and activator of transcription 5 (Stat5) proteins are crucial 
transcription factors controlling processes of hematopoiesis and immunoregulation, 
reproduction, postnatal body growth, senescence, and lipid metabolism 33-36. Stat5 comprises 
two isoforms, Stat5a and Stat5b, which are encoded by two distinct genes in one 
chromosomal locus 33,35-37. Stat5a and Stat5b, which are expressed in numerous cell types, are 
activated by various cytokines and growth factors such as erythropoietin, growth hormone, 
and different interleukins (Figure 2; 33). Key functions of Stat5 proteins include the regulation 
of hematopoiesis 38-40, the modulation of hepatic lipid metabolism and hepatocyte 
physiology41, the control of neuro-endocrine 42 and neuronal functions 43, and the 
development and regulation of the immune system36. Both proteins share a degree of amino 
acid similarity greater than 95%, with differences primarily in the C-terminal transactivation 
domain 37,44. Upon activation, Stat5a and Stat5b can form homo- and heterodimers. The 
promoter responsive elements of Stat5a and Stat5b target genes are similar, some even 
identical. Although there is considerable functional overlap, Stat5a and Stat5b proteins also 
have distinct functions, which were identified by gene targeting 36,45-48. These include 
regulation of the female and male reproductive tracts by Stat5a 45,46,49, while NK-cell 50 and 
liver functions are mediated mainly by Stat5b 36,47. Stat5b constitutes the predominant isoform 
expressed in hepatocytes and is activated by growth hormone, which regulates postnatal body 
growth, sexual maturation, and metabolism 36,47). Moreover, Stat5a and Stat5b are different 
with regard to DNA binding affinity and recycling by tyrosine phosphatases 44. 
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Figure 2. Cytokines, hormones and growth factors that activate Stat5.  
Cytokines stimulating Stat5 tyrosine phosphorylation and nuclear translocation can be grouped 
according to structural homologies, signal transduction pathways and shared receptor chains. Upon 
activation, Stat5 molecules can form dimers, homo- or heterotetramers on DNA (so called oligomers), 
which can induce the formation of DNA loop structures. Unrestrained activation of Stat5 proteins is 
found in the presence of many transforming tyrosine kinases implicated in cancer. Stat5 molecules 
also have an important function in the cytoplasm where they activate the PI3K-Akt pathway.  
 
 
Multiple parameters such as cell- and isoform-specific differences in mRNA 35,36 and 
nucleocytoplasmic shuttling 51,52 influence the non-redundant functions of Stat5 proteins. 
Moreover, additional factors regulate the activation status and target gene specificity of Stat5a 
and Stat5b in order to facilitate the multiple effects of Stat5 proteins on various target tissues. 
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1.4.1  Regulation through the N-terminus of Stat5 
Upon phosphorylation, latent Stat5a and Stat5b monomers can form homo- and 
heterodimers that modulate Stat5 target gene specificity 33. In addition, Stat5 molecules have 
a propensity to form oligomeric structures on chromatin which induce conformational 
chromatin changes (DNA loop formation). Different combinations of tetrameric Stat5a/b 
structures which enable Stat5 to exert all its functions have been identified. The domain 
mediating the formation of oligomeric complexes is the N-terminus 53. This domain is also 
known to be important for (1) the prevention of auto-activation of Stat5a (but not Stat5b; 53,54, 
(2) survival gene regulation 55, (3) cofactor interaction (e.g. glucocorticoid receptor;53,56,57, 
and (4) transformation (Kerenyi MA and Moriggl R, unpublished data). Moreover, several 
short isoforms of Stat5a and Stat5b have been identified.  
 
1.4.2  Stat5 cofactor binding 
Compared to other Stat family members, Stat5a and Stat5b contain only weak 
transactivation domains 44,58. This is why Stat5-mediated transcription requires interaction 
with other transactivating or -repressing factors that co-regulate and modulate cell type-
specific gene expression 33,44,55,59,60. These factors include CBP/p300, SRC-1, and the 
glucocorticoid receptor (GR), which interacts with the N-terminus of Stat5 53,56,57. The GR is 
activated by glucocorticoids (GC), which are secreted in stress conditions by the adrenal 
glands under the control of the hypothalamic-pituitary-adrenal (HPA) axis. GR is expressed in 
most somatic cell types and modulates the transcription of the corresponding target genes 
either as a direct transcription factor or as a cofactor of other transcription factors 61,62. The 
GR has been reported to act mainly as a corepressor, e.g. in NFκB- or AP-1-induced 
transcription 63,64. Interaction between Stat5 and GR was first discovered in mammary 
epithelia 62. Later on it was also found to be crucial for the transcription of growth hormone-
stimulated target genes in the liver 65. Loss of hepatic GR signaling not only leads to reduced 
postnatal body growth but also causes defects in glucose metabolism 66-68. 
 
1.4.3  Stat5 serine phosphorylation  
As a consequence of cytokine stimulation, phosphorylation of a single tyrosine residue 
of Stat proteins was originally thought to be sufficient for their activation. This may hold true 
for Stat2, however, all other Stat proteins have been found to be additionally phosphorylated 
on serine residues upon cytokine stimulation 69. Maximal transcriptional activity of 
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Stat1/3/4—unlike that of Stat5a and Stat5b—has been demonstrated to be substantially 
modulated by serine phosphorylation 69,70. Biochemical and biological functions of Stat serine 
phosphorylation also include DNA binding 71,72, cofactor association 73, immune responses 
74,75, and transformation 76,77. Although no modulatory effects of serine phosphorylation on 
transcriptional activity have been reported for Stat5a and Stat5b proteins, distinct serine 
residues were found to be phosphorylated in their carboxy-terminal transactivation domains 
71,78. These serine moieties are located in conserved PSP motifs at positions 725 (Stat5a) and 
730 (Stat5b) 70. In addition, Stat5a harbors a unique serine residue within an LSP motif 
(Ser779)71, which is the major site of serine phosphorylation in Stat5a 71. Notably, this LSP 
motif is conserved between different mammalian species. The biological significance of Stat5 
serine phosphorylation has long been underestimated. More recently, however, Stat5a serine 
phosphorylation was found to have an essential role in hematopoietic transformation 79. Yet, 
precisely which of the more than 400 serine/threonine kinases are involved in hyperactivating 
Stat5 and thus contribute to Stat5a-mediated transformation still remains to be determined.  
 
1.5  Jak2-Stat5 signaling in disease 
In view of the key role of Stat5 proteins for numerous cellular functions, it is not 
surprising that inappropriate or aberrant Stat5 activation is thought to contribute to a wide 
variety of diseases such as immune deficiency and hyperplasia 23. In fact, the association of 
deregulated Stat5 activity with hematopoietic malignancies is well established. Inappropriate 
Stat5 activation has been shown to cause or contribute to conditions such as 
myeloproliferative disorders 80-83, leukemias54, lymphomas 82,84-88, and autoimmunity 89. 
Furthermore, hyperactivated Stat5a and Stat5b proteins have also been implicated in the 
development of solid tumors 90-99. 
In tumor cells, constitutive activation of Stat5 is linked to deregulated cytokine signaling 100, 
activating mutations in upstream kinases, or chromosomal rearrangements generating fusion 
tyrosine kinases 34. Persistent signaling of Stat5 has been demonstrated to directly contribute 
to oncogenesis by stimulating cell proliferation and preventing apoptosis 101. 
Yet, disruption of Stat5 signaling may also cause severe deficiencies ranging from a defective 
immune response 102-104, to myeloid hypoplasia 39, impaired erythropoiesis resulting in 105, 
complete absence of mammary development during pregnancy, aberrant liver function 48,53 
and metabolic problems 41. Loss of hepatic Stat5 leads to growth deficiency, elevated levels of 
serum GH, lipodystrophy and hepatosteatosis (Kornfeld/Müller in preparation) 41,48,53. 
Furthermore, without hepatic Stat5 the regenerative potential of hepatocytes is diminished 
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following partial hepatectomy. Upon carcinogen challenge, mice were reported to develop 
liver fibrosis and subsequently hepatocellular carcinomas 106.  
A better understanding of the complex network of mechanisms responsible for the 
dysregulation of Stat5 signaling (Figure 3) may serve as a basis for developing novel 
therapeutic strategies targeting Stat5-dependent cancers 107. 
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Figure 3. Stat5 activation induces and cooperates with signaling pathways essential for 
cancer progression. 
Stat5 induces several of the 12 core signaling pathways involved in tumorigenesis 2. Additionally, it 
directly interacts with several key molecules of other core pathways. 
 
 
1.5.1  Stat5 in hematopoietic malignancies 
The transcription factors Stat5a and Stat5b are key gene regulators promoting 
proliferation and survival of hematopoietic cells in response to cytokine‑ and growth 
factor‑induced signaling. Target genes regulated by Stat5 proteins and their cofactors are 
essential for hematopoietic stem cell maintenance, lineage commitment, self-renewal and 
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survival of committed hematopoietic progenitors as well as for mature cells of both myelo-
erythroid and lymphoid lineage 89,108,109. Many leukemic cells persistently show dramatically 
elevated levels of Stat5 activity 80-83,110-113. Constitutive activation of Stat5 may result from 
activating mutations in upstream kinases such as Src, epidermal growth factor receptor 
(EGFR), and Jaks, which are frequently observed in various forms of human leukemia, 
lymphoma and myeloproliferative disease. Furthermore, persistent Stat5 activation has been 
associated with amplification of signaling molecules such as cytokines or growth factors and 
their cognate receptors. Moreover, it has been suggested that serine and/or threonine 
phosphorylation may further amplify the trans-activation potential of Stat5 75,114,115. 
In addition, it has been demonstrated that the transforming capacity of oncogenic Stat5 in 
hematopoietic cells is not limited to its role as a transcription factor in the nucleus. Recent 
studies have also attributed a cytoplasmic role to oncogenic Stat5a. Cytosolic Stat5 has been 
shown to directly interact with the p85 subunit of PI3K and the scaffolding protein Gab2, 
which links Jak/Stat signaling to the activation of PI3K-Akt-mTOR signaling116-118 (Figure 
2+3). This interaction leads to hyperactivation of Akt-signaling, which, in turn, contributes to 
leukemogenesis. In concert with Stat5, Gab2 was also shown to act on many of the key stem 
cell functions 119. Therefore, Akt/mTOR signaling has been proposed as a therapeutic target 
for inhibiting distinct Stat5-mediated survival signals in myeloproliferative neoplasms 120.  
 
1.5.1.1  The hematopoietic system 
Hematopoiesis (from ancient Greek: αΐμα, haima "blood"; ποιεĩν, poiesis "to make") is 
the formation of cellular blood components, which are derived from hematopoietic stem cells 
(HSCs) that ensure life-long organ homeostasis 121. In healthy adults, approximately 1011–1012 
new blood cells are produced daily in order to maintain steady-state levels in the peripheral 
circulation 122. HSCs reside in the bone marrow and have the unique ability to give rise to all 
types of mature blood cells. Owing to their self-renewal capacity, they are also capable of 
maintaining the stem cell pool 123. HSCs give rise to multi-lineage progenitors, which are 
restricted to either the myeloid (common myeloid progenitor; CMP) 124 or the lymphoid 
compartment (common lymphoid progenitor; CLP) 125,126. 
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Blood cells are divided into three main lineages (Figure 4): 
 
    * The vast majority of blood cells are the oxygen-carrying red blood cells, which are 
terminally differentiated enucleated cells of erythroid origin. Erythrocytes originate from 
common myeloid progenitors. 
     * Myelocytes, which include granulocytes, megakaryocytes and macrophages, are also 
derived from common myeloid progenitors and are involved in such diverse roles as innate 
immunity, adaptive immunity, and blood clotting. 
     * Lymphocytes are the cornerstone of the adaptive immune system. They are derived from 
common lymphoid progenitors. The lymphoid lineage is primarily comprised of T-cells and 
B-cells. 
There are also other important cell types such as dendritic cells, mast cells and natural killer 
cells which originate from progenitors of these three main lineages as well. 
 
In the developing embryo, blood formation occurs in aggregates of blood cells in the yolk sac, 
the so-called blood islands. Recently, HSCs have been shown to originate from vascular 
endothelial cells by a process called ‘endothelial hematopoietic transition’ 127-129. During fetal 
development, the liver functions as the main hematopoietic organ, since the bones and 
therefore also the bone marrow develop later130. The spleen and the lymph nodes also 
contribute to blood formation during this phase. As bone marrow develops, it eventually 
assumes the task of forming most of the blood cells for the entire organism. However, 
maturation, activation, and—to some extent—also proliferation of lymphoid cells occurs in 
secondary lymphoid organs (i.e. the spleen, thymus, and lymph nodes). In some cases, the 
liver, thymus, and spleen may resume their hematopoietic function, if necessary. This is 
called extramedullary hematopoiesis and may cause these organs to substantially increase in 
size 131.  
Hematopoietic development and differentiation are precisely regulated by cytokine- and 
growth factor-activated signaling pathways, among which the Jak/Stat pathway plays a major 
role 33,36,132. Many of the regulating cytokines and growth factors activate the transcription 
factor Stat5 or interact with it in the course of signal transduction (Figure 4). The early 
committed progenitors, however, express low levels of transcription factors that may commit 
them to discrete cell lineages. The cell lineage selected for differentiation may be arbitrary or 
depend on external signals received by progenitor cells. Several transcription factors that 
regulate differentiation along the major cell lineages have been isolated such as PU.1, which 
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commits cells to the myeloid lineage, and GATA-1, which has an essential role in 
erythrocytic and megakaryocytic differentiation133,134. Ikaros, Aiolos and Helios transcription 
factors have also been shown to play a major role in lymphoid commitment 135. 
 
1.5.1.2  Stat5 in hematopoietic stem cells and progenitors 
 
Note: An earlier version of sections 1.5.1.2 to 1.5.1.7 was published as a book chapter (Stat5 as Hematopoietic 
Gatekeeper and Oncogene Upon Tyrosine Kinase‑Induced Transformation by Katrin Friedbichler, Marc A. 
Kerenyi, Ernst W. Müllner and Richard Moriggl) in “JAK STAT Pathway in Disease”, edited by Anastasis 
Stephanou and published by Landes Bioscience 2008 (http://www.eurekah.com/chapter/4038; ISBN: 978-1-
58706-315-2; Pub Date: June 11, 2009). 
 
 
Stat5 is activated by a plethora of hematopoietic cytokines and growth factors such as 
erythropoietin (Epo), Tpo, granulocyte/macrophage-colony stimulating factor (GM-CSF), Flt-
3-L, SCF, thymic stromal lymphopoietin (TSLP), IL-2, -3, -4, -5, -7, -9 and -15 (Figure. 4).  
(for review see refs. 33,36,132) Therefore, it plays an important role in orchestrating survival, 
proliferation and differentiation in lineage-restricted progenitors as well as in mature cells of 
both, myelo-erythroid and lymphoid lineages. Among other factors, stem cell factor (SCF), 
thrombopoietin (Tpo), interleukin (IL)-3, Flt-3-ligand (Flt-3L) and their receptors c-kit, c-
mpl, IL-3R and Flt-3 have been implicated in the proliferation and survival of LSKs or multi-
lineage progenitors 136. The receptors mentioned all share the crucial downstream effector 
transcription factors Stat5a and Stat5b (collectively called Stat5). The first data on Stat5 
function in HSCs and multi-lineage progenitors were compromised by the original 
hypomorphic Stat5 knock out 47. Later studies revealed that the animals still expressed 
significant levels of N-terminally truncated Stat5 proteins 33,45,53,137-140. Thus, these animals 
must be seen more as knock-in mice for mutant Stat5 proteins with loss of the N-terminal 
domain. Today, the “old” animal model is referred to as Stat5ΔN/ΔN mouse 47. In 2004, “true 
null protein” Stat5 knock-out mice (Stat5-/-) became available 45. The complete locus for 
Stat5a and Stat5b was flanked with loxP sites which allowed a 110 kb deletion upon Cre 
recombinase action, either in whole animals or specific tissues 137,139,140. Most work 
addressing the role of Stat5 in HSCs and multi-lineage progenitors was performed with 
Stat5ΔN/ΔN mice, which yielded interesting results. However, phenotypes were generally more 
pronounced in fully Stat5-deficient mice 132,139,141,142. Stat5ΔN/ΔN HSCs displayed impaired re-
population capability in both serial as well as competitive reconstitution assays 141,143. As 
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revealed by direct quantitation experiments, impaired re-population was neither due to 
reduced HSC numbers nor to defects in homing 141,143. This already suggested that Stat5 is 
supporting self-renewal of HSCs rather than survival or homing. This interpretation was 
strengthened by competitive reconstitution assays determining the engrafting capabilities of 
wt, Stat5ΔN/ΔN, and Stat5-/- fetal liver cells, demonstrating a more drastic re-population defect 
of Stat5-/- compared to Stat5ΔN/ΔN HSCs 142. Analysis of the Stat5ΔN/ΔN multi-lineage 
progenitor compartment revealed a massive reduction in progenitor numbers, as judged by 
spleen colony-forming units (CFU-S) assays: Stat5ΔN/ΔN multi-lineage progenitors gave rise to 
fewer and smaller CFU-S 141,143. Furthermore, flow cytometry for the apoptosis marker 
annexin V displayed increased cell death of Stat5ΔN/ΔN lin-Sca1- progenitors 143. Thus, Stat5 
apparently has an important function in survival of lineage-restricted progenitors. 
Whether the loss of Stat5 affects CMPs, CLPs, or both has not yet been analyzed in murine 
models. Future studies should address this important question, since it has consequences for 
lymphoid or myeloid hyper- versus hypo-proliferation and potential side effects of future 
therapies targeting Stat5. For example, lentivirus-mediated RNA interference against Stat5 in 
human CD34+CD38- cells derived from umbilical cord blood (resembling murine LSK 
cells)144,145 140,141 revealed a 3.25-fold reduction in stem cell number and a 3.9-fold reduction 
in progenitor cell abundance as determined by long-term culture-initiating cell assays and 
colony-forming cell assays, respectively 144,145. Taken together, data from both murine and 
human studies demonstrate that Stat5 is an important positive regulator for hematopoietic 
stem / progenitor cell fitness. 
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Figure 4. Simplified schematic diagram of the linear hierarchy of hematopoietic cells. 
All cytokines and growth factors in this diagram are involved in the activation of Stat5 in that they 
promote survival, proliferation or differentiation of the respective cell types they have been allocated 
to. Long-term reconstituting hematopoietic stem cells (LT-HSCs) divide into an identical daughter cell 
(self-renewal) and a more committed ST-HSC (short-term reconstituting hematopoietic stem cell). ST-
HSCs give rise to multi-potent progenitors (MPPs). These three cell populations are subsumed as 
“LSK” cells (boxed cells) according to their cell surface marker phenotype (lineage- sca-1+ c-kit+). 
Multi-potent progenitor cells produce the lineage-specific common lymphoid progenitor (CLP), which 
differentiates into all mature lymphoid cells, as well as the common myeloid progenitor (CMP), which 
differentiates into the megakaryocytic-erythroid progenitor (MEP) as well as the granulocytic-
monocytic progenitor (GMP). The MEP and the GMP give rise to all mature cells of both erythroid 
and myeloid lineage. Abbreviations: CFU-E: (colony forming unit erythroid); DC: (dendritic cell); 
EPO: (erythropoietin); GM-CSF: (granulocyte-macrophage colony stimulating factor); IL: 
(interleukin); MCP: (mast cell progenitor); SCF: (stem cell factor); TPO: (thrombopoietin); TSLP: 
(thymic stromal lymphopoietin). 
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1.5.1.3  Stat5 in myelopoiesis and erythropoiesis 
Stat5ΔN/ΔN mouse embryos were found to be anemic, which was attributed to increased 
apoptosis of erythroid progenitor cells in the fetal liver resulting from decreased expression of 
the anti-apoptotic gene Bcl-xL 146. Dolznig and coworkers succeeded in completely rescuing 
this phenotype by ectopic expression of Bcl-xL 56. Adult Stat5ΔN/ΔN mice showed no overt 
erythroid defects in steady state erythropoiesis. Under erythrolytic stress induced by 
phenylhydrazine, however, Stat5ΔN/ΔN mice exhibited a massive delay in recovery 40.  
Complete deletion of both Stat5 genes did not reveal abnormalities in early embryonic 
development but there were significant deviations from expected Mendelian ratios in the late 
stages of embryogenesis. More importantly and in contrast to Stat5ΔN/ΔN mice, all except 1-
2% (instead of 25%) of Stat5-/- animals died perinatally 45,105, when bred in a Sv129 x 
C57BL/6 mixed background. Puzzling but quite common in Jak-Stat-Socs knock-out mouse 
model systems 147, loss of Stat5 genes caused elevated expression and tyrosine 
phosphorylation of Stat1 and Stat3 in Stat5-/- fetal liver-derived hematopoietic progenitors 
(Kerenyi, unpublished data), suggesting compensatory mechanisms 147. The few survivor 
mice died at about 5 weeks of age, which is most likely due to severe autoimmune disease as 
a consequence of a lack of suppressor T-cells 137,140. The vast majority of Stat5-deficient 
embryos developed severe erythroid defects, particularly on pure genetic backgrounds such as 
C57BL/6 or Balb/c. They displayed drastically reduced hematocrit values, massive anemia 
and defects in erythroid iron metabolism due to reduced expression of iron regulatory protein 
2 and the transferin receptor, two newly identified direct targets of Stat5 105,148. The vital role 
of Stat5 in erythropoiesis was further supported by recent findings: (i) Upon transplantation of 
cells into irradiated recipients, persistent activation of Stat5 in Jak2-/-- as well as EpoR-/- fetal 
liver-derived erythroid progenitors proved capable of significantly restoring BFU-E and CFU-
E colony formation in vitro and erythropoiesis in vivo 38. (ii) Gene knock-out mouse studies 
displayed a complete failure of erythroid engraftment upon transplantation of Jak2-/-- 149,150, 
EpoR-/-- 151 or Stat5-/- fetal liver cells into lethally irradiated wt mice 142. 
Stat5 is also a key molecule for myelopoiesis (reviewed in 108). Compared to wt, Stat5ΔN/ΔN 
bone marrow formed less than 50% of myeloid colonies in response to IL-3, GM-CSF, SCF, 
or Flt-3L factor combinations in vitro 47,141. Moreover, Stat5ΔN/ΔN mice displayed 
thrombocytopenia due to defective TPO signaling 141,143,152. These data were corroborated by 
observations of increased apoptosis of Stat5ΔN/ΔN bone marrow cells undergoing IL-3- or GM-
CSF-induced myeloid differentiation in suspension cultures 39. Apoptosis of Stat5-deficient 
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myeloblasts was attributed to loss of Bcl-xL expression, similar to the situation which had 
been found in erythroid cells 39. Stat5ΔN/ΔN bone marrow cells also failed to develop into Th2 
cytokine-producing eosinophilic granulocytes in response to IL-5 153. Likewise, ectopic 
expression of a dominant-negative Stat5 variant (Stat5Δ750; 44) in human CD34+ cord blood 
cells blocked eosinophil differentiation 154. New studies on complete Stat5 deletion revealed a 
role of Stat5 proteins in G-CSF signaling and in the development of inflammatory M2 
macrophages 155. Interestingly, Stat5 can also act as a negative regulator of granulopoiesis: 
Stat5ΔN/ΔN mice displayed mild neutrophilia but had a 25-fold increase in serum G-CSF levels 
156. This was attributed to negative feedback of Stat5 on the G-CSF promoter in liver 
endothelial cells. Moreover, essential roles for Stat5 in myeloid leukemia induced by 
truncated G-CSF receptor have been suggested in a recent study 157.  
In addition, Stat5 is essential for mast cell development. Stat5ΔN/ΔN mice display massively 
reduced mast cell numbers, due to aberrant expression of Bcl-2, Bcl-xL, cyclin A2 and B1 158. 
Stat5 is not only important for mast cell survival and proliferation but was also found to play 
a role in their effector function, as it was shown to be activated upon IgE cross-linkage 159. 
Accordingly, Stat5ΔN/ΔN mast cells displayed defects in degranulation and leukotrien B4 
production 159. Mast cells from Stat5-/- fetal livers were even more severely affected in 
cytokine-dependent proliferation but could be efficiently rescued with wt as well as Stat5aΔN 
142.  
 
1.5.1.4  Stat5 in lymphopoiesis 
Stat5 is activated by all lymphoid cytokines that use the common gamma chain (IL-2, 
IL-4, IL-7, IL-9, IL-15 and IL-21) and exerts important functions in lymphopoiesis such as 
regulation of proliferation, survival and differentiation (Figure 4).  
B-cell development is strictly dependent on IL-7-signaling, as evidenced by IL-7 or IL-7 
receptor (IL-7Rα) knockout mice, which lack mature B-cells due to a complete differentiation 
block at the pre-pro B-cell stage 160. Thus, Stat5 deficiency was assumed to display similar 
defects, since Stat5 is efficiently activated by IL-7 161-163. Interestingly, expression of a 
constitutively active Stat5b allele complemented B-cell development in IL-7Rα-/- mice 164. 
Unexpectedly, Stat5ΔN/ΔN mice did produce mature peripheral B-cells, although in reduced 
numbers. This was originally attributed to an incomplete block at the stage of early pro B-cell 
differentiation 138. These results were extended by recent studies using complete Stat5 
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knockout mice 137,139 and by in vivo experiments employing B-cell specific deletion of 
(CD19cre; 165). IL-7 stimulation of immature lymphocytes also led to robust Stat3 activation, 
which might explain why animals with IL-7 and IL-7Rα deficiency displayed a more drastic 
phenotype. Thus, the exact function of Stat5 downstream of IL-7 is still under debate. It is not 
clear whether Stat5 only promotes B-cell survival or if it is also required for lineage 
commitment. Increased apoptosis of IL-7Rα-deficient B-cells could not be overcome by 
expression of a Bcl-xL transgene 164, which suggests a developmental role of Stat5. Since Bcl-
xL is not expressed in wt B-cells, it should be kept in mind that other anti-apoptotic genes 
such as Mcl-1, which has been described to be important for survival of lymphocytes 166, 
might be able to overcome this defect. After all, several studies have suggested that Stat5 
plays a role in transcriptional control of EBF-1 and/or Pax-5 164,165,167, which are both 
necessary for B-cell development. Stat5-/- B-cell progenitors, however, only partially 
phenocopy the defects of IL-7-, IL-7Rα-, Pax-5-, or EBF-1-deficient mice in VDJ-
immunoglobulin rearrangement and the surprising capacity of B-cells to retro-differentiate to 
T lymphocytes 168,169. Apparently, B cell commitment and the regulation of Pax5 is a more 
complex scenario, which does not solely depend on linear cytokine-transcription factor 
regulation like IL-7-IL-7R-Jak1/3-Stat5. Stat5 might induce only genes important for survival 
and proliferation downstream of IL-7Rα without a direct function in B cell lineage 
determination. 
Considering the importance of IL-2, IL-4, and IL-7 in T-cell development, analysis of the T-
lymphocyte compartment in Stat5ΔN/ΔN mice revealed a surprisingly mild phenotype. There 
was a reduction of peripheral CD8+ T-cells accompanied by a lack of functional NK-cells 170. 
CD4+ and CD8+ T-cells failed to proliferate in response to IL-2 or IL-4 even in combination 
with full T-cell receptor activation and co-stimulation 170,171. Typical activation-specific genes 
like D-type cyclins, c-myc, Pim, Socs, or Bcl-xL were not induced and the T-cells remained 
arrested in G1, although IFN-gamma production was normal 89,170,171. Interestingly, Stat5ΔN/ΔN 
T-cells displayed an activated/memory phenotype (CD44high CD62Llow) 170, suggesting a 
disturbed negative regulation. Consequently, the mice developed autoimmune disease 
accompanied by a reduction in peripheral CD4+CD25+ regulatory T-cells (Treg); at that time 
FoxP3 was not yet known as a Treg specific marker 172-174. Given the necessity of (Stat5-
mediated) IL-2 signaling in Treg development and maintenance, it was reasoned that Stat5 
might not be needed for Treg development but rather for maintenance 172,174. Since IL-2 
signaling activated not only Jak/Stat signaling but also Ras-MAPK and PI3K, the latter 
pathways were consequently considered to be required for Treg development. 
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As in B-cells, analysis of complete Stat5 knockout mice also revealed more drastic T-cell 
phenotypes. While CD8+ as well as CD4-CD8-γδTCR+ T-cell numbers were strongly reduced, 
CD4+CD25+FoxP3+ Tregs were completely absent 137,139,140, which was also true for conditional 
Stat5flLckCre mice. Furthermore, FoxP3, which is necessary and sufficient for polarization of 
naïve CD4+ T-cells to fully functional regulatory T-cells, was identified as a direct 
transcriptional target of Stat5 140,175,176. These findings finally demonstrated that Stat5 was 
indeed required for Treg maintenance as well as for their development and polarization. 
Recently, it was proposed that differentiation of naïve CD4+ T-cells towards the T-helper-17 
(Th17) lineage concomitantly antagonizes T-cell polarization towards CD4+CD25+FoxP3+ 
Tregs, and vice versa 177. Likewise, mice with T-cell specific Stat5 deletion (using Stat5fl/fl-
CD4Cre) were almost completely devoid of Tregs but actually did exhibit increased numbers 
of Th17 cells 140,178. By contrast, conditional deletion of Stat3, which has no effect on 
regulatory T-lymphocyte abundance, led to a loss of Th17 cells. These studies convincingly 
established the intrinsic requirement of Stat5 in polarization towards the Treg and of Stat3 
towards the Th17 helper cell lineage 140,179, as well as the reciprocal relationship between 
Stat3 and Stat5 during T-cell development. Surprisingly, Stat5 also plays a role in T-cell 
lineage commitment, since it suppresses Th1 differentiation and controls Th2 cytokine 
production 180,181.  
 
1.5.1.5  Stat5 as a master regulator of hematopoietic cancers 
So far, Stat5 proteins have been described as master regulators of hematopoiesis, but 
to which extent is elevated Stat5 signaling critically associated with leukemia or lymphoma 
formation? Persistent activation of Stat5 has indeed been observed in a broad spectrum of 
human hematologic malignancies, including chronic myelogenous leukemia (CML), 
erythroleukemia, acute lymphocytic leukemia (ALL), myelo-proliferative diseases (MPDs) 
like polycythemia vera, thrombocytopenia, idiopathic myelofibrosis, or mastocytosis. 
Moreover, several studies reported that distinct types of T- and B-cell lymphomas were 
associated with persistent Stat5 activity (Table 1)82,182,183. Introduction of Stat5 gain-of-
function mutants by retroviral integration and transplant models and massive overexpression 
of wt Stat5a and Stat5b genes 184-186 in transgenic mouse models, respectively, demonstrated 
that Stat5 can promote factor-independent proliferation 38 and tumor initiation in virtually all 
hematopoietic cell types54. Thus, by standard definition, P-Y-Stat5 can be viewed as an onco-
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protein. Importantly, several studies with human leukemic cells have shown that Stat5 is also 
involved in tumor cell maintenance, a feature described as oncogene dependence 144,187,188. 
 
Table 1: Stat5 activation in hematopoietic malignancies 
 
 
 
Constitutive activation of Stat5 can be due to either activating mutations or chromosomal 
translocations in genes of upstream kinases, generating fusion tyrosine kinases, which are 
particularly frequent in leukemias. Alternatively, persistent Stat5 activation can also be 
associated with an amplification of essential signaling components such as growth factors or 
cytokines, or overexpression of their cognate receptor (Figure 5). The ensuing amplification 
of Stat5 signaling drives cells into sustained proliferation, protects against apoptotic signals, 
leads to evasion from the immune system, and finally can render cells almost immortal. Of 
course, these processes do not depend on persistent activation of the Jak-Stat pathway alone 
but are associated with additional oncogene mutations and amplifications as well as silencing 
of tumor suppressors. It is the combined effect of activated oncogenes and silenced tumor 
suppressors—which is likely to be in synergy with P-Y-Stat5—that causes tumor 
development. Identifying disease-specific combinations of these players remains a challenge 
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for future studies, since most work has been focused on Stat5 and the most common 
mutations alone.  
Generally, activation of Stat5 proteins by mutations in upstream tyrosine kinases is mainly 
associated with increased proliferation or survival of hematopoietic cells. This is due to 
positive transcriptional regulation of Stat5 target genes 89,109. These can be involved in cell 
cycle progression (e.g. IL-2Rα, D-type cyclins, c-myc, oncostatin M, IL-7Rα, IL-3Rβ, ALS, 
IGF-1, Pim kinases, epidermal growth factor-receptor [EGF-R], prolactin receptor), survival 
(e.g. A1, Mcl-1, Bcl-2, Bcl-xL, survivin), negative feedback inhibition of tyrosine kinase 
signaling pathways (e.g. CIS, Socs-1-3), lymphocyte function (e.g. FoxP3, CD25, TCRγ/δ 
rearrangement region, perforin, lymphotoxin-α, Pax5, EBF, Glut1) or cofactor regulation (e.g. 
Cited2). 
 
Figure 5. Mutations and expression change leading to persistent Stat activation. 
Persistent activation of Stat5 has been observed in a broad spectrum of human hematologic 
malignancies. It may be attributed to (a) translocations generating fusion tyrosine kinases, (b) 
activating mutations in growth factor receptors, (c) activating mutations in upstream kinases, or 
alternatively be due to an amplification of a signaling component such as (d) autokrine growth factor 
production or (e) receptor overexpression. This leads to hyperactivation of Stat5 downstream targets 
resulting in increased cell proliferation, cell survival, or reduced apoptosis. Multiple phosphorylated 
Stat5 proteins can form dimers or oligomers on DNA molecules. Moreover, secondary 
posttranslational modifications (e.g., P‑Ser/P‑Thr), different splice variants, differential translation or 
deletions can be found. 
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1.5.1.5.1  Stat5 and transforming tyrosine kinases activated by chromosomal 
rearrangement 
Deregulated tyrosine kinase activity promoting leukemogenesis frequently results from 
chromosomal breakage-and-reunion events causing gene fusions. Several examples involving 
translocated tyrosine kinases are known to result in activation of Stat5 (Figure 5a). Probably 
the most prominent and best studied Stat5 activating fusion kinase is Bcr-Abl, the protein 
product of Ph+ t(9;22), the so-called Philadelphia chromosome 189182189, which is responsible 
for >90% of CML, 25-30% of adult and 2-10% of childhood ALL 190 as well as rare cases of 
AML. The reciprocal t(9;22) translocation involves different exon sets of the bcr gene 
(breakpoint cluster region; 191) fused to a common subset of exons from the abl gene, 
generating two alternative chimeric oncogene products – p190 and p210 192,193. p210 is 
responsible for CML, whereas p190 results almost exclusively in adult ALL, and very rarely 
causes AML. The first exon of bcr, which is retained in both isoforms, appears essential for 
constitutive activation of the Abl tyrosine kinase which leads to factor-independent 
proliferation and transformation of hematopoietic cells 194. Carlesso and co-workers were the 
first to demonstrate persistent Stat5 activity in human Ph+ CML cell lines 195. Additional 
studies also found evidence that Stat5 proteins are indeed essential for transformation and 
leukemogenesis 137,145,196,197. The mechanism of Stat5 activation by Bcr-Abl was described as 
being either direct, i.e. without requirement for phosphorylation via Jak kinases 194,195, or 
indirect, i.e. involving tyrosine phosphorylation by Jak2 198 or Src-family kinases 199. One 
prominent example of a target gene exhibiting increased expression levels along the Bcr-Abl-
Stat5 axis is the anti-apoptotic Bcl-XL, whose relevance for hematopoietic development is 
well known 196,199-201. 
Therapy of CML is based on inhibition of Bcr-Abl kinase activity. Inhibitors like Imatinib-
mesylate (Gleevec) or the newer compounds Dasatinib and Nilotinib cause efficient inhibition 
of CML progression as well as suppression of Stat5 activity. This, in turn, leads to a reduction 
in expression of genes like Rad51, D-type cyclins, c-myc, Mcl-1 or Bcl-XL, resulting in 
selective apoptosis of Bcr-Abl expressing cells 199,202-205. The relevance of Stat5 in Bcr-Abl 
induced leukemia progression was underscored by animal studies demonstrating that the 
absence of Stat5a alone 188 or one allele of Stat5a/b (Stat5+/-) reduces the incidence of CML, 
while Stat5-/- fetal liver cells were completely resistant to transformation 137. Similar results 
were obtained by Cain and co-workers, supporting a dosage effect of Stat5 proteins 81. 
Also members of the Jak kinase family (comprising Jak1-3 and Tyk2), the standard upstream 
regulators of Stat activity, can be affected by chromosomal rearrangements leading to aberrant 
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signaling. Such translocations are rare but were reported in human leukemias, suggesting a 
direct Jak-Stat-mediated leukemic process. The leukemia-associated Tel(Etv6)-Jak2 fusion 
protein is formed by fusion of the oligomerization domain of the Ets transcription factor (Tel) 
to the catalytic domain of Jak2 111. Tel-domain-mediated oligomerization then leads to 
constitutive tyrosine kinase activity 206,207 resulting in constitutive Stat activation 206,208. In 
vitro, persistent activation of the Jak-Stat pathway by a Tel-Jak2 fusion protein rendered 
murine hematopoietic IL-3-dependent Ba/F3 cells growth factor-independent 209. This 
phenotype was abrogated upon the expression of dominant-negative Stat5a 209. In vivo, Tel-
Jak2 transgenic mice developed T-cell leukemia associated with constitutive activation of 
Stat5 and Stat1 208. Also the involvement of Tel-Jak2-induced Stat5 activation in the 
development of myelo- and lympho-proliferative disease could be demonstrated in a murine 
transplant model 210. 
 
1.5.1.5.2  Mutated or amplified Jak kinases affecting Stat5 activity 
Enhanced Stat5 activation has been observed in clonal myelo-proliferative disorders 
like polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis 
(IM) 80,211. These diseases originate in multipotent progenitors capable of giving rise to 
erythroid- and as well as myeloid cells. A high proportion of patients were found to carry a 
dominant gain-of-function mutation (Jak2-V617F) in the negative regulatory Jak-homology-2 
(JH2) domain of Jak2 211-217. This mutation was associated with constitutive tyrosine 
phosphorylation of Jak2 and ensuing activation of Stat5 (Figure 5c) 211-214. This constitutive 
activity of Jak2 promoted cytokine hypersensitivity (particularly towards Epo; 218,219 and 
induced erythrocytosis in a mouse model 83,220-222. Mice expressing Jak2-V617F under its 
endogenous promoter exhibited differential expansion of hematopoietic lineages, which was 
dependent on both the presence and level of mutated Jak2 223,224. PV patients with the Jak2-
V617F mutation showed an increased number of hematopoietic stem cells with aberrant 
erythroid potential in peripheral blood. This phenotype was potently inhibited by the Jak2 
inhibitors AG490 225 and TG101358, respectively 226. 
An additional Jak2 gain-of-function mutant (K539L) was found in patients with Jak2-V617F-
negative PV as well as in those with idiopathic erythrocytosis. In Ba/F3 cells expressing 
murine Epo-R, the K539L mutation increased phosphorylation of Jak2 and ERK1/2, as 
compared with cells transduced by wt Jak2 or Jak2-V617F, rendering the cells growth factor-
independent 227. In mice, Jak2-K539L also led to a myeloproliferative phenotype, including 
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erythrocytosis 227. Additionally, Jak2-V617F and another Jak2 mutation (K607N; located in 
the pseudo-kinase domain) were observed in a subset of AML patients 91. 
 
1.5.1.5.3 Mutated growth factor receptors in Jak-Stat signaling 
 
Amplification, overexpression, and somatic mutations of the class III receptor tyrosine 
kinases (RTKs) Flt-3, c-Kit, FMS, and PDGF-R can result in increased receptor signaling, 
eventually leading to tumorigenesis (Figure 5b+e). Due to common structural characteristics, 
it is the activation loops of these RTKs which constitute hotspots for activating mutations.  
Mutations in Flt-3 represent a common genetic lesion in but are rare in adult ALL 228,229. 
Activation of Flt-3 due to internal duplications in the juxta-membrane domain, the most 
frequent and best characterized type of mutation, is found in 20-25% of AML patients230-232. 
Point and deletion mutations in the activation loop of the protein tyrosine kinase domain were 
described in approx. 7% of AML cases 233,234. 
Flt-3 internal-tandem-duplication mutations (Flt-3-ITD) are known to cluster in the juxta-
membrane domain. They cause constitutive activation of the receptor, which becomes 
phosphorylated independent of ligand binding and induces growth factor-independent 
proliferation of hematopoietic cell lines. Aberrant signals emerging from Flt-3-ITD include 
activation of Stat5 235,236 and repression of the myeloid transcription factors Pu.1 and C/EBP-
α. The mechanism of Stat5 activation by Flt-3-ITD is independent of Src and Jak kinases; in 
fact, Stat5 was shown to be a direct target of Flt-3 236,237. Although Flt-3-ITD was sufficient to 
induce MPD in a murine bone marrow transplant model, the AML phenotype observed in 
humans could not be recapitulated 238.  
c-Kit (also designated CD117), the RTK for stem cell factor, is required for normal 
hematopoiesis, melanogenesis, and gametogenesis 239,240. Point mutations in this receptor 
were described to result in ligand-independent tyrosine kinase activity and auto-
phosphorylation, which in turn lead to stimulation of downstream signaling pathways and 
uncontrolled cell proliferation. Consequently, mutations in the c-Kit gene are known to induce 
mast cell leukemia and AML. They cluster in two distinct regions, the juxta-membrane 
domain and the activation loop. Activating point mutations in c-Kit, in particular D816V (241-
244, have been also linked to systemic mastocytosis 245. Mastocytosis is often transient and 
limited in children but persistent and progressive in adults. Occurrence of somatic c-Kit 
mutations correlates with the severity of disease. They are found in a high number of adult 
patients presenting with sporadic mastocytosis as well as in children at risk for extensive or 
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persistent disease 246. The increase in mast cells seen in these patients has been attributed to 
enhanced chemotaxis of CD117-positive cells derived from CD34/CD117 double-positive 
precursors 247. The results obtained in a recent study suggest that a gain-of-function mutant of 
Stat5 can promote mast cell disease in mouse bone marrow transplant models as well 116.  
 
1.5.1.5.4  Amplified signals 
Excessive production of cytokines, amplification of their receptor, as well as autocrine 
cytokine stimulation are additional mechanisms capable of inducing hyperactivation of 
downstream signal transducers (Figure 5 d+e). Several heterozygous mutations in Epo-R with 
increased sensitivity towards Epo were described to lead to strong activation of Jak2-Stat5 248 
and ensuing autosomal-dominant erythrocytosis-1 (ECYT-1) 249,250. The majority of ECYT-1 
Epo-R mutants lacked the C-terminal negative regulatory domain 250. The potential for such 
truncations in the pathogenesis of human erythroleukemia was also revealed by 
characterization of a 3´-end deletion in the Epo-R gene of a cell line overexpressing Epo-R 
and proliferating in response to Epo 251. Furthermore, a point mutation in the mouse Epo-R 
gene resulted in its constitutive activation, leading to erythrocytosis and splenomegaly 252. In 
some AML patients, non-mutated c-Kit and Flt-3 were found to be overexpressed and 
activated. For Flt-3, there was also in vitro evidence that an autocrine loop promotes growth 
and survival of AML blasts 253.  
 
1.5.1.5.5  Constitutively activated mutants of Stat5 inducing transformation 
Stat5 is activated by various oncoproteins exhibiting tyrosine kinase activity and is 
known to have a crucial role in tyrosine kinase-mediated leukemogenesis. Direct evidence 
that constitutive activation of Stat5 by itself can be sufficient to cause cell transformation was 
obtained by analysis of the Stat5 mutants Stat5-1*6 254 and cS5F 54. These constitutively-
active variants were capable of inducing MPD and multi-lineage leukemia in transplanted 
mice 54,117,210. Moreover, cS5F relieved cytokine dependence and prolonged the persistence of 
Stat5 signaling in response to growth factors and cytokines 38,117. Interestingly, constitutively 
active Stat5a-1*6 is able to promote senescence in fibroblasts, similar to oncogenic Ras 255,256. 
The role of cS5F in senescence is currently under investigation (G. Ferbeyre, personal 
communication).  
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1.5.1.5.6  Stat5 as a repressor 
In contrast to its role as a growth stimulator, Stat5 can also act as a repressor of 
proliferation in certain settings. A recent study on NPM-1/ALK anaplastic large T-cell 
lymphomas (ALCL) 88 showed epigenetic silencing of Stat5a but not of Stat5b, through a 
mechanism involving Stat3. Therefore, in this particular lymphoma, Stat5a appeared to act as 
a tumor suppressor by inhibiting NPM1/ALK expression. Further, Stat5 was described to 
induce transcriptional repression as a fusion partner in a leukemic oncogene translocation 
with the nuclear hormone receptor super-family member RAR-α 59,257,258. 
 
1.5.1.6   Stat5 in the diagnosis and treatment of hematopoietic disorders 
As pointed out above, the expression and activity of Stat5 genes and proteins could be 
of substantial diagnostic value, e.g. in CML, which is marked by Stat5 hyperactivation, or in 
ALCL, where Stat5a is typically absent. To date, however, there have been no reports on 
quantitative analyses of Stat5 mRNA, protein and activity levels, although these parameters 
strongly influence cellular response to cytokines, growth factors or aberrant tyrosine kinases. 
Despite the availability of suitable immunostaining protocols with monoclonal antibodies, 
determination of P-Y-Stat5 activity status is not a standard procedure in current clinical 
leukemia staging yet 92,117. 
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Figure 6.  Strategies for targeting Stat5 for leukemia therapy. 
The increasing understanding of the pathways leading to persistent Stat5 activation provides important 
insights into the potential therapeutic use of inhibitor compounds. There are several steps in the 
activation pathway of Stat5, which could potentially serve as direct or indirect targets for therapeutic 
intervention. These include (1) cytokine or growth factor depletion, (2) blocking cytokine receptors by 
receptor antagonists or antibodies, (3) inhibition of Jak or fusion tyrosine kinases, (4) direct 
interference with Stat function by blocking receptor recruitment via the SH2-interaction domain, (5) 
blocking Stat transcription by anti-sense molecules, (6) inhibition of serine kinases, (7) inhibition of 
the transcriptional activity of Stat5 by the use of small molecules that interfere with DNA binding such 
as decoy oligonucleotides, (8) functionally inactive dominant negative Stats, (9) small molecular 
weight inhibitors that bind directly to Stat transcription factors, or (10) targeting negative regulators of 
Stats. 
 
 
1.5.1.7  Implications of Stat5 inhibition for leukemia intervention 
In manuscripts dealing with research on Stat5, discussion sections frequently end with 
the claim that Stat5 is a potential target for chemotherapy in leukemia patients. Indeed, there 
are several steps in the activation pathway of Stat5 which might serve as direct or indirect 
targets for therapeutic intervention (Figure 6). However, in order to avoid raising overly 
optimistic hopes, at least three important aspects need to be clarified before Stat5 can be 
considered as a potential drug target.  
First, Stat5 must be shown to actually drive the malignant behavior of leukemic cells. Further 
studies are required to demonstrate that Stat5 is not only sufficient for tumor initiation but 
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also required for leukemia maintenance. Genetic analyses of leukemia models could help to 
address this issue in the future. 
Second, selective targeting of Stat5 proteins by pharmacological intervention must be 
feasible. Among the seven Stat-family members, Stat5a and Stat5b are the two most closely 
related; differences are restricted to the C-terminal trans-activation domain. Thus, the 
corresponding regions of either both or one of the Stat5 proteins could be targeted. ATP 
binding pockets of kinases are commonly smaller than transcription factor protein-protein or 
protein-DNA interaction surfaces. The size of the latter might make their targeting with small 
molecular weight compounds more difficult. However, there are several reports documenting 
successful inhibition of e.g. Stat3, Gli-1, or TCF-4 transcription factors with small molecules 
259. These mostly mimic amino acid surfaces and block binding properties 260,261. As shown 
for Gli-1, micro-RNAs can serve as an alternative approach, provided the limitations of RNA 
stability and cell-specific delivery can be overcome 262.  
Third, inhibition of Stat5 must not exhibit too severe side effects on normal cells. 
Unfortunately, this may not be the case: Stat5-deficient mice are completely devoid of mature 
B-lymphocytes, NK-cells, γδ T-cells, and regulatory CD4+CD25+ FoxP3+ T-cells. While the 
loss of mature B- and NK-cells leads to severe impairment of the immune system, loss of 
regulatory T-cells results in severe autoimmune reactions from the remaining immune system. 
Furthermore, Stat5 deficiency results in a strong reduction of fetal erythropoiesis, although 
adult red cell formation may be less affected. Overall, there might be a therapeutic window 
for the use of Stat5 inhibitors but caution is necessary when determining to which extent Stat5 
activity can be reduced for treating leukemia without causing unacceptable side effects.  
These considerations bring us back to Bcr-Abl, the best-studied example for the therapeutic 
potential of targeting Stat5 in CML. The sensitivity of CML to Bcr-Abl tyrosine kinase 
inhibitors used in conventional chemotherapy is due to ‘Bcr-Abl oncogene addiction’ 187. 
Interestingly, Pimozide, a known chemotherapeutic agent, was identified to block P-Y-Stat5 
activity in synergy with Bcr-Abl kinase inhibitors (Nelson et al., Abstract 2953, ASH 
meeting, Atlanta, 2007). The precise mechanism of Pimozide action, however, remains 
puzzling. Ongoing research in animal models tries to resolve the question whether Jak2 and/or 
Stat5 are required for the initial transformation phase of Bcr-Abl induced CML only or if 
these proteins are also needed for the maintenance of advanced-stage CML. These 
considerations entail genetic evaluation of the therapeutic potential of targeting Stat5a/b 
proteins. Technically, these studies are based on mice with floxed Stat5 or floxed Jak2 genes 
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crossed with mice carrying an inducible Cre recombinase. The disease phenotype of animals 
after Cre-mediated Stat5 or Jak2 deletion might have an impact on decisions for future 
therapeutic intervention strategies converging on the Jak-Stat pathway. 
 
 
1.5.2 Stat5 in solid tumors 
 
While the functions of Stat5 in the hematopoietic system are already well established, 
its role in solid organs and associated diseases has only recently become a focus of interest. 
To date, Stat5 has been demonstrated to be constitutively activated in a variety of cancers 90. 
Apart from its role in the expression of anti-apoptotic proteins contributing to tumor 
progression 263, Stat5 has recently been shown to be involved in EMT 95,96,264. Although 
Stat5a and Stat5b share high homology at the amino acid level, their activation state varies in 
different cancer types. Stat5a has been implicated in breast cancer 92, whereas Stat5b has been 
correlated with aggressiveness and progression of prostate cancer 93,94,265,266. Constitutive 
activity of Stat5, predominantly of Stat5b, has also been reported for squamous cell 
carcinoma of the head and neck (HNSCCs) 97-99,267,268. 
Notably, hyperactivation of Stat5b has also been linked to increased aggressiveness of human 
hepatocellular carcinomas (HCC) 264,269. Moreover, it has been suggested that also deletion of 
Stat5ab in mouse hepatocytes promotes the development of HCC by induction of 
hepatosteatosis 270 and fibrosis formation due to the increased half-life of the TGF-β protein, 
which mediates hepatic stellate cell activation and enhanced growth hormone-induced Stat3 
activation 106. 
 
1.5.2.1   Liver structure and function 
The liver consists of four lobes, two of which are the main lobes--the right lobe, which 
is by far the larger, and the left lobe. Two small lobes lie behind the right lobe. Each lobe is 
made up of multisided functional units called lobules (Figure 7). 
Each lobule consists of a central vein surrounded by hepatocytes, the most abundant cell type 
within the liver, grouped in sheets or bundles of hexagonal shape. Most liver functions are 
executed by hepatocytes. They originate from undifferentiated liver progenitor cells, the so-
called oval cells, which express markers of both hepatocyte lineages and biliary epithelium 
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(alpha-fetoprotein, gamma-glutamyl transpeptidase, cytokeratin 19, OC.2, glypican-3 and 
OV-6; 271,272). 
Cavities known as sinusoids separate the groups of hepatocytes within a lobule. The space 
between a hepatocyte and a sinusoid is termed space of Disse (or perisinusoidal space). It 
contains blood plasma as well as dormant hepatic stellate cells representing 5-8% of the total 
number of liver cells 273,274. In the normal liver, stellate cells constitute the major storage 
depot for vitamin A and are described as being in a quiescent state. Following liver injury, 
stellate cells are able to change into an activated state which is characterized by proliferation, 
contractility, reduced vitamin A storage, and chemotaxis. Activated stellate cells are also 
involved in collagen deposition in the liver, which can lead to cirrhosis 275. Another important 
hepatic cell type residing in close vicinity to the sinusoidal endothelial cells and attached 
lymphocytes are the liver macrophages, also called Kupffer cells 276,277. 
The sinusoids give the liver a spongy texture and enable it to hold large amounts of blood. 
The liver is supplied with oxygenated blood from the heart via the hepatic artery and with 
compound-rich and partially oxygenated blood which it receives from the gastrointestinal 
tract, the pancreas and spleen via the portal vein. The hepatic artery and the portal vein branch 
into a network of capillaries that empty into the sinusoids. Through the fenestrated 
endothelium of the sinusoids, hepatocytes absorb nutrients and oxygen from the blood as it 
flows through the sinusoids. At the same time, they filter out wastes and poisons from the 
blood and secrete sugar, vitamins, minerals, and other substances into the blood. The 
sinusoids drain into the central veins, which join to form the hepatic vein through which the 
blood leaves the liver. Hepatocytes also secrete bile which collects in the bile capillaries, 
which then unite, forming bile ducts leading into the cystic/hepatic duct and finally into the 
storage depot, the gall bladder. Bile from the liver and gall bladder flows into the small 
intestine through the common bile duct to facilitate emulsion and reabsorption of dietary 
lipids. The blood and bile flow between adjacent liver lobules is maintained by the periportal 
arterioles, venules and bile ducts in each portal tract of the lobules 278. 
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Figure 7.  Liver lobule structure. 
Blood enters the liver lobules through branches of the portal vein and hepatic artery, and then flows 
through a network of capillaries—the so-called sinusoids—which are lined with hepatocytes and 
Kupffer cells. The latter play a role in blood formation and the destruction of cellular debris. 
Hepatocytes remove toxic substances such as alcohol from the blood and simultaneously secrete sugar, 
vitamins, minerals, and other substances into the sinusoids, which drain into the hepatic venules). 
These join to form the hepatic vein through which the blood leaves the liver. Hepatocytes also secrete 
bile which is collected in the bile capillaries; they unite to form bile ducts leading into the hepatic and 
cystic ducts and finally to the gall bladder, the storage depot for bile (adapted from 279).  
 
 
 
 
The liver performs various complex functions; in particular, it plays a crucial role in 
nutritional homeostasis and the regulation of blood glucose levels by gluconeogenesis and 
glycolysis. Hepatocytes are also able to store excess blood glucose as glycogen, a process 
which is controlled by insulin. As the central metabolic organ, the liver has additional 
essential functions including lipid and protein metabolism 280, production of heat to regulate 
overall body temperature, clearance of hormones, hemoglobin molecules, toxins, or other 
xenobiotics, production and storage of vitamins 281, storage of lipids, iron, copper, and blood, 
as well as synthesis of cholesterol, heparin, bile, complement factors, lipoproteins, and main 
plasma proteins such as albumin, globulin, prothrombin, and fibrinogen 282. Moreover, the 
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liver synthesizes and secretes growth factors, cytokines and hormones 283,284. The liver is also 
the central organ for hematopoiesis in the developing embryo 285. 
 
1.5.2.2  Pathogenesis of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the 
fifth most common cancer and the third leading cause of cancer death worldwide. Among the 
numerous etiologic risk factors, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infection and associated liver cirrhosis rank as the major causes of HCC and statistics show 
that they are implicated in more than 70% of HCC cases 305. The accumulation of different 
genetic alterations secondary to inflammation and oxidative DNA damage eventually leads to 
malignant transformation. Regardless of the etiologic factor, malignant transformation of 
hepatocytes is believed to occur as a result of increased liver cell turnover that is induced by 
chronic liver injury and compensatory proliferation of differentiated hepatocytes which are 
normally quiescent 286-288 (Figure 8). 
Single transformed cells constitute preneoplastic lesions which may progress to HCC by 
clonal selection of genetically altered cells. Although the natural history and pathologic 
characteristics of human hepatocellular carcinoma are well documented, its molecular 
pathogenesis is still poorly understood. Detailed analysis of HCC development in 
experimental animals and the comparison of the results with HCC in humans, however, have 
identified several genomic and molecular alterations as contributing factors to HCC 269,289,290. 
Clinical protocols for the treatment of liver cancer still heavily rely on surgical intervention. 
Therefore, a more detailed understanding of the underlying molecular mechanisms and a 
definition of proteins involved in the progression of HCC is fundamental to the development 
of effective preventive and therapeutic regimens for HCC. 
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Figure 8. Pathogenesis of human hepatocellular carcinoma (HCC).  
Hepatocarcinogenesis is a multistep process evolving from chronic hepatitis to cirrhosis to dysplastic 
nodules and ultimately to HCC. This development may take decades and involves the progressive 
accumulation of different genetic alterations eventually leading to malignant transformation in the 
context of inflammation and oxidative DNA damage. 
 
 
1.5.2.3  Risk factors 
In addition to the risk factors for HCC mentioned above, toxins and drugs (e.g. 
alcohol, aflatoxins, microcystin, anabolic steroids), metabolic liver disease (e.g. hereditary 
hemochromatosis, alpha 1-antitrypsin deficiency), steatosis, non-alcoholic fatty liver disease 
as well as diabetes often represent cofactors contributing to chronic inflammation (Figure 8). 
Among these, obesity-induced hepatosteatosis and its more severe complication nonalcoholic 
steatohepatitis (NASH), which are classified as non-alcoholic fatty liver disease (NAFLD), 
are increasingly recognized as the most common causes of liver disease, second only to 
hepatitis C with respect to numbers of patients progressing to cirrhosis 291,292.  HCV infection 
and NAFLD, which in combination carry an even higher risk for HCC, can both lead to 
endoplasmic reticulum (ER) stress and accumulation of reactive oxygen species (ROS) within 
liver parenchymal cells, which, in turn, causes chronic liver damage 293.  
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1.5.2.3.1  Chronic inflammation 
A short-lived, controlled inflammatory response is required to protect the body against 
pathogens, damaged/aberrant cells, and other harmful stimuli (= acute inflammation mainly 
mediated by polymorphonuclear leukocytes (PMNs) such as granulocytes, eosinophils, mast 
cells, and neutrophils). However, if this response fails to eliminate the injurious stimulus, the 
inflammation is amplified and becomes chronic in an attempt to resolve the situation (= 
chronic inflammation mediated by mononuclear cells such as lymphocytes, macrophages, and 
monocytes). This causes damage to the adjacent healthy tissue, which leads to progressive 
disease. Inflammatory cells have been shown to manipulate the micro-environment around 
tumors, which initially promote the generation of an inflammatory environment294 by 
contributing to proliferation, survival and migration 295-299. Hallmarks of cancer-associated 
inflammation include the presence of infiltrating leukocytes (e.g. neutrophils, dendritic cells, 
macrophages, eosinophils, mast cells, and lymphocytes), cytokines, chemokines, growth 
factors, lipid messengers, and matrix-degrading enzymes.  
The underlying causes of chronic hepatitis include hepatitis virus infection, allograft rejection 
following bone marrow transplantation, primary biliary cirrhosis (PBC), autoimmune 
hepatitis, primary sclerosing cholangitis bile duct obstruction (by gallstones or external 
obstruction by cancer), drug/toxin-induced chronic hepatitis (certain medications, plants and 
above all alcohol), and metabolic disorders such as alpha l-antitrypsin deficiency, 
hemochromatosis, and Wilson's disease 300-303. Regardless of its etiology, chronic hepatitis is 
typically characterized by lymphoid infiltrates in the portal tracts and, to a variable extent, in 
the periportal zones within the hepatic lobules. 
Chronic inflammation of the liver has been clearly linked to HCC 304. The geographical 
distribution of HCC was shown to coincide with the distribution of HBV and HCV infections. 
Similar to nonviral liver disease, HBV and HCV infections may give rise to chronic liver 
injury with subsequent progression to severe fibrosis and cirrhosis, which is the major risk 
factor for developing HCC. However, HCC may also arise in the absence of cirrhosis. In this 
case, it is likely to be mediated by HBV and HCV proteins with oncogenic properties 
including the HBx gene. Additionally, HBV can integrate into the host genome, which then 
leads to changes in genomic function or chromosomal instability. For both HBV and HCV 
infection, antiviral therapy and vaccination have been shown to decrease the risk of HCC 
development 305. 
 
 Introduction  
 
 34
1.5.2.3.2  Obesity / Metabolic syndrome 
 
The prevalence of overweight and obesity, defined by a body mass index (BMI) higher 
than 25, has become a major concern in the industrialized world over the past two decades 
306,307. In 2003, approximately two-thirds of US adults were overweight or obese, and there 
were 300 million obese adults worldwide 306. By the year 2008, a staggering 32 percent of 
children and teens in the United States were found to be obese 308. This development must be 
mainly attributed to a lack of physical activity and excessive calorie intake leading to 
increased body fat content. Obesity strongly correlates with the metabolic syndrome (also 
known as syndrome X or the dysmetabolic syndrome), a term designating a cluster of 
metabolic risk factors and pathologic conditions including insulin resistance (which refers to 
the diminished ability of cells to respond to the action of insulin in promoting the transport of 
glucose from the blood to the muscles and other tissues), essential hypertension, type-II 
diabetes mellitus, hyperlipidemia, cholesterol abnormalities, low circulating high-density 
lipoprotein, and an increased risk for coagulation disorders 309-311. Another condition 
associated with the metabolic syndrome is a clinicopathologic condition called non-alcoholic 
fatty liver disease (NAFLD) representing a wide spectrum of non-alcohol-induced liver 
damage, ranging from simple fatty liver (steatosis) to non alcoholic steatohepatitis (NASH), 
advanced fibrosis and cirrhosis, and chronic liver disease 293. The true prevalence of NAFLD 
is unknown, but it is estimated that 10–24% of the general population in different countries 
might be affected. 
Although the link between obesity, diabetes and cardiovascular disease is well established, the 
relationship between obesity and different types of cancer has hitherto received comparatively 
little attention. More recent epidemiological studies, however, indicate that obesity plays an 
important role in the substantial increase in the incidence and/or deaths from a wide range of 
cancers 306,312,313. Different mechanisms have been proposed by which obesity may induce or 
promote tumorigenesis. These include the metabolic (insulin resistance & type II diabetes) 
and endocrine manifestations (high insulin and IGF-1 levels & localized inflammation) of 
obesity as well as the resulting alterations in the secretion of cytokines (IL-6, TNF-α, serum 
amyloid A), peptide hormones (e.g. growth hormone, IGF-1, insulin, leptin, adiponectin, and 
resistin), and steroid hormones (e.g. estrogen, testosterone) by white adipose tissue 293,313,314 
The largest increase in cancer risk in individuals with high BMIs was observed for 
hepatocellular carcinoma. Compared to normal-weight controls, men with a BMI of 35–40 
were found to have a 4.52-fold increase in HCC risk 306, which is not surprising since the 
association between hepatosteatosis and the development of HCC is already well-established 
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291,292. Like adults, obese children are at high risk of developing diabetes, high blood pressure, 
fatty livers, and other obesity-related health conditions. In this context, it is of note that 
exposure to the risk factors responsible for HCC development begins at a very early age 
already (Figure 8). Consequently, obesity in the Western world, particularly in children, needs 
to be considered a serious public health concern 306,315. Hence, a better understanding of the 
mechanisms by which obesity contributes to the pathogenesis and progression of HCC is 
urgently needed, as are new approaches for therapeutic intervention. 
 
1.5.2.4  Growth hormone signaling 
In the liver, a potent activator of Stat5 is growth hormone (GH) signaling through the 
growth hormone receptor (GHR) 316. As its name suggests, GH is considered to be the most 
important endogenous regulatory factor in postnatal body growth, which also controls cellular 
reproduction and regeneration. GH signaling also affects metabolism, cardiac and immune 
function 317, mental agility and aging 318. GH is a single-chain polypeptide hormone that is 
synthesized, stored, and secreted into the bloodstream by the anterior pituitary gland. There 
are several molecular isoforms of GH circulating in the plasma. About half of the GH in the 
circulation is bound to GH-binding protein (GHBP), which is derived from the GH receptor 
319. GH in humans has been shown to be released nearly continuously in females and 
intermittently—particularly during REM sleep—in males. GH secretion is under strict 
hormonal control. Growth hormone-releasing hormone (GHRH) and ghrelin 320 are the most 
significant stimulators of GH production, while somatostatin produces a strong inhibitory 
effect. Both GHRH and somatostatin are released into the portal system by the hypothalamus. 
Other factors stimulating GH release include acute stress, sex hormones, hypoglycemia, low 
body weight, and vigorous exercise, while hyperglycemia and obesity inhibit GH release 
321,322. 
Furthermore, GH secretion is negatively regulated on different other levels. GH is under the 
inhibitory control of IGF-1, its major protein effector transcribed by Stat5 in the liver. 
Circulating concentrations of IGF-1 and GH itself directly control GH serum levels either by 
acting on the pituitary or by stimulating hypothalamic somatostatin production. A lack of 
hepatic Stat5 results in low levels of circulating IGF-1 65 and high plasma levels of GH and 
insulin 41,53. This condition, which is termed GH insensitivity, may lead to growth retardation 
in association with immune deficiency 323-326. Glucocorticoids (GC) were also found to 
selectively reduce cellular signaling in response to GH. This negative regulation appears to be 
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due to a decrease in the number of GH receptors in the plasma membrane 327. Regulation of 
growth hormone secretion is also mediated by signals produced by adipose tissue. GH 
secretion is negatively regulated by free fatty acids (FFA) and positively regulated by 
leptin328. 
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Figure 9. Growth hormone signaling.  
Growth hormone (GH) acts by binding to the extracellular domain of the GH receptor (GHR), where 
one molecule of GH binds two GHRs 329.  The dimerized GHR then relays its signal by recruiting 
cytoplasmic tyrosine kinases, predominantly Jak2 and Src kinases, which serve to direct multiple 
signals through different signaling pathways, thereby triggering a number of cellular effects. Some of 
these involve the activation of transcription from target genes (activation of Stat5 or SHC), while 
others involve metabolic changes (activation of IRS results in the induction of an insulin-like action of 
GH; 330). A number of signaling proteins containing SH2 domains bind to the GHR-Jak2 complex and 
often form multi-protein complexes.  Substrates for GHR-Jak2 activation include Stats, SHCs (Src 
homology 2a collagen-related), GLUT1 (glucose transporter 1), and IRSs (insulin receptor substrate). 
 
 
After binding to the GHR, the initial event in GH signaling is the activation of Jak2.  This, in 
turn, activates multiple signaling cascades mediating the effects of growth hormone, which 
include cellular proliferation, differentiation and migration, prevention of apoptosis, 
cytoskeletal reorganization and regulation of metabolic pathways (Figure 9). A number of 
signaling proteins and pathways have been shown to regulate the transcription of GH-
responsive genes. These include (i) the Jak/Stat pathway (mainly via Stat5 but also via 
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Stat1/3), (ii) insulin receptor substrates (IRS)-1 and IRS-2, which mediate some of the 
metabolic effects of GH, (iii) the mitogen activated protein kinase (MAPK) pathway, which is 
linked to the regulation of cellular growth and/or differentiation, and (iv) the PI3K-Akt-
mTOR pathway mediating survival signals for the cells. In the regulation of specific genes, 
cross-talk among these signaling cascades is assumed to enable the diverse effects of GH 331.  
 
1.5.2.5   Effects of GH signaling 
As evidenced by the height extremes in people with abnormal circulating growth 
hormone levels or mutations in core genes of the GH pathway disrupting GH-signaling 
(Laron’s syndrome) 104,332, the major function of GH is growth regulation of body height as 
well as of all internal organs excluding the brain. In addition, GH has important physiological 
and metabolic functions affecting almost all tissues in the human organism. 
First of all, GH controls the physiology and pathophysiology of the liver. As discovered by 
using mouse gene knockout models 47,48,333, multiple effects of GH are executed by the direct 
activation of hepatic Stat5a and Stat5b which, in turn, mediate the transcription of genes such 
as cytochrome p450 components, insulin-like growth factor-1 (IGF-1) and acid labile subunit 
(ALS) 334-336. Together with IGF-1 binding protein 3, the latter two proteins constitute a 
bioactive form of IGF-1 337-339, which influences many important parameters promoting 
cellular growth 36,41,53. The effects of GH in liver epithelial cells 340, adipocytes 341, and 
mesenchymal cell types such as chondrocytes342 are mediated predominantly by Stat5b. 
 Furthermore, growth hormone also has sexually dimorphic effects on liver gene transcription 
48. Stat5b has been shown to be the key intracellular mediator of the stimulatory effects of GH 
pulses on male-specific liver gene transcription, while the more continuous pattern of GH 
exposure down-regulates the Stat5b signaling pathway in the female liver. Contrary, both 
Stat5a and Stat5b are required for constitutive expression of certain GH-regulated CYP 
enzymes in the female but not in the male liver 343. Thus, GH activation of both Stat5 
proteins, which act as homodimeric and heterodimeric complexes, respectively, is an 
important regulator of the sex-dependent and gene-specific effects that GH exerts on liver 
cells 344. 
Moreover, GH has important effects on body composition, as it decreases body fat mass and 
increases lean body mass. GH is one of the most important anabolic agents which enhances 
whole-body protein synthesis, increases muscle mass, influences electron transport, and 
increases plasma glucose levels 318,345. Furthermore, bone and connective tissue, where GH 
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stimulates collagen synthesis and the activity of chondrocytes, are also effector tissues of 
GH/IGF-1 346,347. In addition, GH regulates bone density and maintains a balance between 
osteoclasts and osteoblasts. 
GH is also known to increase the metabolic rate. This can—at  least partly—be explained by 
enhanced lipid oxidation due to increased substrate availability, which is mediated by its 
lipolytic effects on adipose tissue 348-350. Moreover, GH reduces glucose tolerance, limits fatty 
acid synthesis in adipose tissue 351, increases the levels of circulating FFA, and plays a major 
role in modulating insulin sensitivity. Multiple mechanisms appear to be involved in this 
modulatory effect. GH does not interact directly with the insulin receptor, although it shares 
several post-receptor signaling events with insulin. Also, GH has been shown to decrease the 
expression of the insulin-sensitizing adipo-cytokines adiponectin and visfatin 314. High levels 
of GH are known to induce a reduction in insulin receptor levels and impairment of its kinase 
activity. Circulating IGF-1 also participates in the control of insulin sensitivity and plays an 
important role in the hormonal balance between GH and insulin. This signaling crosstalk 
might be involved in the diabetogenic effects of GH.  
Current research continues to reveal other potential roles of GH, including the regulation of 
cardiac, renal and immune function, mental agility and aging 318,352. 
 
1.5.2.6  Growth hormone in clinical use 
 Pathologic conditions of deregulated GH signaling result from either GH excess, 
which is most commonly due to pituitary adenomas, or GH deficiency, which is manifested 
by short stature, truncal obesity, hyperinsulinemia, and delayed sexual maturity. Pituitary 
tumors, which are mostly benign, gradually produce more and more GH. This causes a 
condition called acromegaly, which is accompanied by insulin resistance, rare forms of type II 
diabetes, neurological problems, and impairment of sexual function.  Conventional primary 
therapy for acromegaly includes primary surgery followed by external pituitary radiotherapy 
and treatment with somatostatin analogs or dopamine agonists. Hormone treatment aims at 
reducing serum GH and IGF-1 to levels known to reverse the increased mortality associated 
with untreated acromegaly 353,354. 
The use of recombinant GH, which was restricted to the treatment of GH-deficient children 
for many years, has now been widened to various other clinical conditions including Turner 
355, Noonan 356,357, and Prader-Willi syndromes 358, chronic renal failure, and cystic fibrosis 
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359. Recent discoveries of severe or moderate disturbances in GH/IGF-1 axis activity in many 
metabolic disorders associated with dwarfism, have suggested the use of GH therapy also in 
adults for indications such as GH deficiency, short bowel syndrome, and HIV-associated 
wasting 359-361. 
Additionally, GH supplementation has been suggested for malnutrition due to short bowel 
syndrome, renal failure, cancer cachexia, or pulmonary diseases, for severe catabolic states 
such as sepsis, trauma, severe burns, chronic fatigue syndrome or after gastrointestinal 
surgery, as well as for nutritional support, weight management, diabetic foot ulcers, infertility, 
osteoporosis, and anti-aging therapy 360. Opinions on the efficacy of these therapeutic 
approaches vary from enthusiastic to very critical. Moreover, since the 1970s, GH has been 
used by athletes as an anabolic agent to enhance their performance in sports. Although 
supplying human growth hormone for this purpose is illegal, its use has grown in popularity 
with athletes of all levels over the past decade. This may partly be due to the fact that human 
GH is less easily detected than most other performance-enhancing drugs 362-364.  
 
1.5.2.7  GH signaling in HCC 
Growth hormone-deficient patients treated with human pituitary GH at young ages 
were followed for cancer incidence and cancer-related mortality for a period of 35 and 40 
years, respectively 365. Compared to the general population, they were found to have a 
significantly increased overall cancer mortality rate, particularly colorectal cancer and 
Hodgkin’s disease 365.This is in line with an increasing body of literature which suggests that 
patients with acromegaly 366, adults with elevated concentrations of circulating IGF-1 367-
372and taller individuals 373 are at increased risk of developing epithelial cancers. Conversely, 
a common polymorphism in the human GH gene was found to be associated with reduced 
concentrations of GH and IGF-1 and, even more significantly, to be inversely correlated with 
colorectal cancer risk 374. Hence, the increased cancer risk in patients treated with GH might 
be related to an increase in the concentrations of IGF-1 and IGF-binding proteins, which 
together act as a proliferative growth factor. By activating the PI3K/AKT, Ras/Raf, and 
MEK/ERK signaling pathways, GH and its mediator IGF-1 inhibit apoptosis and stimulate 
proliferation in both normal and tumor cells 375. Additionally, GH signaling has been 
suggested to play a role in integrin-mediated cell spread 376. Moreover, high serum levels of 
IGF-1 may contribute to the development of HCC in patients suffering from acromegaly or 
those receiving recombinant growth hormone over a long period of time 377-380. There is 
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increasing interest in elucidating the association between different GH functions and liver 
disease because elevated serum GH levels are often detected in patients presenting with liver 
conditions associated with an increased risk of liver cancer such as cirrhotic and/or 
functionally impaired livers 381-385. Chronic liver damage, regardless of its etiology, is a well-
known risk factor for hepatocarcinogenesis 386 but it is still uncertain whether the elevated 
serum GH levels of these patients contribute to this risk.  
In order to better understand the effects of systemic GH overexpression, mice were 
engineered to express human, rat, or sheep growth hormone from a transgene under the 
control of a Zn2+-ion-inducible promoter, thus mimicking long-term treatment with the 
peptide hormone 304,387-390. Growth hormone, when overexpressed in GH-transgenic mice, 
was found to promote the development of hepatocellular adenomas and carcinomas within 12 
months 387,389,390. Highly increased rates of hepatocellular proliferation were observed to 
precede the onset of hepatic inflammation, a characteristic feature of liver pathology in GH-
transgenic mice. Although the rates of hepatocellular apoptosis were elevated in non-tumor 
tissue, this was largely balanced by the increased proliferation rate 389. In tumor tissue, 
however, the marked increase in GH-stimulated proliferation of tumor cells was demonstrated 
to outbalance the increased rate of apoptosis. The pathologic changes in the liver preceding 
the development of HCC in GH-transgenic mice, which range from chronic inflammation, 
fibrosis, to cirrhosis, and the development of liver cell adenomas, are similar to those 
increasing the risk of human patients for developing HCC. This could have major 
implications for the more than 100,000 patients worldwide estimated to have received 
growth-hormone therapy and calls for a reassessment of the risks and benefits of GH therapy, 
particularly its use in long-term treatment and for more controversial indications, e.g. the use 
of GH as an ‘anti-aging’ regimen. 
 
1.6  Conditional gene deletion using the Cre/LoxP system 
The Cre-LoxP system allows for targeting and recombination of a specific DNA 
sequence with the help of the Cre recombinase 391, a technology which is often used in the 
generation of knockout and knock-in mice as well as animals with conditionally targeted 
genes. The selected DNA sequence, which is essential for the function and/or structure of the 
targeted protein, is flanked by foreign 34-base-pair-long palindromic DNA sequences (loxP) 
thus yielding a ‘floxed allele’. The recombined genomic sequence can either be limited to 
small domains of the protein—resulting in non-functional or truncated proteins—or it can 
span the whole locus of the targeted gene. For conditional inactivation of the GR, for instance, 
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only the first zinc finger in the DNA-binding domain was targeted, leading to disruption of 
the gene 392. A different approach was used for conditional Stat5 deletion. The whole 
chromosomal locus of 110 kb containing Stat5a and Stat5b was flanked and upon Cre activity 
both Stat5 isoforms were excised 45. 
When cell- or tissue-specific promoter sequences are used, the expression of Cre recombinase 
is restricted to specific tissues or cell types (conditional knockout). Cre activity induces DNA 
recombination of the floxed alleles, which, depending on the orientation of the loxP sites 
(parallel or anti-parallel), results either in excision or inversion of the respective DNA 
sequences 393. Knockout of certain genes can lead to embryonic lethality, which makes it 
impossible to obtain adult animals for studying the effects of the gene under investigation. 
The use of inducible Cre recombinases, however, provides a way to knock out genes in a 
spatially and temporally controlled manner. 
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2. Aim of the thesis 
 
Stat5 proteins are crucial transcription factors mediating cytokine and growth factor 
responses in the hematopoietic system. They have been shown to regulate proliferation, 
differentiation, and apoptosis of epithelial cells. Deregulation of Stat5 activity has been 
associated with a wide range of hematopoietic malignancies and several solid tumors. 
However, the role of Stat5 proteins in hepatocarcinogenesis remains elusive. In independent 
studies we focused on: 
 
1)  the mechanisms by which constitutively activated Stat5 (cS5) contributes to multi-
lineage leukemia or myeloproliferative disorders (MPD). 
2)  the analysis of the effects of hepatic Stat5 protein ablation on liver function and 
the development of hepatocellular carcinoma (HCC) secondary to hyperactivated 
Jak2-Stat5 signaling. 
 
In our studies, we used compound knockout mice and transplant mouse models together with 
molecular biology techniques such as quantitative mRNA analysis, protein biochemistry and 
immunohistochemistry. 
(i) We were able to demonstrate for the first time that phosphorylation of Ser779 in Stat5a has 
an essential role in hematopoietic transformation induced by oncogenic Stat5a but is not 
essential for normal Stat5a function.  
(ii) We could also show that constitutively phosphorylated Stat5a effectively activates the 
PI3K/Akt pathway via protein-protein interaction with the Gab2 scaffold protein. 
(iii) Furthermore, we were able to demonstrate that deletion of hepatic Stat5 and/or the 
glucocorticoid receptor leads to severe steatosis and lipodystrophy in a compound knockout 
mouse model. 
(iv) Moreover, we were able to descibe that loss of hepatic Stat5 function increases the 
incidence of HCC in an inflammatory liver cancer model. 
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The present thesis comprises the following four original manuscripts: 
 
 
(i) Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic 
transformation 
 
Katrin Friedbichler, Marc A. Kerenyi, Boris Kovacic, Geqiang Li, Andrea Hoelbl, Saliha 
Yahiaoui, Veronika Sexl, Ernst W. Müllner, Sabine Fajmann, Sabine Cerny-Reiterer, Peter 
Valent, Hartmut Beug, Fabrice Gouilleux, Kevin D. Bunting, and Richard Moriggl 
 
Published in Blood 2010 (Epub ahead of print) 
 
This work is the first to describe a role of Stat5a serine phosphorylation which is not essential 
for its normal function but may be crucial for its leukemogenic potential. The paper provides 
novel insight into the biological importance of two serine phosphorylation sites in Stat5a that 
could serve as a potential therapeutic target for hematologic malignancies. This represents the 
first major function identified for these enigmatic serine phosphorylation sites in Stat5a. 
Further studies will be required to elucidate the regulation and function of these 
phosphorylation sites in human hematopoietic neoplasias. 
 
 
 
(ii) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI 3-kinase 
signaling cascade 
 
Noria Harir, Cédric Boudot, Katrin Friedbichler, Karoline Sonneck, Rudin Kondo, Séverine 
Martin-Lannerée, Lukas Kenner, Marc A. Kerenyi, Saliha Yahiaoui, Valérie Gouilleux-
Gruart, Jean Gondry, Laurence Bénit, Isabelle Dusanter-Fourt, Kaïss Lassoued, Peter Valent, 
Richard Moriggl and Fabrice Gouilleux 
 
Published in Blood 2008 
 
This article demonstrates that constitutive activation of the Stat5-PI3K-Akt-cascade controls 
neoplastic mast cell (MC) development. Retrovirally transduced active Stat5 (cS5F) was 
found to trigger PI3K and Akt activation, and to transform murine bone marrow progenitors 
into tissue-infiltrating MCs. In patients with mastocytosis, Stat5 was also found to be 
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activated in primary neoplastic Kit D816V(+) MCs, where it was localized in the cytoplasm 
and formed a signaling complex with PI3K, which resulted in Akt activation. Finally, knock-
down of either Stat5 or Akt activity caused growth inhibition of neoplastic Kit D816V(+) 
MCs. These data suggest that a downstream Stat5-PI3K-Akt signaling cascade is essential for 
Kit D816V-mediated growth and survival of neoplastic MCs. 
 
 
 
(iii) Compound Loss of Hepatic Signal Transducer and Activator of Transcription 5 and 
Glucocorticoid Receptor Signaling Leads to Severe Steatosis and Peripheral 
Lipodystrophy in mice 
 
Jan-Wilhelm Kornfeld1*, Kristina Mueller2*, J. Andrew Pospisilik3, Katrin Friedbichler2, 
Gerda Egger4, Harald Esterbauer5, Peter Hasselblatt6, Marc A. Kerenyi7, Kay-Uwe Wagner8, 
David Engblom9, Guenter Haemmerle10, Dagmar Kratky11, Veronika Sexl12, Lukas Kenner2, 
Luigi Terraciano13, Rudolf Zechner11, Guenther Schuetz14, Markus H. Heim15 and Richard 
Moriggl2  
 
Prepared for submission 
 
This work addresses the question of how the two interacting transcription factors Stat5 and 
GR regulate lipid metabolism. In our study, deletion of hepatic Stat5b caused systemic growth 
hormone resistance, while GR deletion resulted in marked hypercortisolism. Surprisingly, the 
combination of GH resistance and hypercortisolism in Stat5/GR mutants led to massive 
peripheral lipodystrophy and fat deposition in the liver. Compound Stat5/GR knockout mice 
displayed rapidly progressive steatosis and steatohepatitis, whereas Stat5 knockout mice 
exhibited only a mild phenotype. Growth hormone (GH)-activated Stat5b effectively 
repressed Srebp1 mRNA transcription, thereby keeping de novo lipogenesis low. Importantly, 
hepatic Stat5b activity is also reduced in patients with steatosis. In summary, our results 
indicate that Stat5 and GR control hepatic lipid metabolism by acting on both liver and 
adipose tissue. 
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(iv) Loss of hepatic Stat5a/b increases HCC incidence and aggressiveness but abrogates 
negative side effects of GH overexpression in a murine inflammatory liver cancer model 
 
 
Katrin Friedbichler, Madeleine Themanns, Kristina Mueller, Jan-Wilhelm Kornfeld, Luigi 
Terracciano, Andrey Kozlov, Susanne Haindl, Tricia Behling, Lukas Kenner, Thomas Kolbe, 
Mathias Müller, Kenneth Snibson, Markus Heim, and Richard Moriggl 
 
Prepared for submission 
 
Using growth hormone transgenic mice (GHtg mice) and conditional knockout mice lacking 
hepatic Stat5 (Stat5Δhep, AlfpCre), we have analyzed the roles of Stat5b in inflammatory liver 
cancer caused by hyperactivated GH signaling. Our study revealed that Stat5b is essential for 
postnatal body growth and that the polymorphic nuclear shape and increased size of 
hepatocytes observed in GHtg mice is clearly dependent on Stat5b. Surprisingly, the tumor 
phenotype in GHtg mice was aggravated upon deletion of Stat5 and was associated with 
increased fat deposition in the liver (hepatosteatosis), which was also observed as a result of 
double knock-out of Stat5 and the GR in the liver. These results suggest that in GHtg mice 
deletion of hepatic Stat5 proteins leads to enhanced tumor formation secondary to increased 
lipid synthesis, loss of hepatoprotective mediators, and compensatory Stat3 activation.
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3. Results 
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Abstract 
 
Stat5 transcription factors are essential gene regulators promoting proliferation, survival, and 
differentiation of all hematopoietic cell types. Mutations or fusions of oncogenic tyrosine 
kinases often result in constitutive Stat5 activation. We have modeled persistent Stat5 activity 
by using an oncogenic Stat5a variant (cS5). To analyze the hitherto unrecognized role of Stat5 
serine phosphorylation in this context, we have generated cS5 constructs with mutated C-
terminal serines 725 and 779, either alone or in combination. Genetic complementation assays 
in primary Stat5null/null mast cells and Stat5N T-cells demonstrated reconstitution of 
proliferation with these mutants. Similarly, an in vivo reconstitution experiment of transduced 
Stat5null/null fetal liver cells transplanted into irradiated wild-type recipients revealed that these 
mutants exhibit biological activity in lineage differentiation. By contrast, the leukemogenic 
potential of cS5 in bone marrow transplants decreased dramatically in cS5 single-serine 
mutants or was completely absent upon loss of both serine phosphorylation sites. Our data 
suggest that Stat5a serine phosphorylation is a prerequisite for cS5-mediated leukemogenesis. 
Hence, interference with Stat5a serine phosphorylation might provide a new therapeutic 
option for leukemia and myeloid dysplasias without affecting major functions of Stat5 in 
normal hematopoiesis. 
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Introduction 
 
Hematopoietic development is regulated by cytokine- or growth factor-activated signaling 
pathways, among which the Janus kinase (Jak)/signal transducer and activator of transcription 
(Stat) pathway plays a major role1-3. Four Jak kinases and seven Stat proteins regulate a wide 
spectrum of cellular functions such as proliferation, survival, and differentiation4. Stats are 
latent transcription factors which constantly shuttle between the nucleus and the cytoplasm. 
Their activity is tightly regulated by protein tyrosine kinases. Phosphorylation of a 
positionally conserved tyrosine residue triggers dimerization, efficient nuclear translocation, 
and subsequent binding of Stats to specific promoter sequences5. Target genes regulated by 
Stat5 proteins and their co-factors are essential for hematopoietic stem cell maintenance, 
lineage commitment, self-renewal and survival of committed hematopoietic progenitors as 
well as for mature cells of both myelo-erythroid and lymphoid lineage6-8. Although there is 
considerable functional overlap, Stat5a and Stat5b proteins also have distinct functions due to 
isoform-specific differences in mRNA levels3,5, nucleo-cytoplasmic shuttling9,10, and 
activation by tyrosine and/or serine phosphorylation11. 
Hyperactivated Stat5a and Stat5b proteins have been implicated in several hematopoietic 
malignancies and many solid tumors1-3. Yet to date, there are no reports of activating 
mutations in Stat5 proteins. Persistent tyrosine phosphorylation of Stat5 was found to be 
caused by deregulated cytokine signaling12 or perturbation of upstream molecules, which 
mostly results from receptor mutations or chromosomal rearrangements. Well-known 
examples of this are the point mutation Jak2-V617F13,14 and chromosomal translocations such 
as Bcr-Abl15,16. Furthermore, it has been shown that the presence of Stat5 proteins is required 
for Bcr-Abl-induced transformation and development of leukemia17. This is why Stat5 
proteins and their activation status are thought to have a key role in leukemogenesis. 
Moreover, the transforming capacity of oncogenic Stat5 is not limited to its role as a 
transcription factor in the nucleus. Recent studies have demonstrated that oncogenic Stat5a 
also has a cytoplasmic role which links Jak/Stat signaling to the activation of the PI3K-Akt-
mTOR signaling pathway via Gab218-20 and that Stat5 acts as a repressor of Bcl-2 member-
regulating miRNAs 15/1621. 
In addition to tyrosine phosphorylation, the activity of several Stat proteins was shown to be 
modulated by serine phosphorylation (reviewed in 22). In the highly homologous Stat5a and 
Stat5b proteins, distinct serine residues in the carboxy-terminal transactivation domain, the 
least conserved region of Stat proteins2,3, were found to be phosphorylated. These serine 
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moieties, however, are located in perfectly conserved PSP motifs at positions 725 (Stat5a) and 
730 (Stat5b)11. In addition, Stat5a harbors a unique serine residue within an LSP motif 
(Ser779)23, which is also found in mouse, rat, pig, and human Stat5a sequences. As shown by 
Beuvink et al., Ser779 is the major site of serine phosphorylation in Stat5a23. However, the 
biological significance of Stat5 serine phosphorylation and particularly its proto-oncogenic 
functions have not yet been clarified. Although serine phosphorylation has been demonstrated 
to substantially modulate the transcriptional activity of Stat1 and Stat3 proteins22, it was long 
thought to have a minor role in Stat5 function11,23-27. Using a mouse transplant model28,29, the 
present study is the first to provide evidence that serine phosphorylation plays a crucial role in 
Stat5-driven leukemogenesis. 
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Materials and Methods 
 
Human patient samples 
Primary leukemic cells were isolated from BM aspirates or PB using Ficoll and washed in 
ice-cold PBS supplemented with complete protease inhibitors (Roche) and phosphatase 
blockers (1 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate). Informed consent was 
obtained in each case prior to PB donation or BM puncture. Characteristics of the patients are 
shown in Supplementary Table 1. For control purposes, two patients with normal BM 
(complete remission from AML after chemotherapy) were examined. The study was approved 
by the institutional review board of the Medical University of Vienna and was conducted in 
accordance with the Declaration of Helsinki. 
 
Animals, primary cell isolation, retroviral infection, proliferation assays and transplantation 
Bone marrow (BM) transplantation BM was harvested from femurs and tibias of 6-week-old 
male mice (C57/B6xSv129j F1) and cultured for 24h in DMEM, 15% FCS containing IL-3 
(R&D Systems, 25 ng/ml), IL-6 (R&D Systems, 50 ng/ml) and SCF (200 ng/ml) (stem cell 
medium, SCM). In the presence of 6 µg/ml of polybrene, cells were subsequently co-cultured 
with confluent ecotropic producer cell lines for 72 hrs in SCM. After 48 hrs of co-culture, BM 
cells were analyzed for GFP expression by flow cytometry. Lethally irradiated (10 Gy) wild-
type (wt) female recipients (C57/B6xSv129j F1) were reconstituted with an equal amount of 
transduced (GFP+) LSK (Lingeage-Sca1+c-Kit+) cells by tail vein injection (6x103). 
Transplanted mice were monitored for disease onset by means of blood analysis at regular 
intervals, starting four weeks after transplantation. All transplanted mice were housed in a 
special pathogen–free environment and monitored daily. The study was performed under the 
animal license form BMWF-66.009/0139-C/GT/2007 according to standard ethical 
guidelines. 
Fetal liver cell transplantation Stat5abnull/null fetal liver cells (CD45.2) were transduced 
with either the vector control or wt Stat5a or the S5-SASA variant. All three groups of cells 
were transplanted into lethally irradiated CD45.1 recipient mice. Two months after 
transplantation, the mice were bled and analyzed for donor engraftment, GFP expression and 
lineage repopulation (CD8, B220, Gr-1 & Ter-119). Donor cells were identified and the 
absolute number of donor-derived cells of the various lineages quantified by means of 
CD45.2 staining30. GFPtg mice served as positive controls. 
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T-cell complementation assay T-cells were isolated from the spleens of 8-week-old 
wild-type and Stat5a/b-deficient (Stat5N/) mice without splenomegaly31,32. Naïve splenic 
T-cells were stimulated with a monoclonal -CD3 antibody (145.2C11; Pharmingen; 1:1000) 
and IL-2 (500 U/ml; R&D Systems). Freshly isolated primary wt as well as Stat5-deficient 
splenocytes were co-cultured with confluent ecotropic producer cell lines for 72 hrs, in the 
presence of 500 U/ml of IL-2 and 6 µg/ml of polybrene. Then the cells were expanded in the 
presence of 500 U/ml of IL-2 for 14 days to enrich for transduced cells. Having reached an 
infection rate of 40-80%, proliferating T-cells were deprived of IL-2 for 18 hrs and 
subsequently incubated as triplicates in round-bottom 96-well plates for 36 hrs at a density of 
1x105 cells per well in medium supplemented with different concentrations of IL-2. In the last 
18 hrs, 3H-thymidine (0.2 µCi/well) as well as a repeat dose of IL-2 were added. The 
proliferation rate was determined by measuring thymidine incorporation with a beta-counter. 
 
Mouse peripheral blood (PB) hematology and FACS 
PB was obtained by puncturing the retro-orbital venous sinus with a microcapillary tube. To 
obtain white blood cell counts (WBC), PB was analyzed using the Vet animal blood counter 
(Scil animal care). For multi-lineage analysis, PB cells were stained with fluorescence-
conjugated antibodies (all from BD Biosciences) against Ter-119 (PE), GR-1 (APC), Mac-1 
(PE-Cy7), CD19 (APC-Cy7), CD3 (PerCp), Sca-1 (PE-Cy7), c-Kit (Cychrome), Flt3 (PE), 
and Thy1 (APC). An Annexin V (PE; BD Biosciences) antibody was used to assess apoptosis 
in transduced Ba/F3 cells. The samples were analyzed by flow cytometry (FACS Canto, 
Becton-Dickinson). 
 
Cell culture, plasmids, transfection of Ba/F3 cells and reagents 
All Stat5a mutants were generated by PCR mutagenesis and verified by sequencing. A 
constitutively active mutant of Stat5a (cS5, also known as S711F33, which in murine Stat5a is 
in fact a mutation of serine 710 to phenylalanine) was used as described previously28,29. Stat5a 
serine mutants were generated by substituting alanines for serines at amino acid positions 725 
and/or 77923. All constructs were cloned into the murine bi-cistronic retroviral vector 
pMSCV-IRES-eGFP. NIH-3T3-based, ecotropic, replication-incompetent, retroviral gp+E86 
producer cell lines were generated and selected for high viral titers (approx. 5x106 
particles/ml as tested in NIH-3T3 cells) by FACS sorting. Producer cells were maintained in 
DMEM, whereas Ba/F3, K562, Ku-812, Mv4.11, and MOLM13 cells were grown in RPMI 
1640. Both media were supplemented with 10% FCS, L-glutamine (2 mM) and 
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penicillin/streptomycin (10 U/ml, 10 µg/ml). Parental Ba/F3 cells were grown in the presence 
of IL-3 (2 ng/ml). 
 
Immunohistochemistry and immunocytochemistry 
Immunohistochemistry was performed on sections prepared from paraffin-embedded 
formalin-fixed spleen, liver, and BM specimens using H&E staining. Blood smears and 
cytospins were stained with the Hemacolor rapid staining kit (Merck). Cytospins were 
prepared at a maximal density of 2x105 cells/ml. Stained sections and cytospins were 
analyzed by light microscopy. Images were captured with a PixeLINK camera and the 
corresponding acquisition software on a Zeiss Imager Z.1 (magnification: ×100, ×200 or 
×400) at a color temperature of 1300K. 
 
Immunoblotting and DNA binding assays 
Sample preparation and Western blotting were performed using standard techniques. Hybond 
nitrocellulose membranes were incubated with antibodies raised against the following 
proteins: phospho-tyrosine-Stat5ab (#05-495, Upstate; #71-6900, Zymed; #9351, Cell 
Signaling), phospho-serine-726/731-Stat5ab (#36153; Abcam), Stat5ab (#610192, BD 
Transduction Laboratories; N20, #836, C17, #835, Santa Cruz), HSC70 (#7298, Santa Cruz, 
loading control), tubulin (#T-9026, Sigma, loading control) and actin (#A5316, Sigma, 
loading control). Polyclonal rabbit sera against phospho-serines 725 and 779 of Stat5a 
(Eurogentech; Stat5a-S725 – H2N-DQAPS(PO3H2)PAVC-CONH2; Stat5a-S779 – H2N-
LDARLS(PO3H2)PPAGLFC-CONH2) were generated and tested by the group of VS. 
Eurogentech antibodies were used unless indicated otherwise. EMSA was performed for 
Stat5a dimers or tetramers using the β-casein response element alone or in tandem as 
described previously2,28. For Stat5 supershifts the C17 antibody (#835, Santa Cruz) was used. 
 
Statistics 
All values are represented as means ± standard deviation if not indicated otherwise. WBC and 
Ba/F3 proliferation quantifications were evaluated for significance using the two-tailed 
student test. A p-value below 0.05 was considered significant for all analyses. Differences 
between experimental groups were considered significant at * p < 0.05, ** p < 0.01 or *** p < 
0.005. Kaplan Meier plots were analyzed for significance using the logrank test. All 
calculations were performed using the GraphPad Prism 4 software. 
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Results 
Stat5a Ser725 and 779 are phosphorylated in human leukemic cell lines and primary 
patient samples 
The association of persistent Stat5 tyrosine phosphorylation with various hematologic 
malignancies is well established. However, there is still little information on the significance 
of serine phosphorylation for the proto-oncogenic functions of Stat5. We, therefore, 
investigated whether Stat5 is at all serine phosphorylated in leukemic cell lines expressing 
highly activated Stat5 as well as in primary patient samples. Specific antisera were generated 
which are directed against the mapped serine phosphorylation sites 725 and 779 of Stat5a, 
flanking the C-terminal transactivation domain34, 35. Two individually derived human chronic 
myeloid leukemia (CML) cell lines (K562 and Ku812) expressing Bcr-Abl p210 fusion kinase 
and two human acute myeloid leukemia (AML) cell lines (Mv4.11 and MOLM13) expressing 
Flt3-ITD and MLL-fusion proteins were analyzed. As shown in Fig.1A, both bcr/abl+ CML 
lines displayed very high levels of Stat5 tyrosine phosphorylation (pY-Stat5), whereas the two 
AML cell lines exhibited lower levels. MOLM13 showed a very weak tyrosine 
phosphorylation signal, which may be attributed to reduced expression of total Stat5 protein. 
Similarly, Stat5a Ser779 phosphorylation, which was pronounced in the CML samples, was 
hardly detectable in the AML cell lines. Contrary, equal levels of Ser725 phosphorylation 
were found in all samples tested. 
Furthermore, different B-cell (REH) and T-ALL- (CCRF-CEM, MOLT-4, Jurkat, HPB-ALL), 
CTCL (cutaneous T-cell lymphoma; Mac-2A) as well as Burkitt lymphoma (DAUDI, 
RAMOS) and non-Burkitt lymphoma (RL-7) cell lines were analyzed for serine 
phosphorylation. All B-cell as well as the Mac-2A and the CCRF-CEM lines were found to 
express significant levels of Ser779 phosphorylation (Fig.1B). Ser725 phosphorylation was 
present to a lesser extent in all T- and B-cell lines except for Jurkat cells. A murine T-cell 
lymphoma line (EL-4), which was also included in the analysis, was positive for Ser725 and 
Ser779 phosphorylation. Interestingly, some cell lines displayed serine phosphorylation in the 
absence of significant pY-Stat5. While both Ser725/779 and tyrosine were phosphorylated in 
Mac-2A, Daudi, and—to a lesser extent—in Ramos and REH cells, there was marked serine 
phosphorylation in the transformed cell lines CCRF-CEM and RL-7 without pY-Stat5. It 
should be noted that the CML line K562 was used as a positive control and the samples were 
transferred to the membranes by semi-dry instead of wet blotting in this assay only. However, 
it was confirmed by a separate experiment that the K562 signals in the Western blots 
displayed in Fig.1A and Fig.1B were consistent (data not shown). 
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Moreover, primary samples from AML, ALL, and CML patients were subjected to Western 
blot analysis and were found to be strongly phosphorylated not only at the critical tyrosine 
694 residue but also at serines 725 and 779, which is unique to Stat5a.  A comparison of 
leukemia patient samples and healthy individuals revealed that Stat5a Ser779 phosphorylation 
was not detected in healthy individuals, whereas serine 725 was found to be phosphorylated 
in all primary samples (Fig.1C). 
 
Fusion proteins regulating Stat5 activity induce Ser725/779 phosphorylation in Ba/F3 
cells 
To substantiate our findings, the well-established hematopoietic Ba/F3 cell line was used. We 
generated several Ba/F3 derivatives expressing various oncogenic mutations known to 
activate Stat5, including Bcr-Abl p210, Tel-Jak1/2/3, Tel-Abl, and oncogenic Stat5a (cS5) 
itself. Expression of these oncogenes rendered the cells capable of growing in the absence of 
IL-3. Starved and stimulated parental Ba/F3 cells as well as Stat5a (S5) overexpressing 
gpE+86 fibroblasts served as controls. As expected, parental Ba/F3 cells, which had been 
starved for 20 hrs, did not display pY-Stat5 phosphorylation. Under these conditions, Stat5 
phosphorylation at the serine sites investigated was insignificant. By contrast, IL-3 
stimulation resulted in highly tyrosine-phosphorylated Stat5 with concomitant 
phosphorylation of Ser725 and Ser779. Similar results were obtained in all Ba/F3 cell lines 
harboring upstream fusion tyrosine kinases. Upon expression of these kinases, strong 
induction of Stat5a Tyr694, Ser725, and Ser779 phosphorylation was observed (Fig.1D). 
Overall, these data suggest that persistent Stat5 activation is associated with Stat5a 
Ser725/779 phosphorylation. 
 
Lack of serine phosphorylation does not alter the biochemical properties of Stat5a 
Different mutant Stat5a variants mimicking persistent Stat5 activation were used to study the 
role of serine phosphorylation in steady-state hematopoiesis and in the context of Stat5 
hyperactivation-driven leukemia. These constitutively active (cS5) and wild-type (S5) Stat5a 
constructs harbored point mutations at two distinct C-terminal serine residues (Ser725 and 
Ser779; Fig.2A). All mutants were subsequently expressed by pMSCV-IRES-eGFP 
retroviruses and packaging cell lines (gpE+86) were generated, which expressed comparably 
high titers of the respective retroviral particles. In gpE+86 cells, expression of serine 
phosphorylation was confirmed at residues Ser725 and Ser779, respectively (data not shown). 
The biochemical properties of all Stat5a variants were assessed to verify their activity. First, 
Results  
55 
activating tyrosine phosphorylation (Y694) of the Stat5a variants was examined in stimulated 
and unstimulated 293T cells co-transfected with the erythropoietin (Epo) receptor (Fig.2B). 
Upon Epo stimulation, activated Stat5 was detected in S5 as well as cS5 constructs. In 
addition, all cS5 proteins showed persistent tyrosine phosphorylation without cytokine 
stimulation. It should be noted that Stat5a is constitutively phosphorylated on both serine 
residues when overexpressed in 293T cells (Suppl.Fig.1). Furthermore, significant differences 
in DNA binding properties were excluded by means of EMSA using the β-casein response 
element (Fig.2C). The cS5 mutants were found to bind DNA even without cytokine 
stimulation and in the absence of serine phosphorylation. In a next step, 2-times Stat5 
responsive elements were used to test the tetramer formation capability of cS5 mutants, which 
is essential for their leukemogenic potential28 (Fig.2D). No significant impairment of tetramer 
formation was observed in the cS5 variants, which all showed enhanced tetramerization on 
the 2x β-casein element compared to wt Stat5a. Interestingly, mutation of either serine 725 or 
779 appeared to enhance tetramer formation, whereas cS5-SASA, similar to wt Stat5a, 
displayed reduced tetramerization, which might be attributed to diminished oligomer stability. 
These experiments confirm intact biochemical activity for all constructs, which prompted us 
to perform cell culture experiments to test their biological activity. 
 
Stat5a serine phosphorylation is not essential for mast cell and T-cell proliferation 
We investigated whether the above-mentioned Stat5a mutants were also capable of 
reconstituting proliferation of primary Stat5-deficient cells, namely Stat5abnull/null mast cells 
and Stat5ΔN/ΔΝ T-cells (Fig.3). For this purpose, mast cells derived from Stat5abnull/null fetal 
livers were transduced with different Stat5a retroviral constructs (Fig.3A). As reported by 
Shelburne et al., 200336, Stat5-deficient mast cells are incapable of proliferating in vitro. 
Retroviral transduction with wt Stat5a and S5-SASA, however, was found to restore 
proliferation and compensate for Stat5 deficiency. This was also true for splenic T-cells 
isolated from Stat5ΔΝ/ΔΝ mice, which fail to proliferate in vitro in response to IL-2 and T-cell 
receptor activation31,32 (Fig.3B). However, re-expression of biologically functional Stat5a 
serine mutants was able to restore T-cell proliferation in culture at levels which were similar 
for all mutants (Fig.3C). It is of note that in the absence of IL-2, T-cells reconstituted with the 
four cS5 mutants showed a higher proliferation rate than cells transduced with wt Stat5a 
constructs. These findings demonstrate that a lack of serine phosphorylation in Stat5a proteins 
does not affect their ability to restore Stat5-induced proliferation. 
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Stat5a serine phosphorylation plays a minor role in lineage repopulation 
To further investigate the role of Stat5a serine phosphorylation in hematopoiesis, an in vivo 
reconstitution assay was performed. Stat5abnull/null fetal liver cells (CD45.2) were transduced 
either with the vector control, with S5 or S5-SASA and transplanted into lethally irradiated 
CD45.1 recipient mice (Fig.3D-G and Suppl.Fig.2A-D). Fetal livers of GFP-transgenic 
animals with intact Stat5 loci were used as controls (Suppl.Fig.2A-D). Analysis of peripheral 
blood (PB) and donor chimerism (CD45.1/CD45.2 system;30) performed 8 weeks after 
transplantation did not reveal significant differences between wt Stat5a and the S5 double-
serine mutant (Fig.3D-G). As in GFPtg controls, more than 80% of peripheral blood cells were 
donor-derived in the two transplant groups (Suppl.Fig.2). Moreover, animals reconstituted 
with S5 and S5-SASA infected fetal liver cells showed comparable numbers of transduced 
(GFP+) donor-derived (CD45.2+) B-cells, T-cells, granulocytes, and erythrocytes. As 
compared to the vector control (Suppl.Fig.2), Stat5 deficiency was best compensated for in B-
cell and erythroid lineages. The two Stat5a variants also compensated for Stat5 deficiency in 
CD8+ cells, though to a lesser extent which might be attributable to the lack of Stat5b. In the 
granulocyte lineage, reconstitution with Stat5a did not have significant beneficial effects. 
These results indicate that—relative to vector controls—both Stat5a proteins are functional 
with respect to lineage repopulation. 
 
Constitutively active Stat5a confers factor-independent survival of Ba/F3 cells only in 
the presence of Ser725/779 moieties 
When we analyzed selected aspects of normal Stat5 function, Stat5a serine phosphorylation 
was not found to be of crucial importance. Therefore, we decided to investigate whether 
serine phosphorylation is required for the transforming capacity of persistently tyrosine 
phosphorylated Stat5a, particularly in view of our findings in human leukemic cell lines. 
Constitutive activation of Stat5 is known to provide survival and proliferation stimuli that 
result in cytokine-independent cell expansion1. Hence, all cS5 mutants and the S5 construct 
were expressed in factor-dependent Ba/F3 cells to assess their ability to confer factor-
independent proliferation (Fig.4A). Upon cytokine withdrawal, only cells harboring the 
constitutively active Stat5a mutant with intact serine phosphorylation sites were able to 
survive (Fig.4B). All other cS5 derivatives underwent apoptosis (Fig.4C), despite the fact that 
they displayed constitutive phosphorylation of Y694 in the absence of IL-3 (Fig.4D). Thus, 
cS5 serine mutants exhibit a behavior similar to that of parental BaF/3 and S5-transduced 
cells (Fig. 4B+4C). These data suggest that, in addition to the constitutive activity of the cS5 
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mutant, phosphorylation of both serine residues is required to abolish IL-3 dependence of 
Ba/F3 cells. 
 
Loss of serine phosphorylation delays disease onset in transplanted mice 
Since loss of serine phosphorylation proved to have a strong impact on the transforming 
capacity of oncogenic Stat5a in Ba/F3 cells, we investigated its role in a multi-lineage 
leukemia transplant model. All constitutively active Stat5a mutants were retrovirally 
transduced into wt BM cells and an equal number of transduced LSK-cells (Suppl.Table 2) 
was transplanted into lethally irradiated mice. Flow cytometric analyses of transduced BM 
cells revealed no lineage skewing due to ectopic expression of any of the retroviral constructs 
(Suppl.Table 2). Strikingly, periodic analysis of PB over 40 weeks demonstrated that mice 
which had been transplanted with cS5 serine mutants remained disease-free for significantly 
longer periods than those animals that had received cS5-infected BM cells (Fig.5A). While 
cS5-transplanted mice succumbed to leukemia within 10 weeks after BM transplantation, 
single serine mutants developed signs of disease only four months after transplantation. 
Notably, cS5-SASA-transplanted mice remained disease-free throughout the period of 
analysis (40 weeks), even though GFP+ cells were detected in the PB of all transplant groups. 
Multi-lineage leukemia in cS5-transplanted mice28 was marked by a tremendous increase in 
white blood cells (WBC), ranging from 15.000 to 120.000 cells/ml at 8 weeks after 
transplantation (Fig.5B, left panel). FACS analysis demonstrated that this increase was due to 
myelodysplasia, which was first observed at 4 weeks after transplantation. A dramatic rise in 
the number of GFP+ myeloid cells was detected not only in PB but also in the bone marrow 
and spleen (Fig.5C & Suppl.Fig.3A). Histologically, myelodysplasia in cS5-transplanted mice 
was confirmed by blood smears and sections of the liver, spleen, and BM at 8 weeks after 
transplantation28 (Fig.6A). 
By contrast, no signs of disease were detectable at 8 weeks after transplantation in animals 
that had received BM infected with cS5 serine mutants. As measured in the PB, their WBC 
counts were in the range of those seen in mice transplanted with the vector control (Fig.5B; 
left panel). In flow cytometry analysis, all serine mutants showed a significant number of 
GFP+ cells, most of which were CD3+ lymphoid cells and Gr-1+ myeloid cells (Fig.5C; left 
panel). At 8 weeks after transplantation, histologic analysis of mice injected with serine 
mutants yielded similar results as for vector controls (Fig.6A). Even at 32 weeks after 
transplantation, the WBC counts of single-serine mutants were only slightly elevated 
compared to vector controls (Fig.5B; right panel). However, the overall percentage of GFP+ 
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cells in Stat5a single-serine mutants increased to 30-40% of WBCs. Both in the PB and in the 
spleen, this increase was more pronounced in the CD3+ and Gr-1+ population than in the Gr-
1+ Mac-1+ myeloid cells (Fig.5C; right panel & Suppl.Fig.3A). The absence of GFP+ Gr-1+ 
Mac-1+ myeloid cells in PB cannot be explained by an altered total number of myeloid cells at 
any point of analysis because it was not different from that observed in vector controls 
(Suppl.Table 3). Interestingly, the total number of lymphoid cells in the PB of single-serine 
mutants was not affected by the increase in GFP+ cells either. Conversely, the increase in 
GFP+ cells in terminally ill cS5-transplanted mice resulted in a higher total number of 
myeloid cells. In the BM of both single-serine transplant groups the number of GFP+ cells 
was too low to be assigned to a specific lineage (Suppl.Fig.3A). This was also true for all 
samples obtained from cS5-SASA-transplanted mice (Fig.5C; right panel & Suppl.Fig.3A). 
No increase in the GFP+ population was seen in vector controls (Fig.5C; right panel & data 
not shown for BM and spleen). At 32 weeks, an increased number of lymphoid cells was also 
detected in the blood smears of cS5 single-serine mutants (Fig.6B). When comparing the two 
mutants, cS5-S725A-transplanted mice were found to have a slightly stronger disease 
phenotype with additional disruption of spleen architecture and infiltration of the liver by 
hematopoietic cells. cS5-SASA-transplanted mice did not show any signs of disease 
throughout the period of analysis (40 weeks). In Western blot analyses, significant Stat5a 
Ser779 phosphorylation was detected in the spleens of diseased cS5 and cS5-S725A mice, 
whereas there was no significant Stat5 serine phosphorylation in cS5-S779A-transplanted 
mice and disease-free animals (Suppl.Fig.3B). It should be noted that the difference in Ser779 
phosphorylation levels of the two cS5 mice was due to their different disease stages. Since the 
lack of C-terminal serine phosphorylation was found to prolong disease-free survival in mice, 
these results strongly suggest a role of Stat5 serine phosphorylation in myeloid dysplasia. 
 
 
Discussion 
Constitutive activation of Stat5 was shown to be directly involved in oncogenic 
transformation1-3. In addition to activating tyrosine phosphorylation, serine phosphorylation 
has been found in most Stat proteins. The latter has been shown to be important for maximal 
transcriptional activity of Stat1/3/4 but not of Stat5a and Stat5b22. Biochemical and biological 
functions of Stat serine phosphorylation also include DNA binding23,37, co-factor 
association38, immune responses39,40, and transformation41,42. Interestingly, we found the C-
terminally mapped serines of Stat5a (Ser725/779) to be highly phosphorylated in human 
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bcr/abl+ CML samples, human lymphoma cell lines, primary leukemia patient samples, and 
Ba/F3 cells overexpressing different fusion tyrosine kinases. It is of note that strong Ser779 
phosphorylation was detected in primary AML, ALL, and CML patient samples but not in 
healthy individuals. These findings suggest that Stat5a serine phosphorylation may have an 
essential role in hematopoietic transformation. 
To evaluate the importance of Stat5a serine phosphorylation at residues 779 and 725 for 
hematopoietic cells, different wt (S5) and point-mutated hyperactive Stat5a (cS5) variants 
exhibiting intact biochemical activity were used. Notably, all hyperactivated mutants showed 
the same capacity to form tetramers, which is essential for the leukemogenic potential of 
Stat528. Similar to serine mutants of human Stat5a43, all wt and hyperactive constructs were 
able to rescue the phenotype of primary Stat5-deficient splenocytes. Likewise, reconstitution 
of lethally irradiated mice with Stat5-deficient fetal liver cells harboring the double-serine 
mutant of wt Stat5a resulted in lineage repopulation comparable to that seen in mice 
transplanted with Stat5a-transduced fetal liver cells. As in Stat5ab-/- animals17,44-46, 
transplantation of Stat5null/null fetal livers induced lymphopenia and anemia. Unlike vector 
controls, both Stat5a variants were able to compensate for Stat5 deficiency in B-, T- and 
erythroid cell lineages. These data suggest that serine phosphorylation has only a minor role 
in normal hematopoiesis, which is in line with previous reports11,23-25. Yet, the significance of 
serine phosphorylation for other aspects of hematopoiesis, such as homing, migration, and 
stress hematopoiesis still remains to be elucidated. 
Intriguingly, the present study revealed that phosphorylation of both serines is a prerequisite 
for factor-independent growth of Ba/F3 cells. Mutation of either of the two serine residues 
was found to abolish factor-independent survival of Ba/F3 cells, even though Stat5 was highly 
tyrosine phosphorylated. This suggests that Stat5a serine phosphorylation is essential for the 
transformation of hematopoietic cells. Indeed, loss of Stat5a serine phosphorylation had a 
strong impact on the transforming capacity of constitutively active Stat5a in a BM transplant 
model. Substitution of a single C-terminal serine by alanine proved sufficient to significantly 
delay disease onset in cS5-transplanted mice, while mutation of both C-terminal serines 
abrogated leukemia development. Retroviral integration of all retroviral cS5-constructs 
including cS5-SASA was verified in splenocytes of transplanted mice (by sequencing 
retroviral insertion; data not shown) and GFP+ cells were traceable in all animals throughout 
the period of analysis. Interestingly, we observed a lineage shift in mice transplanted with 
serine-mutant cS5 variants. The serine mutants did not show expansion of the myeloid 
lineage, as was observed in cS5 transplanted animals, but an increase in CD3+ population. 
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This was not due to a reduction in the total number of myeloid cells, which was similar to that 
found in vector controls. Presumably, it was the shift of GFP expression to the lymphoid 
lineage that prevented myeloid expansion and thus rapid onset of disease. Skewing to specific 
lineages and differences in transduction rates during the initial culturing and infection phase 
were precluded by administering the same number of transduced LSK-cells to each animal. 
The reduced transforming capacity of cS5 serine mutants might be explained by alterations in 
the transcriptional profile. The serine phosphorylation sites are in close vicinity to the 
amphipathic α-helix within the transactivation domain of Stat5a, which is negatively 
charged34. Stat5a and Stat5b contain only weak transactivation domains34,47. This is why 
Stat5-mediated transcription requires binding of factors that co-regulate gene expression cell 
specifically34. Serine phosphorylation at the C-terminal tail of Stat5 proteins might be 
essential for creating a more acidic, negatively charged surface which is able to attract 
positively charged co-factors or other transcription factors. Alternatively, unknown factors 
such as different cellular location of Stat5a41,48 or altered accessibility for tyrosine 
phosphatases might contribute to the reduced transforming capacity of serine mutants. 
In conclusion, our data suggest that Stat5a Ser725/779 phosphorylation is indispensible for 
hematopoietic transformation. As it is not conserved in Stat5b, the region of Stat5a 
encompassing Ser779 might provide a particularly attractive target for future therapeutic 
strategies in leukemia and myeloid dysplasias. Thus, identification of the kinase responsible 
for phosphorylating Ser779 in Stat5a would be the first essential step towards the 
development of a suitable inhibitor. Unlike Stat1 and Stat3, Stat5 proteins are not considered 
substrates of extracellular signal-regulated kinases (ERKs) that bind to PSP motifs24,49,50. 
Hence, Stat5 regulation may be different from that of other Stats51. There are several kinases 
that may control Stat5a serine phosphorylation, including stress kinases, CDKs, and Pim 
kinases. Elucidating the impact of eliminating serine phosphorylation in transformed cells 
might, therefore, be a step forward in the development of a novel therapeutic concept for 
hematopoietic malignancies which has no major side effects on normal hematopoiesis.  
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Figures and Figure Legends 
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Figure 1: Ser725/779 residues are significantly phosphorylated in transformed cell lines and primary 
samples from leukemia patients. 
(A) The C-terminal serine residues 725 and 779 of Stat5a were found to be considerably 
phosphorylated in human leukemic cell-lines. K562 and Ku-812 were used as representative CML 
samples, and Mv4.11 and MOLM13 for AML. In Western blot analysis, Ser779 was found to be 
phosphorylated predominantly in CML samples, whereas Ser725 phosphorylation (Abcam 
antibody) was detected in all leukemia cell lines. S5-expressing gpE+86 fibroblasts served as 
controls. A representative blot of three independent experiments was chosen.  
(B) Different transformed human T- and B-cell lines, Mac-2A (CTCL), MOLT-4, CCRF-CEM 
Jurkat, HPB-ALL (all T-ALL) as well as DAUDI and RAMOS cells (Burkitt-lymphoma), REH 
(B-ALL) and RL-7 (non-Burkitt lymphoma) cell lines were analyzed for serine phosphorylation 
by Western blot. Daudi cells as well as CCRF-CEM and Mac-2A cells were found to be strongly 
positive for Ser725 (Eurogentech & Abcam) and Ser779 phosphorylation. While Mac-2A, Daudi, 
and— to a lesser extent— in Ramos and REH cells showed Ser779 phosphorylation in addition to 
Tyr-phosphorylation, Ser779 phosphorylation was largely independent of Tyr-phosphorylation in 
CCRF-CEM and RL-7 cells. In all B cell lines except Daudi cells, Ser725 phosphorylation was 
very low but clearly detectable. A murine T-cell lymphoma line (EL-4) was included in the 
analysis; it was positive for Ser779 phosphorylation, which was independent of Tyr-
phosphorylation. The CML line K562 was used as positive control. Similar results were obtained 
in three individual experiments.  
(C) Protein analysis of primary samples from AML (n=4), ALL (n=2), and CML (n=2) patients as 
well as from healthy individuals (n=2) revealed that Stat5a and Stat5b are strongly phosphorylated 
not only at the critical tyrosine 694 residue but also at serine 725, and Stat5a additionally at serine 
779. Serine 779 phosphorylation was not detected in healthy individuals, whereas serine 725 was 
found to be phosphorylated in all samples tested. GpE+86 cells expressing S5 were used as 
controls for all analyses. The experiments were performed in duplicate. 
(D) Ba/F3 cells were engineered by retroviral transduction to overexpress the cS5 variant as well 
as fusion kinases which are known to activate Stat5a and Stat5b in human patients. Modified 
Ba/F3 cells were subjected to immunoblot analysis to evaluate Stat5 tyrosine and serine 
phosphorylation. Ser725 (Abcam antibody) and Ser779 were strongly phosphorylated in all 
factor- independent lines. Parental Ba/F3 cells starved for 20 hrs and cells re-stimulated with IL-3 
as well as S5-expressing gpE+86 fibroblasts served as controls (exposed on the same blot; 
interjacent bands were cut). The blots are representatives of four individual experiments. 
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Figure 2: Stat5a mutants exhibit unchanged biochemical properties. 
(A) Schematic representation of mutant Stat5a proteins. The oncogenic Stat5a mutant cS5 contains a Ser to Phe 
mutation at position 710, which renders it constitutively active. The Stat5a mutants S725A, S779A, and SASA 
carry single or double Ser to Ala substitutions. (B) 293T cells were transfected with the wt (S5) and hyperactive 
(cS5) mutant Stat5a constructs indicated and stimulated via the erythropoietin (Epo) receptor. Cells were treated 
(+) with 50 U of Epo or left untreated (-). Whole cell extracts were prepared and subjected to Western blot 
analysis to evaluate tyrosine phosphorylation. (C) Erythropoietin-stimulated extracts from (B) were subjected to 
EMSA using the β-casein site to study the DNA binding properties of the different wt Stat5a and hyperactive 
Stat5a mutants. Equal dimer activity was established before analyzing the extracts in tetramer assays as 
described previously2,28. (D) Tetramer formation of the Stat5a mutants indicated was analyzed with Epo-
stimulated 293T cell extracts from (B) using a 2x β-casein binding element. All Stat5a derivatives were found to 
bind to the site as tetramers. Compared to dimers, tetramers were more stable towards competition by cold DNA. 
The absence of cold DNA (0) represents the saturated binding reaction. This was followed by a 100x 
competition by cold DNA for 5, 10, and 25 min. cS5, cS5-S725A and cS5-S779A form tetramers with enhanced 
DNA binding activity, which was in contrast to wt Stat5a (S5) and cS5-SASA. The data are representative for 
three individual transfections. 
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Figure 3: Wild-type and constitutively active Stat5a mutants show full biological activity in Stat5ab-
deficient cells and in a fetal-liver cell transplant. 
(A) Mast cells derived from Stat5abnull/null fetal livers were transduced with Stat5a-expressing retroviral vectors. 
Following transduction, the percentage of GFP+ cells was assessed at various points of time. The results obtained 
on days 3, 5, and 8 and those of days 10, 14, and 16 are summarized in “week1” and “week2”, respectively. 
Uninfected cells were used as negative controls without retroviral vector. (B) Unlike primary wt splenocytes, 
primary Stat5ΔN/ΔN T-cells were not able to proliferate in response to saturating doses of IL-2 and T-cell receptor 
activation by α-CD331. The values given are representative of 6 independent measurements ± SEM. (C) 
Thymidine incorporation assay of starved and IL-2 re-stimulated T-cells. Primary Stat5-deficient T-cells 
(Stat5ΔN/ΔN) were transduced with different retroviral Stat5a constructs labeled with a GFP marker. When 
Stat5ΔN/ΔN T-cells were reconstituted with wt Stat5a or a biologically functional Stat5a mutant, they fully 
regained their proliferation capacity, while non-infected cells underwent apoptosis. All wt and constitutively 
active Stat5a mutants were able to rescue the proliferation defect of Stat5ΔN/ΔN T-cells. In contrast to wt mutants, 
cS5 mutants showed slightly increased thymidine incorporation even without cytokine stimulation. The results 
represent four independent experiments. 
(D-G) Stat5abnull/null fetal livers (CD45.2) were retrovirally transduced with wild-type Stat5a (S5) and S5-SASA 
vectors and transplanted into lethally irradiated CD45.1 recipients. Mice were bled 8 weeks after transplantation 
and analyzed by FACS for donor engraftment (CD45.2)30, GFP expression, and lineage repopulation. 
Repopulating capacity was assessed for (D) B-cells (B220) as well as for (E) T-cells (CD8), (F) granulocytes 
(Gr-1) and (G) erythrocytes (Ter119). For each lineage, marker expression was plotted against GFP expression 
(left), GFP expression against CD45.2 expression of the donor (middle), and marker against CD45.2 expression 
(right). Both S5 and S5-SASA-reconstituted animals exhibited normal hematopoiesis in all lineages analyzed 
(n=2 per group). 
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Figure 4: cS5 confers factor-independent survival in the presence of intact serine phosphorylation only. 
(A) Growth factor-dependent Ba/F3 cells were transduced with the different cS5 constructs and wt Stat5a as 
indicated and FACS-sorted for GFP+ cells. Upon IL-3 withdrawal, apoptosis was analyzed by FACS using an 
Annexin V antibody at 72 hrs and at 7 days. cS5-expressing cells were the only ones able to survive without 
cytokine stimulation. All other mutants underwent apoptosis following factor depletion in three individual 
experiments. (B) Transduced and FACS-sorted Ba/F3 cells were analyzed for GFP expression by flow cytometry 
and showed a consistently high percentage of GFP+ cells. (C) Representative cytospins of IL-3-dependent Ba/F3 
cells transduced with the indicated Stat5a variants and kept in medium with/without addition of IL-3. After 7 
days, all transduced cells proliferated in the presence of cytokine. However, only cS5-transduced Ba/F3 cells 
were repeatedly able to grow independent of IL-3. Cells transduced with wt Stat5a, cS5-S725A, cS5-S779A, and 
cS5-SASA were not transformed to factor independence and underwent apoptosis, similar to untransduced Ba/F3 
controls without IL-3. (D) Cell lysates from sorted GFP+ cells were prepared and analyzed by immunoblotting 
with the indicated antibodies. Parental Ba/F3 cells showed weak expression of total Stat5, which was strongly 
tyrosine phosphorylated upon IL-3 stimulation. In all Ba/F3 cells transduced with the different cS5 constructs, 
Stat5 was highly tyrosine phosphorylated in the absence of cytokine stimulation. 
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Figure 5: Loss of Stat5a serine-phosphorylation delays disease onset in transplanted mice. 
(A) Kaplan-Meier plot of cS5 vs. cS5-S725A-, cS5-S779A-, and cS5-SASA-transplanted mice. GFP vector-
transplanted mice were included as controls. All cS5-transplanted mice died within 10 weeks. In contrast, cS5-
SASA-transplanted mice remained disease-free and disease onset in cS5 single serine mutants was significantly 
delayed (p<0.0001). All groups were monitored over a period of 40 weeks after which all mice were sacrificed 
and analyzed (n≥8). (B) WBC count of transplanted mice at 8 weeks (left) and 32 weeks after transplantation 
(right). PB hematology revealed a dramatic increase in WBC in cS5-transplanted mice after 8 weeks. By 
contrast, all serine mutants showed a slight increase in WBCs after 32 weeks only. (C) FACS analysis of PB for 
representative cS5 vs. cS5-S725A-, cS5-S779A, and cS5-SASA-transplanted mice at 8 and 32 weeks after BM 
transplantation. The overall number of GFP+ cells is displayed in the histogram. All cS5-transplanted mice were 
found to present with severe myelodysplasia when GFP+ cells were gated for lymphoid (CD3 and CD19) and 
myeloid (Gr-1 and Mac-1/CD11b) markers, respectively. Conversely, all serine mutants showed an increase in 
GFP+ lymphoid cells (mainly CD3+ cells) and in Gr-1+ cells. 
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Figure 6: Alterations of organotypic structures in cS5-transplanted mice and cS5 serine mutants 
(A) At 8 weeks after BM transplantation, histopathologic analysis of PB, liver, spleen, and BM revealed signs of 
leukemia in cS5-transplanted mice, including elevated numbers of myeloid and lymphoid cells in the PB and 
disruption of spleen germinal center architecture with concomitant splenomegaly. Additionally, the liver portal 
tracts and parts of the liver parenchyma in these mice were diffusely infiltrated by hematopoietic cells. Blast-like 
cells were detected in the BM. Contrary, mice transplanted with cS5 serine mutants did not show any 
abnormalities and histologically resembled the MSCV vector controls. (B) At 32 weeks after transplantation, 
mice transplanted with cS5 single-serine mutants showed increased numbers of lymphoid cells in PB, with cS5-
S725A-transplanted mice displaying a stronger phenotype characterized by disruption of the splenic architecture 
and infiltration of the liver by hematopoietic cells. cS5-SASA-transplanted mice did not show any signs of 
disease throughout the period of analysis. For each transplant group, a minimum of 8 mice was analyzed, which 
all displayed similar histologic features (magnifications: spleen 100x; liver 200x, BM and blood smear 400x). 
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Supplementary Table 1: Detailed patient data 
Primary human leukemic cells were obtained from BM or PB of four patients with AML, two patients with Ph- 
ALL, and two patients with CML in chronic phase (all samples were obtained at the time of diagnosis). Control 
samples were taken from AML patients in complete remission. The diagnoses were made according to FAB 
criteria. 
* Transient increase in blasts shortly after chemotherapy. 
Abbreviations used: AML, acute myeloid leukemia; sAML, secondary AML after myelodysplastic syndrome; 
ALL, acute lymphoblastic leukemia; Ph- c-ALL, Philadelphia negative common ALL; Ph- pre-B-ALL, 
Philadelphia negative pre-B-ALL; CML, chronic myeloid leukemia; CR, complete remission; CP, chronic phase; 
M2, acute myeloblastic leukemia, with maturation; M5, acute monoblastic leukemia; WBC, white blood cell 
count; PB, peripheral blood; BM, bone marrow; complex karyotype, ≥ three chromosomal abnormalities. 
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Supplementary Table 2: Infection rates of transduced bone marrow cells after 48 hours 
The percentages of GFP+ cells in donor BM are listed after 48 hrs of co-culture with the respective producer 
cells. The percentages of total GFP+ BM cells are presented in the first column, those of GFP+ cells of the 
lymphoid lineage in the second, and of the myeloid lineage in the third. In the fourth column, the percentages of 
GFP+ lymphoid progenitors and in the fifth column the percentages of GFP+ myeloid progenitors are displayed 
relative to all progenitor cells. The percentages of GFP+ hematopoietic stem cells are shown in the last column. 
The data represent four individual experiments. 
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Supplementary Table 3: Total numbers of lymphoid and myeloid cells in the peripheral blood of 
transplanted mice 
The percentages of lymphoid and myeloid cells in the PB of all transplant groups are shown at 8 and 32 weeks as 
analyzed by flow cytometry. The number of myeloid cells is clearly increased in diseased cS5-transplanted mice 
(8 weeks), whereas it is unchanged in all serine mutants (n≥8). 
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Supplementary Figure 1: Stat5 is constitutively phosphorylated on Ser725 and Ser779 when expressed in 
293T cells 
293T cells were transfected with wt Stat5a (S5) and stimulated via the erythropoietin (Epo) receptor. Cells were 
treated (+) with 50 U of Epo or left untreated (-). Whole cell extracts were prepared and subjected to Western 
blot analysis to evaluate tyrosine and Ser725/779 phosphorylation. GpE+86 cells expressing wt Stat5a were used 
as positive control. 
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Supplementary Figure 2: Control animals used in the Stat5null/null fetal-liver transplant 
Stat5abnull/null fetal livers (CD45.2) were retrovirally transduced with MSC vector and transplanted into lethally 
irradiated CD45.1 recipients. Fetal livers of GFP-transgenic mice harboring an intact Stat5 locus were used as 
controls. Mice were bled 8 weeks after transplantation and analyzed by FACS for donor engraftment (CD45.2), 
GFP expression, and lineage repopulation. Repopulating capacity was assessed for (A) B-cells (B220), (B) T-
cells (CD8), (C) granulocytes (Gr-1), and (D) erythrocytes (Ter119). For each lineage, marker expression was 
plotted against GFP expression (left), GFP expression against CD45.2 expression of the donor (center), and 
marker against CD45.2 expression (right). Mice receiving vector-transduced Stat5abnull/null fetal liver cells 
displayed a lymphopenic and anemic phenotype. GFPtg mice served as controls for normal lineage composition 
(n=2 per group). 
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Supplementary Figure 3: Analysis of PB, BM, and spleens from transplanted mice at the time of sacrifice 
(A) FACS analysis of BM and spleen samples from representative cS5-, cS5-S725A-, cS5-S7279A-, and cS5-
SASA-transplanted mice at the time of sacrifice. In cS5-transplanted mice, there was a marked increase in GFP+ 
myeloid cells, not only in PB but also in the bone marrow and spleen. In cS5 single-serine mutants, the increase 
in GFP+ lymphoid cells, which was seen in the PB, was less pronounced in the bone marrow and spleen. In cS5-
SASA-transplanted animals, there was significant, albeit low GFP expression in the bone marrow and spleen at 
the endpoint of analysis. (B) The spleens of transplanted mice were subjected to Western blot analysis to 
determine Stat5a serine phosphorylation. Strong Ser779 phosphorylation was detected in diseased cS5- and cS5-
S725A-transplanted mice, whereas Ser725 was only weakly phosphorylated in cS5-reconstituted mice. A 
stronger signal for Ser779 phosphorylation was obtained in terminally diseased cS5 mice exhibiting high WBCs 
and expressing a high percentage of GFP+ cells, while a weaker signal was seen in mice with lower WBCs and 
lower GFP expression. No serine phosphorylation signal was detected in diseased cS5-S779A-transplanted mice 
and all healthy animals tested. GpE+86 fibroblasts expressing exogenous S5 were used as positive control. All 
samples were exposed on the same blot but the membrane was cut to present the data more clearly. Similar 
results were obtained in three independent analyses. 
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Abstract 
 
Hepatic steatosis is one hallmark of non-alcoholic fatty liver disease (NAFLD), which is the 
most common chronic liver disease in the western world. Growth hormone (GH) is a pivotal 
hormone in regulating postnatal growth and energy metabolism. Glucocorticoids (GC) play an 
essential role in glucose homeostasis as well as in response to physiological and metabolic 
stress. GH-activated Stat5 and GC-triggered glucocorticoid receptor (GR) activation were 
shown to interact in the transcriptional control of genes important for postnatal body growth. 
Here, we address the question how Stat5 and GR proteins regulate lipid metabolism. Control 
and GR knockout mice displayed normal liver morphology, whereas steatosis and 
hepatomegaly were observed in Stat5 and Stat5/GR mutants. While steatosis in the Stat5 
mutants remained mild, compound deletion of Stat5 and GR induced severe, progressive 
steatosis and steatohepatitis. Loss of hepatic Stat5 caused systemic growth hormone resistance 
and GR deletion resulted in prominent hypercortisolism. Interestingly, the combination of 
both conditions in Stat5/GR mutants led to massive peripheral lipodystrophy and hepatic fat 
delivery. Genes involved in lipogenesis were induced in Stat5 deleted livers, possibly as a 
result of enhanced expression of the key regulators in triglyceride synthesis sterol regulatory 
element binding protein 1 (Srebp-1) and peroxisome proliferator receptor (Pparg). GH-
activated Stat5b was shown to interact with the promoter of Srebp-1 and efficiently represses 
Srebp-1 mRNA transcription in vivo. Importantly, hepatic Stat5b activity is also reduced in 
steatotic patients. Conclusion: Here, we show that Stat5 and GR do not synergistically control 
hepatic lipid metabolism. While GH-Stat5 signaling alone is essential for normal intrahepatic 
lipid metabolism, activation of both signaling pathways stimulate regional lipolysis and 
hepatic FFA flux in an additive manner. 
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Introduction 
 
Hepatic steatosis is estimated to impact ~25% of the Western population (Angulo, 2002) and 
is related in many cases with insulin resistance and type II diabetes. Steatosis is usually the 
first manifestation of non-alcoholic fatty liver disease (NAFLD). Under certain circumstances 
it may lead to cirrhosis, inflammation and even liver cancer (Torres and Harrison, 2008). The 
onset of steatosis is closely associated with obesity and insulin resistance (Utzschneider and 
Kahn, 2006) and it is regarded as hepatic manifestation of the metabolic syndrome 
(Marchesini et al., 2003). The causal relationship between these metabolic disorders, 
however, remains controversial (Monetti et al., 2007). Steatosis can either result from 
excessive fatty acid (FA) synthesis relative to oxidative clearance (Bradbury and Berk, 2004). 
Alternatively, elevated lipid hydrolysation in the adipose tissue or impaired hepatic release of 
lipids can lead to the net deposition of fat in hepatocytes (Bradbury, 2006). FA synthesis, 
clearance and release are, among others, regulated by neuroendocrine factors such as growth 
hormone (GH) or glucocorticoids (GC), which mediate signals to modulate multiple processes 
including growth, digestion, energy supply and adipose tissue turnover. Stat5a and Stat5b are 
broadly expressed transcription factors, which mediate the body’s response to numerous 
cytokines such as GH (Kornfeld et al., 2008), although the liver was shown to predominantly 
express the Stat5b isoform. Activation and loss-of-function studies have demonstrated the 
critical role of hepatic Stat5b in the GH-driven regulation of postnatal body growth, largely 
attributed to the transcription of IGF-1 (insulin-like growth factor-1) in hepatocytes (Kornfeld 
et al., 2008; Yakar et al., 2002). We have recently shown that hepatic GR acts as a cofactor 
for Stat5b, binding its N-terminus upon GH activation and supporting IGF-1 transcription 
(Engblom et al., 2007). Disruption of this STAT5-GR protein interaction led to defects in 
postnatal body growth (Engblom et al., 2007; Tronche et al., 2004). Furthermore, genes 
involved in sexual dimorphism and detoxification have been shown to be regulated by this 
synergistic STAT5-GR axis (Engblom et al., 2007). Apart from mediating the growth-
promoting effects of GH, IGF-1 has additional metabolic effects, e.g. inhibiting the 
hypothalamic release of lipolytic GH (Teglund et al., 1998; Udy et al., 1997). Impairment of 
this auto-inhibitory GH-IGF-1 feedback loop (Woelfle et al., 2003) leads to GH resistance, a 
condition that is characterized by low levels of liver-derived IGF-1 and high serum 
concentrations of lipolytic GH. Stat5 has been implicated in this process, because Stat5-
deficient mouse models exhibit characteristic serum alterations reminiscent of GH Resistance 
(Teglund et al., 1998; Udy et al., 1997). Clinically, GH resistance is of rising interest since it 
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is tightly associated with the metabolic syndrome (Johannsson and Bengtsson, 1999). The 
stress mediator GC constitutes another critical arm of the HPA axis. Like GH, they regulate 
their own secretion through an autocrine negative feedback loop, the impairment of which 
leads to hypercortisolism (Garrapa et al., 2001). Coupling GC resistance to a pre-existing GH 
resistance has been reported to induce massive increases in hormone-sensitive-lipase (HSL)-
mediated fat tissue lipolysis in vitro (Fain et al., 2008). We identified novel roles for Stat5 in 
regulating hepatic lipid homeostasis via the transcriptional repression of Srebp-1. The clinical 
importance of Stat5b in regulating hepatic lipid metabolism was supported by the observation 
that human steatosis samples showed reduced levels of Stat5b activity. Compound deletion of 
Stat5 and the GR led to an aggravation of disease due to the combination of GH resistance 
and hypercortisolism causing depletion of peripheral adipose stores (lipodystrophy) and the 
concomitant fat delivery to the liver. This redistribution of body fat exacerbated the 
underlying steatosis and resulted in late-stage liver conditions such as steatohepatitis at young 
ages. 
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Materials and Methods 
 
Animals 
Mutant mice carrying hepatocyte-specific deletion of the glucocorticoid receptor (GRKO), 
Stat5 (S5KO) or both (DKO) were generated and maintained on a mixed background as 
described (Tronche et al., 2004). Mice not harboring the cre recombinase served as controls 
(Control). Mice were kept at the Decentralized Biomedical Facilities, Medical University of 
Vienna (MUW) under standardized conditions, and all animal experiments were carried out 
according to an ethical animal license protocol and contract approved by the MUW and the 
Austrian Ministry (BMBWK) authorities. Mice were fed a standard diet for nursing pups 
(Ssniff EF, R/M Kontrolle, Sniff GmbH). The nutrient composition as indicated by the 
manufacturer was: 22.1% raw protein, 4.5% raw fat, 46.8% starch and 108 % glucose.  
 
Quantitative Reverse Transcription Polymerase Chain Reaction  
For quantitative reverse transcription polymerase chain reaction (qRT-PCR), one microgram 
of total RNA was reverse-transcribed into complementary DNA using a commercially 
available kit (Applied Biosystems). PCR products were obtained using gene-specific, intron-
spanning primers. The SYBR green method was used for quantification of the PCR product 
and relative messenger RNA abundance was calculated using the ∆Ct-method. Messenger 
RNA (mRNA) levels were normalized to murine GAPDH. Primers sequences are available 
upon request. 
 
Histology and Immunohistochemistry 
Tissues were removed quickly and fixed in 4% phosphate-buffered formalin for 48 hrs 
followed by embedding into paraffin using standard procedures. Sections (2-4 μm thick) were 
cut and stained with hematoxylin and eosine (HE) for standard histology. Hepatic lipids were 
visualized on cryosections (5 μm thick) by staining with the lipophillic Sudan III dye. For 
electron microscopy, mouse livers were cut into 1-2 mm thin pieces and fixed overnight in 
1.6% glutaraldehyde. For evaluation of fibrosis, 5 μm thick sections were stained with Sirius 
Red. Quantification of adipose tissue cellularity in HE-stained sections was performed with 
the HistoQuest analysis software (TissueGnostics GmbH, Vienna, Austria; 
www.tissuegnostics.com) using a minimum of four fields of view. Briefly, the cell 
circumference and cell area were quantified and the ratio plotted on the y-axis as an indicator 
of adipocyte cell density in a given microscope field. High y-values represent a high 
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adipocyte density. The x-axis values represents the intensity of hematoxylin staining of 
individual cells and were set arbitrarily =1. For immunohistochemical detection of pY-Stat5 
in paraffin sections of liver biopsies, slides were incubated human pY-Stat5 (#71-6900, 
dilution 1:1,000, Zymed).  
 
Western Blot and Immunoprecipitation  
Livers were homogenized as described (Engblom et al., 2007). Fourty micrograms of liver 
homogenate were subjected to SDS-PAGE, transferred to nitrocellulose membranes and 
incubated with antibodies against C/EBPα (sc-061X; dilution 1:2000), C/EBPβ (sc-150X; 
dilution 1:2000), PPARg (sc-7273; dilution 1:2000), SREBP-1 (sc-13551; dilution 1:2000), 
HSC70 (sc-7298; dilution 1:20000), GR (sc-1004; dilution 1:2000, all from Santa Cruz 
Biotechnology, Santa Cruz, CA), Stat5b (rabbit polyclonal antibody, epitope aa775-788; 
dilution 1:5000), pY-Stat5 (#71-6900, Invitrogen, Carlsbad, CA, dilution 1:1000). For 
immunodetection of human pY-Stat5b, 1.5 mg of total protein extract were precipitated with 
rabbit polyclonal antibodies against Stat5b (epitope aa775-788) and probed with a pY-Stat5 
antibody (#71-6900, Invitrogen; dilution 1:1000). Antigen-specific binding of antibodies was 
visualized using a commercial ECL system (Pierce Biotechnology, Rockford, IL). 
 
Animal Procedures and Serum Biochemistry 
Total lipids were extracted by the method of Folch (Folch et al., 1957) and dried in a stream 
of nitrogen and redissolved by brief sonication in 1% Triton X-100. Plasma TG and FFA 
levels were determined using colometric assays (ThermoElectron and Wako Chemicals). 
Plasma GH, IGF-1, Leptin, TNFα and Resistin concentrations were determined using ELISA 
kits (Millipore). Corticosterone and ACTH levels were quantified using RIA kits (MP 
Biochemicals). Serum levels of alanine aminotransferase (ALT), alkaline phosphatase (AP) 
and total cholesterol were measured using Reflotron system-based test-strips (Roche). For 
some experiments, mice were injected intraperitoneally (i.p.) with 2 mg/kg recombinant hGH 
(Immunotools) and sacrificed at indicated time points. Dexamethason (20 mg/L, Sigma, 
Steinheim, Germany) was administrated in the drinking water for 14 consecutive days. 
RU486 (20 mg/kg, Sigma, Steinheim, Germany) was dissolved in sunflower oil and given by 
i.p. injections for 14 consecutive days. Control mice received daily oil injections. Mice were 
sacrificed by asphyxiation and blood was harvested by heart puncture. Specimens from liver 
and white adipose tissue were removed, snap-frozen in liquid nitrogen and stored at -80 °C for 
biochemical analyses.  
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Chromatin Immunoprecipitation 
Livers were harvested from untreated and GH injected control (2µg/g body weight, 30 
minutes, n=4/group). After tissue homogenization, chromatin was cross-linked, isolated and 
sonicated. DNA-bound Stat5 was precipitated with a rabbit anti-Stat5 antibody (#sc-835x; 
Santa Cruz Biotechnology, Santa Cruz, CA) pre-bound to magnetic beads (Dynabeads M280 
Sheep anti-Rabbit IgG; Invitrogen, Carlsbad, CA). To exclude unspecific chromatin binding 
of the Stat5 antibody, we performed the ChIP in parallel with a rabbit-IgG antibody. Analysis 
of loci containing putative Stat5 binding sites was performed by qRT-PCR. Sequence 
conservation alignments between mouse (mm9), rat (rn4) and human (hg18) sequence 
annotations was performed using ECR browser (www.dcode.org) and TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html). Primers for qRT-PCR containing Stat5 binding 
sites are available upon request. 
 
Human liver samples 
Human steatosis liver samples were obtained from the repository of the Department of 
Pathology at the General Hospital of Vienna. The samples were obtained with informed 
consent as part of a protocol approved by the Internal Review Board. The specimens were 
collected at the time of liver surgery and snap-frozen in liquid nitrogen. The extent of liver 
fatty degeneration (low-grade, high-grad steatosis and controls) was confirmed by a board-
certified pathologist (L.K.) utilizing hematoxylin/eosine stainings of respective tissue paraffin 
sections. 
 
Statistical Analyses 
All data unless indicated otherwise are mean ± SEM. Data sets were compared for statistical 
significance using the two-tailed t-test.  
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Results 
 
Recently, we have demonstrated that hepatic GH signaling regulates postnatal body growth, 
using hepatocyte-specific and domain-selective deletions of Stat5 and the GR in mice. The 
existence of a linear Stat5-GR signal transduction pathway in the liver was shown to control 
an unexpectedly large part of the GH-responsive transcriptome, including genes essential for 
postnatal body growth and sexual maturation (Engblom et al., 2007; Tronche et al., 2004). In 
order to determine whether hepatic Stat5 and the GR either independently or synergistically 
affect hepatic lipid metabolism, we crossed mice harboring conditional alleles for GR and 
Stat5 with transgenic mice expressing the cre-recombinase under the control of albumin 
promoter and alpha-fetoprotein enhancer elements (Alfp-cre). Hepatocyte-specific GR 
(GRKO) and Stat5 (S5KO) mutants, as well as Stat5/GR double mutants (DKO) and all 
respective controls were born healthy and at Mendelian ratios. Efficient deletion of Stat5 and 
GR proteins was confirmed by Western blot analysis and immunohistochemistry 
(Supplemental Fig. 1A, Supplemental Fig. 3B and data not shown).  
 
Stat5/GR Knockout Mice Develop Marked Hepatic Steatosis and Steatohepatitis 
Macroscopic analysis of mutant animals revealed graded hepatic pathologies between the 
individual genotypes. Whereas control and GRKO mice displayed normal liver morphology, 
hepatic steatosis and hepatomegaly were observed in S5KO and DKO mutants as early as 4 
weeks of age. While steatosis in the S5KO mutants remained mild and stable at all time points 
analyzed, DKO mice displayed a marked and progressive pathology exhibiting ~4-fold 
increases in liver mass by 12 months of age (Fig. 1A, B) and an 8-fold rise in hepatic 
triglyceride (TG) content as early as 2 months of age (Fig. 1C). Irrespective of the liver-
specific deletion of Stat5 and GR proteins, mutant animals showed modest increases (+17%; 
GRKO) or decrease (-28%; S5KO) in white adipose tissue (WAT). In clear contrast, DKO 
animals displayed a dramatic depletion of WAT stores (-58%; Fig. 1A, B). Characteristic 
serum alterations such as hyperglycemia, hyperinsulinemia and elevated resistin levels in both 
Stat5-deficient lines suggested hepatic insulin resistance following Stat5 loss. Also 
noteworthy were elevated serum ALT and AP levels, indicative of progressive liver 
parenchyma damage secondary to Stat5 deletion (Tab. 1). Histopathology analysis displayed 
only baseline or mild pathologies in control (Fig. 1C, G, and L) or GRKO animals (Fig. 1D, H 
and M). Intriguingly, marked age-dependent micro- and macrovesicular steatosis in livers 
from both S5KO (Fig. E, I and N) and DKO (Fig. F, K and O) mice suggested a critical role 
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for Stat5 in the regulation of hepatic lipid homeostasis. As an additional proof for the severity 
of disease in DKO mice, fatty degeneration of hepatocytes was detected microscopically as 
early as 8 weeks of age (Supplemental Figure 1B), progressing to late-stage conditions such 
as steatohepatitis at later time-points (Figure 1P-Q). Of note, only minor fibrotic degeneration 
or necrotic death was observed in DKO livers (Figure 1S). A detailed histopathology analysis 
of disease progression in mutant mice is given in Supplemental Table 1.  
Recently, the development of steatosis upon the hepatocyte-specific loss of Stat5 using the 
Albumin-cre recombinase was reported (Cui et al., 2007). The authors observed a state of 
glucose intolerance and insulin resistance in the mutant mice. To verify this observation in 
our experimental settings, we performed glucose and insulin tolerance tests. Intraperitoneal 
insulin administration revealed blunted hypoglycemic responses in S5KO and DKO mice. 
Glucose tolerance tests confirmed impaired overall glucose homeostasis in S5KO and DKO 
mice, yet revealed only mild metabolic disturbances in the GRKO mice. While GRKO and 
S5KO mice displayed mild glucose intolerance in response to 1 g/kg oral glucose, DKO mice 
exhibited more severe glucose intolerance than either of the single mutants alone, indicating 
at least in part additive mechanisms (Supplemental Fig. 2A). We further asked whether Stat5 
constitutes a component of the IR signalosome as suggested (Chen et al., 1997). Western blot 
analysis revealed severely impaired IR signal transduction following insulin administration in 
both Stat5-deficient lines in vivo. Tyrosine phosphorylation of the insulin receptor beta-
subunit (IR-beta), insulin-response substrates -1 and -2 (pY-IRS-1 and -2) and serine 
phosphorylation of the downstream effector kinase AKT (pS-AKT) were severely reduced in 
DKO livers. Changes in S5KO livers were more modest relative to the DKO mutants with 
reductions in phosphorylation only observed for pY-IRS-1 and pS-AKT (Supplemantal Fig. 
2B). Additionally, a compensatory activation of Stat1 and Stat3 signaling pathways triggered 
through GH-activated Jak2 was observed upon deletion of hepatic Stat5 using the Albumin-
cre. The conditional deletion of Stat5 in hepatocytes using Alfp-cre recombinase did not 
result in aberrant Stat1/3 activation under basal conditions. However, upon additional GH 
stimulation, levels of tyrosine phoshorylated Stat1 and Stat3 were strongly elevated in S5KO 
hepatocytes (Supplemental Fig. 3C, D). 
Taken together, deletion of Stat5 in hepatocytes using Alfp-cre (S5KO) causes mild, stable 
steatosis that, when coupled to GR-signaling loss initiates overt and progressive 
steatohepatitis. Moreover, hepatocyte-specific deletion of Stat5 alone or in combination with 
GR leads to marked hepatic insulin resistance and molecular impairments in insulin receptor 
signal transduction.  
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Additive Effects of GH and GC Signaling on WAT lipolysis 
One explanation for hepatic triglyceride accumulation is that alterations in metabolism result 
in an increased TG breakdown in adipocytes and release of free fatty acids (FFA). The severe 
fatty liver degeneration accompanied by a depletion of WAT observed in DKO mice 
suggested an enhanced lipolysis and FFA flux to the liver. Histolopathological analysis of 
WAT from DKO mice confirmed peripheral lipodystrophy characterized by a marked 
reduction in white adipocyte cell size compared to control and single knockout mice (Fig. 2A 
and B). The measurement of serum FFA subsequently confirmed significantly elevated levels 
of circulating FFA in DKO mice (Fig. 2C). Total levels of Stat5 and GR proteins were 
unaltered in WAT of mutant animals. However, white adipocytes of mice lacking hepatic 
Stat5 and both GR deficient lines showed increased activation of Stat5 and GR, respectively 
(Fig. 2E, and data not shown). Serum analysis of both Stat5 deficient lines revealed strongly 
elevated levels of GH, secondary to the loss of negative regulation from the low circulating 
IGF-I levels (Fig. 2D, left row). Rather unexpectedly, GRKO and DKO mutants displayed 
elevated serum levels of corticosterone (Cort) and its positive regulator adrenocorticotropic 
hormone (ACTH), indicative of systemic hypercortisolism secondary to hepatic GR loss 
(Figure 2D, right row). Simultaneous administration of GH and the synthetic glucocorticoid 
Dexamethasone (Dex) was reported to synergistically induce lipolysis in human adipose 
tissue in vitro. This combined effect exceeded GH-mediated lipolysis alone (Fain et al., 
2008). Therefore, we examined the expression of adipose triglyceride lipase (Atgl) and 
hormone sensitive lipase (Hsl), the predominant lipase genes in WAT. Quantitative RT-PCR 
showed a significant up-regulated expression of both Hsl and Atgl in WAT of DKO mice 
compared to control mice and the respective single knockout animals. Moreover, the 
expression level of Perilipin (Plin), a major coating protein of mature adipocytes, was 
severely down-regulated exclusively in DKO WAT. These observations suggest that the 
combination of GH resistance and hypercortisolism secondary to the loss of hepatic Stat5 and 
the GR might modulate the lipolytic cascade and enhances lipolysis in WAT of DKO mice. 
 
Pharmacological Phenocopy of the DKO Mice Disease Phenotype 
To eventually confirm that a synergistic GH and GC-mediated lipolysis account for the 
dramatic depletion of peripheral fat stores in DKO mutants, we administered Dex to 6-months 
old S5KO mice for 14 days. Whereas no effect of Dex treatment was observed in livers and 
WAT of control animals, Dex-treated S5KO mice developed massively enlarged livers, 
accompanied by a remarkable decrease in WAT size (Figure 3A-B). The extent of fat 
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accumulation in livers of Dex-treated S5KO mice paralleled the liver phenotype observed in 
DKO mice (~20% LW/BW ratio). Histopathological analysis of livers and WAT from Dex-
treated S5KO mice confirmed a severe fatty degeneration of hepatocytes and the associated 
reduction in adipocyte cell size compared to Dex-treated controls. Moreover, S5KO mice 
developed massive perilobular fibrosis after short-term Dex-treatment (Figure 3C, yellow 
arrows). Additionally, to determine if the inhibition of GC-GR signal transduction in WAT 
might circumvent adipocyte lipolysis, we treated 6-months old DKO mice for 14 day with the 
GR antagonist RU486. Macroscopically no considerable changes in liver and WAT size of 
RU486-treated DKO mice compared to control animals could be observed (Fig.3C-D). 
However, RU486 treatment of DKO mice significantly decreased the levels of serum FFA to 
similar levels of RU486 and vehicle treated control mice (Fig. 3E). 
 
Hepatic deletion of Stat5 induces SREBP-1 and PPARg-dependent lipogenesis  
Since liver steatosis can either result from imbalances in FA synthesis and combustion or 
from an imbalanced build-up versus shuttling of lipids out of the hepatocyte, we examined 
these processes in more detail. As no apparent alterations in lipoprotein particle-mediated 
shuttling of TG were observed (Supplemental Fig. 4), we investigated whether lipid 
accumulation in S5KO and DKO livers were caused in part by enhanced hepatic lipogenesis. 
Affymetrix® whole-genome expression analysis and subsequent molecular transcription factor 
signature analysis demonstrated an increased expression of genes controlled by the key 
lipogenic regulators Srebp-1 and Pparg in S5KO and DKO livers. In contrast, GRKO mice 
did not exhibit a similar induction of lipogenic genes (Supplemental Tab. 2). Indeed, qRT-
PCR and Western blot analysis confirmed strong induction of Srebp-1 and Pparg mRNA in 
both Stat5-deficient lines and at protein level respectively. Gene expression of pro-lipogenic 
Srebp-1 (Fasn, Scd1 and Scd2) and Pparg targets (Dgat1, Dgat2, Cd36, Fabp4 and Mod1) 
were concomitantly shown to be significantly increased. Furthermore, C/EBPα and C/EBPβ 
two transcription factors which control adipogenesis and lipogenesis together with PPARg 
(Yeh et al., 1995), were elevated on mRNA and protein level in S5KO and DKO mice (Fig. 
4A and B). A bidirectional, inhibitory crosstalk between Stat5 and PPARg as well as the 
negative regulation of C/EBPα by GH-activated Stat5 has already been described (Shipley 
and Waxman, 2004) Rastegar et al., 2000). To investigate whether the up-regulation of Srebp-
1 is a direct consequence of hepatic Stat5 loss, we performed bioinformatical screenings for 
putative Stat5 responsive elements in the murine Srebp-1a and Srebp-1c promoter region. 
Using chromatin immunoprecipitation analysis significant enrichment of Stat5 binding to the 
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Srebp-1a promoter and weaker binding to the promoter region of Srebp-1c after GH 
stimulation of control livers could be determined (Fig. 4C). Additionally, Stat5 tyrosine 
phosphorylation upon GH stimulation of control livers led to a marked and time-dependent 
decrease of hepatic Srebp-1a and Srebp-1c mRNA levels (Fig. 4D). These results suggest that 
GH-activated Stat5b controls hepatic lipid metabolism in a direct as well as indirect manner. 
In contrast to the regulation of GH-mediated postnatal body growth by Stat5 and GR 
(Engblom et al., 2007), the regulation of hepatic lipid metabolism seems to be independent of 
Stat5-GR transcriptional synergism (Fig. 4E). This finding is supported by the observation, 
that the N-terminal deletion of Stat5 (as present in Stat5∆N mice) does not cause steatosis, as 
determined by histopathological analysis and Sudan III staining of Stat5∆N livers 
(Supplemental Fig. 5A, B). Finally, we addressed the question, whether Stat5 activity is 
impaired in human steatotic livers. Immunoprecipitation and immunohistochemistry analysis 
of liver biopsies from healthy individuals and steatotic patients revealed reduced level of 
Stat5b tyrosine phosphorylation in low- and high-grade steatotic livers, while total Stat5b 
levels were unchanged (Fig. 5A-C). 
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Discussion 
GH and GC signaling is well known to exerts numerous important metabolic functions 
through out the body, e.g. in response to metabolic stress. Defects in both signaling pathways 
have been implicated in the metabolic syndrome and NAFLD (Lonardo et al., 2006; Targher 
et al., 2006), might suggesting a role of their downstream mediators Stat5 and the GR in the 
development of these diseases. There are remarkable parallels between GH deficiency in 
adults and the metabolic syndrome and the latter with NAFLD (Adams et al., 2004; Ichikawa 
et al., 2003; Johannsson and Bengtsson, 1999). Furthermore, it has been shown that GH and 
IGF-1 are predictors for the development of steatosis and fibrosis in NAFLD patients, and 
that hepatic steatosis could be reversed upon hormone replacement (Ichikawa et al., 2007; 
Takahashi et al., 2007). Disruption of GH and GC signal transduction in mouse livers upon 
combined deletion of hepatic Stat5 and GR induced severe, progressive steatosis and 
steatohepatitis, with late-stage disease markers present as early as 8 weeks of age. Marked and 
graded steatosis was additionally observed upon loss of hepatic Stat5 alone, but not in mice 
lacking the GR. The development of liver steatosis in mice upon loss of hepatic Stat5 or the 
growth hormone receptor (GHR) has recently been described (Cui et al., 2007; Fan et al., 
2009). On the molecular level, lack of hepatic Stat5 was reported to induce an up-regulation 
of Pparg and its target gene Cd36, whereas the loss of GHR in hepatocytes additionally 
resulted in enhanced Srebp-1c expression. In parallel, our global gene expression profiling 
revealed a Srebp-1 and Pparg-mediated induction of pro-lipogenic genes in Stat5 deficient 
livers independently of a cofactor interaction with the GR. These findings could be confirmed 
by qRT-PCR and on protein level. The contribution of Srebp-1c and Pparg dependent de novo 
lipogenesis to the development of hepatic steatosis has been explored in various animal 
models with insulin resistance and fatty livers (Browning and Horton, 2004). Previous studies 
have also indicated that Srebp-1c can transcriptionally activate Pparg (Kim et al., 1998), 
contrarily, a bidirectional, inhibitory crosstalk between Stat5 and Pparg has been described 
(Shipley and Waxman, 2004). Additionally, our data demonstrate, that GH-activated Stat5 
directly interacts with the promoter of both Srebp-1 isoforms, and that the expression of both 
isoforms is severely down-regulated in liver after GH stimulation. Thus, we hypothesize, that 
hepatic Stat5 constitutes a negative regulator of liver de novo lipogenesis exerting its 
functions via repression of Srebp-1, Pparg and C/ebpa (Rastegar et al., 2000) transcription. 
As no alteration of the expression profile of pro-lipogenic transcription factors was observed 
in GRKO livers, we consider the induction of Srebp-1 and Pparg mediated de novo 
lipogenesis as a primary effect of Stat5 deficiency alone. In addition, the N-terminal deletion 
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of Stat5 (as present in Stat5∆N mice) does not cause steatosis, excluding a Stat5-GR synergism 
in regulating hepatic lipogenesis. Importantly, down-regulation of hepatic Stat5b activity was 
also detected in liver biopsies of steatosis patients. The degree of human steatosis correlated 
with the reduction of Stat5b tyrosine-phosphorylation. This observation might shed light on 
the striking parallels between defects in GH signaling and the metabolic syndrome in humans 
(Johannsson and Bengtsson, 1999). Disturbance of GH-Stat5 signaling may also play a role in 
the development and progression of human metabolic disease. A strong relationship between 
hepatic steatosis and insulin resistance has been observed in humans as well as in animal 
models of NAFLD (Angulo, 2002; Cui et al., 2007; Fan et al., 2009). Supported by in vivo 
glucose and insulin tolerance testing of S5KO and DKO mutants, hepatocyte-specific deletion 
of Stat5 caused insulin resistance and glucose intolerance. This hepatocyte-autonomous 
process was independent of macroscopic changes in peripheral adipose tissues. There are two 
putative explanations for the initiation of insulin resistance observed upon hepatic deletion of 
Stat5: (i) Insulin resistance is secondary to abrogated Stat5 repression of Srebp-1/Pparg-
driven lipogenesis and thus unbalanced hepatic lipid biosynthesis. A similar effect has been 
reported upon short term high-fat diet feeding of mice which first develop primary steatosis 
and only subsequently develop concomitant insulin resistance (Samuel et al., 2004). A 
relatively sluggish SREBP-1c-dependent decrease in IRS-2 transcription initiates the delayed 
insulin resistance. Indeed, reduced levels of IRS-2 protein and high Srebp-1c levels were 
observed in livers from S5KO and DKO mutants. (ii) Alternatively, hepatic insulin resistance 
in S5KO and DKO animals could be due to a putative docking function of Stat5b within the 
insulin receptor signaling complex. Based primarily on Yeast 2-Hybrid studies (Sawka-
Verhelle et al., 2000) this effect is thought to be independent of Jak2 activation (Storz et al., 
1999). In support of this notion, we detected defective signal transduction from the IR after 
insulin administration in both Stat5-deficient mouse strains, which suggests a docking 
function for Stat5b in hepatic insulin/IGF-1 signal transduction. In addition to the prevalence 
in insulin resistant states, steatosis is also observed in lean, but lipodystrophic patients where 
the extent of hepatic fat accumulation correlates with the degeneration of peripheral fat depots 
(Garg, 2000). Simultaneous elevation of GH and GC induces excessive peripheral Hsl-
mediated lipolysis, exceeding lipolysis exerted by lipolytic GH alone (Fain et al., 2008; 
Ottosson et al., 2000), a process shown to depend on Stat5 in adipose tissues (Fain et al., 
1999). Interestingly, while elevations of GH in S5KO mice and GC in GRKO mice produced 
only mild redistribution of lipid stores, DKO mice exhibited a marked redistribution of lipids, 
which was consistent with lipolysis through elevated GH and GC levels. The mobilization of 
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peripheral lipid stores was ubiquitous, depleting various peripheral fat stores (WAT, BAT and 
subcutaneous fat). Direct activation of adipose tissue GR and Stat5 protein was demonstrated 
by enhanced nuclear translocation of GR or phosphorylation of Stat5 proteins, respectively. In 
the downstream lipolytic cascade, the down-regulation of Plin (Ren et al., 2006) and 
activation of Hsl and Atgl (Schweiger et al., 2006; Watt and Steinberg, 2008) cooperatively 
regulate the full lipolytic reaction in adipocytes. Our results indicate that Atgl and Hsl mRNA 
were up-regulated exclusively in WAT of DKO mice, which is consistent with previous 
observations that simultaneous administration of GH and dexamethasone increased Atgl and 
Hsl mRNA in primary adipocytes. Additionally, down-regulation of Plin mRNA was 
observed. Hence, the DKO mouse model presented here is reminiscent of human 
lipodystrophies and implicates hepatic Stat5 and GR for the first time in the development of 
peripheral lipodystrophy in vivo (Aoki et al., 2003). It also highlights the necessity of proper 
lipid maintenance between hepatic and peripheral lipid stores, the malfunctioning of which 
can elicit steatosis independently of defects in hepatic lipid metabolism itself. We here 
provide evidence for the role of hepatic Stat5 and the GR in keeping unwanted HPA activity, 
GH/IGF-1 and insulin levels balanced. The observed imbalances lead to deleterious effects on 
the adipose tissues, causing atrophy of peripheral fat stores and a concomitant redistribution 
of body fat. The pronounced hypercortisolism observed upon loss of hepatic GR could 
correlate with serum glucose sensing (Rogoff et al., 2007). No liver-derived mediators other 
than glucose have been reported to negatively regulate ACTH/GC secretion in the pituitary 
and hypothalamus. Interestingly, defects in hepatic gluconeogenesis leading to hypoglycemia 
have been linked to an elevated secretion of ACTH and GC. This suggests that serum glucose 
might inversely correlate with GC levels. Mice conditionally deleted for hepatic GR exhibit 
defects in serum glucose availability (Opherk et al., 2004). Hypoglycemia might be a state, 
DKO and GRKO mice are susceptible under conditions of low nutrient supply causing a 
compensatory ACTH/GC secretion to mobilize energy. 
Collectively, our study defines unexpected and essential roles for Stat5 and GR in hepatic and 
peripheral lipid homeostasis. A functional Stat5-GR cofactor interaction is only important for 
the transcription of growth-promoting and sexual dimorphic genes. The pathologies observed 
in both S5KO and DKO mutant animals recapitulate many aspects of human NAFLD 
development and progression. Our animal models help to understand the complex 
development of fatty liver disease. 
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Tables 
 
Table 1. Biochemical and metabolic serum parameters in mutant mice.  
 
  Con GRKO S5KO DKO 
Age  8 weeks 
52 
weeks 
8 weeks 
52 
weeks 
8 weeks 
52 
weeks 
8 weeks 
52 
weeks 
Parameter n=         
ALT (U(l) 7 57 ± 5 83 ± 15 63 ± 4 ND 94 ± 6c 
562 ± 
151c 
191 ± 
49c 
614 ± 
126c 
ALP (U/l) 7 45 ± 11 37 ± 17 59 ± 3 ND 64a ± 4 69 ± 4 642 ± 5 66 ± 2 
TG (mg/dl) 8 
174 ± 
34 
160 ± 
26 
84 ± 12a ND 
165 ± 
22 
180 ± 
32 
179 ± 
24 
177 ± 
12 
Cholesterol 
(mg/dl) 
5 
158 ± 
23 
118 ± 
10 
98 ± 26 
143 ± 
30 
132 ± 
15 
171 ± 
34 
203 ± 
15 
267 ± 
12a 
FFA (mmol/l) 5 
0.84 ± 
0.2 
0.71 ± 
0.1 
0.69 ± 
0.1 
0.54 ± 
0.1 
0.77 ± 
0.1 
0.95 ± 
0.2 
1.11 ± 
0.2 
0.67 ± 
0.1 
Glucose 
(mg/dl) 
         
fed 7 
130 ± 
21 
149 ± 
22 
73 ± 5 ND 
199 ± 
23a 
190 ± 
13a 
222 ± 
24a 
220 ± 
37a 
after 4h fast 8 182 ± 9 ND 
187 ± 
11 
ND 
179 ± 
15 
ND 
219 ± 
11a 
ND 
after 16h fast 8 73 ± 4 ND 84 ± 7 ND 91 ± 8a ND 92 ± 14a ND 
Insulin 
(pg/ml) 
7 
173 ± 
25 
ND 
108 ± 
27 
ND 
482 ± 
63c 
ND. 
401 ± 
25c 
ND 
Leptin (ng/ml) 8 0.6± 0.1 
9.4 ± 
1.2 
2.1 ± 
0.5a 
10.8 ± 
1.0 
0.9 ± 
0.1a 
4.8 ± 
1.2b 
0.8 ± 
0.1 
6.6 ± 
1.9b 
TNFa (pg/ml) 8 
3.9 ± 
0.8 
5.1 ± 
1.2 
2.1 ± 
0.7 
5.6 ± 
1.9 
4.6 ± 
1.0 
5.4 ± 
2.3 
4.4 ± 
1.6 
10.0 ± 
2.0c 
Resistin 
(ng/ml) 
8 
3.3 ± 
0.4 
2.6 ± 
0.5 
1.6 ± 
0.2b 
1.9 ± 
0.3 
5.5 ± 
0.7a 
3.3 ± 
1.0 
6.1 ± 
0.4c 
4.2 ± 
0.7b 
Mice were fed with standard chow and sacrificed by carbon dioxide asphyxiation. Results are 
expressed as mean ± SEM for indicated numbers of mice from each genotype. ALP, alkaline 
phosphatase; ALT, alanine transaminase; FFA, free fatty acids; ND = not determined; TG, 
triglycerides; TNF, tumour necrosis factor alpha. All values represent mean ± SEM a = p-Value 
<0.05 vs. Control, b = p-Value <0.01 vs. Control, c = p-Value <0.001 vs. Control  
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Figures and Figure legends 
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Figure 1. Liver steatosis in S5KO and DKO animals. 
(A) Macroscopic appearance of livers and peripheral adipose tissues in mutant and control mice at 
indicated time points. (B) Liver/body weight (LW/BW) and white adipose tissue/body weight ratios 
(WAT/BW) in male mice at indicated time points (n=8/genotype/timepoint). * = p-Value <0.05, ** = 
p-Value <0.01, *** = p-Value <0.001 vs. controls. All data represent mean ± SEM. (C) Hepatic 
triglyceride content in 8 weeks old male mice. Data represent mean ± SEM (n=5/genotype). (D) Liver 
histology was performed with livers from 6 months old mice unless stated otherwise. (a-d, m-o) Tissue 
sections were stained with HE. (e-h) Lipid accumulation was visualized by Sudan III on cryosections. 
(i-l) Electron microscopy analysis of subcellular fat distribution in glutaraldehyde-fixed liver samples 
(cytoplasmic lipid droplets, green arrows; intrahepatic glycogen granules, black arrows) of 2-months 
old mice. (m-o) Steatohepatitis (infiltrative foci, yellow arrows) in HE stainings of DKO mutants at 2, 
6 and 9 months of age. (p) Sirius Red staining for fibrotic changes in DKO mutants at 9 months of age.  
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Figure 2. Combination of GH resistance and hypercortisolism leads to peripheral lipodystrophy 
in DKO animals.  
(A) Histology of white adipose tissue (WAT). WAT of male mice at 12 months of age was stained 
with HE. (B) Quantification of white adipocyte cell density. HE-stained sections were used to analyze 
cell density applying image analysis. (C) Levels of FFA were determined in 8 week old mutant mice 
using colorimetric assays. (D) Levels of GH and IGF-1 were determined by ELISA. Levels of 
corticosterone and ACTH were determined by RIA in mice of indicated age (n=8/genotype). (E) 
Representative Western blot of white adipose tissue homogenates from 8-weeks old male mice. 
Expression levels of Stat5 and GR proteins were determined using specific antibodies. HSC70 served 
as loading control. (F) Relative mRNA levels of genes with functions in adipocyte lipolysis were 
quantified by qRT-PCR in WAT from 12-month old mice. Ct values were normalized to GAPDH 
(∆Ct method, n=4/genotype). 
For serum parameters and qRT-PCR: * = p<0.05, ** = p-Value <0.01. Error bars represent mean ± 
SEM 
Results  
121 
 
 Results 
 
 122
Figure 3. Pharmacological phenocopy of the DKO phenotype. 
(A) Macroscopic appearance of livers and WAT from S5KO mice following 14 days of Dexamethason 
(Dex) or control (PBS) treatment (Black arrows highlight local lipid patches). (B) Liver weight/body 
weight (LW/BW, left) and WAT weight/body weight ratio (WAT/BW, middle) of 6-months old 
mutant mice of indicated genotypes and treatment. (C) Histological analysis of liver and WAT using 
HE-stained sections from control and S5KO mice following Dex treatment (black arrows highlight 
fibrotic areas). (D) Macroscopic appearance of livers and WAT from DKO mice following 14 days of 
RU486 or control (oil) treatment. (E) Liver weight/body weight (LW/BW, left) and WAT weight/body 
weight ratio (WAT/BW, middle) of 6-months old mice of indicated genotypes and treatment. (F) 
Levels of FFA were determined after RU486 or control treatment of control and DKO mice using a 
colorimetric assay. For FFA levels: * = p<0.05, ** = p<0.01. Error bars represent mean ± SEM 
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Figure 4. Induction of PPARg/SREBP-1 mediated lipogenesis upon hepatic Stat5 loss. 
(A) Relative mRNA levels of genes with functions in hepatic lipid metabolism were quantified by 
qRT-PCR in livers from 8-weeks old mice. Ct values were normalized to GAPDH (∆Ct method, 
n=6/genotype). (B) Representative Western blots showing protein expression of hepatic lipogenic 
transcription factors. HSC-70 served as loading control.  (C) Chromatin immunoprecipitation (ChIP) 
demonstrating Stat5 binding to promoter regions of Srebp-1a and Srebp-1c. The Stat5 target gene Igf-
1 serves as a positive control. Values are represented as fold induction versus a downstream region of 
Cis not containing Stat5 responsive elements. (D) Changes in relative hepatic Srebp-1c and Srebp-1a 
mRNA levels following GH administration for indicated durations in vivo (n=6/group). (E) Schematic 
illustration of synergistic growth promotion by hepatic Stat5 and the GR (left). In contrast, up- 
regulation of genes involved in hepatic FA biosynthesis is predominantly dependent on Stat5 (right).  
For qRT-PCR analysis and ChIP: * = p<0.05, ** = p<0.01, *** = p<0.001. Error bars represent mean 
± SEM.  
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Figure 5. Stat5 activity is reduced in human steatosis. (A) The extent of liver fatty degeneration 
(low-grade, high-grad steatosis and controls) was confirmed by a board-certified pathologist (L.K.) 
utilizing HE stainings of respective tissue paraffin sections.  (B) 
Quantification of phosphorylated Stat5 (pY-Stat5) or total Stat5b (Stat5b) in livers from eight steatotic 
(4 low-grade, S1-S4 or 4 high-grade, S5-S8) and eight control patients (C1-C8) using 
immunoprecipitation analysis (upper panel). Equal Stat5 and protein input were shown by immunoblot 
analysis (lower panel). HSC70 served as loading control. (C) Representative immunohistochemical 
staining for pY-Stat5 in liver biopsies of steatosis patients. 
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Supplemental data: 
 
Materials and Methods: 
 
Western Blot and Immunoprecipitation 
Fourty microgram of liver homogenate were subjected to SDS-PAGE, transferred to nitrocellulose 
membranes and incubated with antibodies against Stat1 (#610115; dilution 1:1000; BD), pY-Stat1 
(#9167; dilution 1:1000), Stat3 (#9132; dilution 1:1000; BD) and pY-Stat3 (#9131; dilution 1:1000; all 
three from Cell Signaling), GR (sc-1004; dilution 1:2000), Stat5b (rabbit polyclonal antibody, epitope 
aa775-788; dilution 1:5000), anti-total-AKT (sc-8312; dilution 1:2000; both Santa Cruz), anti-pS-AKT 
(#9271S; dilution 1:250; New England Biolabs). For immunoprecipitation, 1.5 mg of total protein 
were precipitated using antibodies against total-IRS-1 (#06248), total-IRS-2 (#06506, both Upstate 
Biotech.) or the Insulin receptor beta chain (IR-beta, sc-711, Santa Cruz) and probed with the anti-
phosphotyrosine-specific antibody 4G10 (#dilution 1:1000, Millipore).  
 
Histology and Immunohistochemistry 
Liver tissue was fixed in 4% phosphate-buffered formalin for 48 hrs followed by embedding into 
paraffin using standard procedures. Sections (2 µm thick) were cut and stained with hematoxylin and 
eosine (HE) for standard histology. Hepatic lipids were visualized on cryosections (5 μm thick) by 
staining with the lipophillic Sudan III dye (). Immunohistochemistry was performed on paraffin 
sections (2 µm thick) using pY-Stat1 (#9167; dilution 1:50), pY-Stat3 (#9131; dilution 1:50) and pY-
Stat5 (#9314, dilution 1:50) antibodies (Cell Signaling). 
 
Insulin and Glucose Tolerance Test 
Insulin tolerance tests (ITT) were performed following a 4 h fast, oral glucose tolerance tests (OGTT) 
after an overnight fast. Glucose was orally administered at a final concentration of 1 g/kg, human 
insulin (0.75 U/kg; Novo Nordisk) was injected intraperitoneally. Blood samples were taken from the 
tail vein at indicated time points and glucose levels determined using a glucometer (OneTouch Ultra, 
LifeScan). Plasma insulin was determined using an enzyme-linked immunosorbent assay (ELISA; 
Crystal Chem Inc). 
 
Lipoprotein Profile  
Plasma samples of five fed mice of each genotype were pooled and compared with five control 
littermates. Lipoproteins were isolated by FPLC. 200 µl pooled plasma samples were subjected to 
FPLC analysis and lipoproteins were eluted with 10 mM Tris-HCl, 1 mM EDTA, 0.9% NaCl, and 
0.02 %NaN3 (pH 7.4). Fractions of 0.5 ml each were collected and lipids (triglycerides and total 
 Results 
 
 128
cholesterol) assayed enzymatically using commercially available kits. To enhance sensitivity, reaction 
buffers were supplemented by the addition of sodium 3, 5-dichloro-2-hydroxy-benzenesulfonate. 
 
Microarray analysis  
We performed a specific analysis for genes involved in lipid metabolism on raw data from a recent 
study as described (Engblom et al., 2007). Messenger RNA from three livers was pooled on each 
array, three arrays were used for each mutant group (S5KO, GRKO and DKO) and nine arrays for the 
control group (litter-mates to the mutant mice). Arrays were normalized using GCRMA in affylmGUI. 
Significance levels were calculated in affylmGUI. In order to find molecular signatures in the data we 
looked for coordinated changes in functional gene-sets using MAPPFinder (Doniger et al., 2003). We 
limited the analysis to around one hundred hand-picked, pre-defined groups, of which some where 
custom-made from papers describing profiles from the livers of mice lacking different transcription 
factors or administered with specific agonists or antagonists. Many lists were also taken from the 
GSEA software and consist of genes with certain motifs in their promoter regions as identified in a 
systematic study of regulatory motifs in mammals (Xie et al., 2005). The two criteria for inclusion of 
genes in the MAPPFinder-analysis were p<0.001 or p<0.05. This was done to pick up high magnitude 
changes of small groups of genes and low-amplitude changes in large groups, respectively. Gene-sets 
with p-value <0.05 after correction for multiple comparisons were considered as significant. 
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Supplemental Figures and Figure Legends 
 
 
 
Supplemental Figure 1. Deletion of Stat5 and GR in hepatocytes and degree of histological 
steatosis. 
(A) Representative Western blots of liver homogenates from 8-weeks old male mice.Total levels of 
Stat5 and GR in control and mutant livers were determined using specific antibodies. HSC70 served as 
loading control. (B) The degree of histological steatosis in mutant livers at 2 months of age was scored 
semi-quantitatively by two board-certified liver pathologists (M.H. and L.T.) 
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Supplemental Figure 2. Hepatic deletion of Stat5 using Alfp-cre results in insulin resistance and 
impaired hepatic insulin receptor signaling. 
(A) Insulin Tolerance Tests (ITT): Insulin was administered through intraperitoneal injection 
following a 4h fast. Blood glucose levels were determined at given time points (upper panel). Oral 
Glucose Tolerance Tests (OGTT): Mice were fasted overnight and glucose was orally administered. 
Blood glucose levels were determined at given time points (middle panel). Plasma insulin levels 
following OGTT challenge. The insulin levels were determined by ELISA (lower panel). For 
ITT/OGTT analysis: n=6-8/genotype; * = p<0.05, ** = p<0.01, *** = p<0.001 vs. controls. Error bars 
in ITT/OGTT assays represent mean ± SEM. Male mice were analyzed at 8-weeks of age for ITT and 
OGTT. (B) Phosphorylation status of proteins implicated in insulin receptor downstream signaling 
following insulin challenge in 8 week old mutant mice. Levels of phosphorylated and total protein 
were determined 15 min after intraperitoneal injection of insulin by immunoprecipitation and 
phospho-tyrosine/serine-specific immunoblot analysis. HSC70 served as loading control.  
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Supplemental Figure 3. Compensatory Stat1 or Stat3 activation upon hepatic deletion Stat5 
using Alfp-cre. 
(A) Representative Western blots of liver homogenates from 8-weeks old male mice. Amount of 
phosphorylation and total levels of Stat1, Stat3 or Stat5 in control and S5KO livers either without or 
upon GH treatment were determined using specific antibodies. HSC70 served as loading control. IFN-
g and IL-6 treated livers served as a positive control. (B) Immunohistochemistry of phoshorylated 
Stat1, Stat3 and Stat5 levels in control and S5KO livers of 8-weeks old male mice either without or 
upon GH treatment. 
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Supplemental Figure 4. Hepatic lipoprotein particle profiles  
(A) Lipoproteinparticle-mediated lipid shuttling in mutant mice. Lipoprotein distribution was analyzed 
by FPLC fractionation and subsequent TG and total cholesterol quantification in each fraction 
(n=5/genotype).  
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Supplemental Figure 5. Analysis of Stat5∆N livers. 
(A) Representative histology analysis of liver sections from 6-months old Stat5∆N or control male 
mice. Tissue sections were stained with HE or Sudan III dye to visualize hepatic fat content. (B) 
Liver/Body weight (LW/BW) ratio in 6-months old male mice of indicated genotypes. 
(n=4/genotype); error bars represent mean ± SEM. 
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Supplemental Tables 
 
Supplemental Table 1. Detailed pathology of mutant mice analyzed at indicated time-points. 
 
Genotype 
Age 
(month
s) 
Steatosis 
(Type) 
Steatosis 
(%) 
Inflammato
ry 
Infiltrates 
Ballooni
ng 
Nodules 
Lobular 
Fibrosis 
Portal 
Fibrosis 
         
Con 
 
 
2 
0 0 0 0 0 0 0 
0 0 1 0 0 0 0 
6 
0 0 lob1 3 0 0 0 
Micro / 
Macro 
40 lob1 0 0 ND  
Micro / 
Macro 
75 lob1 1 0 
Pv1 / 
Pc1 
0 
0 0 1 0 0 0 0 
9 
Micro 30 0 2 0 
Pv1 / 
Pc1 
1 
0 0 lob1 / por1 0 0 ND  
12 
 
0 0 0 2 0 0 0 
Macro 60 0 1 0 ND  
Micro / 
Macro 
35 lob1 / por1 1 0 
Pv1 / 
Pc1 
1 
Micro / 
Macro 
45 lob2 / por2 0 0 
Pv1 / 
Pc1 
1 
Macro 30 lob1 / por1 0 0 
Pv1 / 
Pc1 
1 
         
 
 
 
 
 
 
GRKO 
2 
 
Macro 30 0 3 0 0 0 
Micro 35 lob1 1 0 0 0 
0 0 0 0 0 0 0 
Micro / 
Macro 
50 lob2 / por1 1 0 
Pv1 / 
Pc1 
0 
6 
Micro / 
Macro 
60 lobular 2 1 0 0 0 
Micro / 
Macro 
80 lob1 1 0 Pv1 0 
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Micro / 
Macro 
40 lob2 0 0 Pv1 1 
9 
Micro / 
Macro 
70 lob 1 0 0 Pv1 0 
Micro / 
Macro 
60 lob1 / por1 1 0 0 0 
Macro 25 lob 1 0 0 Pv1 0 
Macro 35 lob1 / por1 3 0 Pv1 1 
12 
Micro / 
Macro 
90 lob1 / por1 1 0 0 0 
Micro / 
Macro 
90 lob1 2 0 
Pv1 / 
Pc1 
0 
         
 
 
 
 
 
 
 
 
 
S5KO 
 
2 
Micro 40 0 0 0 Pv1 1 
Micro 30 lob1 0 0 0 0 
Micro 40 lob1 0 0 0 1 
Micro 85 lob1 0 0 0 0 
6 
Micro / 
Macro 
80 lob1 1 0 
Pv1 / 
Pc1 
0 
Micro / 
Macro 
95 lob1 / por1 1 0 0 0 
Micro / 
Macro 
40 lob1 1 0 
Pv1 / 
Pc1 
0 
Micro 75 0 1 0 0 0 
9 
Micro / 
Macro 
95 lob1 / por1 2 0 Pv1 0 
Micro / 
Macro 
75 lob1 / por1 1 0 
Pv2 / 
Pc2 
1 
Micro / 
Macro 
60 lob1 1 0 0 0 
Macro 50 lob1 / por2 1 0 Pv1 1 
12 
Micro / 
Macro 
90 lob1 / por1 1 0 0 0 
Micro / 
Macro 
65 lob1 / por3 1 0 
Pv1 / 
Pc1 
2 
Micro / 
Macro 
60 lob1 / por1 0 0 Pc1 1 
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Micro / 
Macro 
40 lob1 / por2 2 0 
Pv2 / 
Pc2 
1 
Macro 10 0 0 0 
Pv3 / 
Pc3 
3 
         
 
 
 
 
 
 
 
 
 
DKO 
2 
Micro 90 lob1 0 0 0 0 
Micro 70 lob1 0 0 0 0 
Micro 80 0 0 0 0 0 
Micro 90 0 0 0 ND  
6 
Micro 90 lob1 0 0 Pv1 0 
Micro 90 lob2 2 0 ND  
Micro 90 lob1 / por1 1 0 0 0 
9 
Micro / 
Macro 
90 lobular 1 2 0 
Pv2 / 
Pc2 
 
Macro 80 lobular 2 0 0 0 0 
Micro / 
Macro 
90 lob1 / por1 1 DN 
Pv2 / 
Pc2 
0 
Micro / 
Macro 
90 lob3 / por2 2 DF 
Pv2 / 
Pc1 
1 
12 
Micro / 
Macro 
90 lob1 1 0 
Pv2 / 
Pc2 
0 
Micro / 
Macro 
70 lob1 / por1 1 DN 
Pv3 / 
Pc3 
0 
Micro / 
Macro 
80 lob1 1 DF 
Pv2 / 
Pc2 
0 
Macro 80 lob1 / por1 1 DF 0 0 
Micro / 
Macro 
70 lob1 0 0 0 0 
Macro 70 lob1 / por2 0 0 0 0 
DN, Dysplastic Nodule; DF, Dysplastic Focus; lob, lobular; Micro, microvesicular; Macro, 
macrovesicular; ND, not determined; por, portal; Pv, perivenular; Pc, pericellular;  
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Supplemental Table 2. Transcription factor signature analysis of genes statistically 
upregulated in Affymetrix expression profiling. 
Symbol Name TF pathway DKO S5KO GRKO 
Verified 
(qPCR) 
          
Lipid metabolism, lipogenic 
p=0.022 
(for PPARg 
) 
x-fold 
 
p-
value 
x-fold 
 
p-
value 
x-fold 
 
p-
value 
 
PPARg PPARgamma  1,77 0,004 1,68 0,006 1,38 0,071 X 
SCD1 
stearoyl-Coenzyme A 
desaturase 1 
PPAR/ 
Srebp-1c 
1,53 0,009 1,31 0,076 1,40 0,028 X 
SCD2 
stearoyl-Coenzyme A 
desaturase 2 
Srebp-1c 9,13 0,000 4,76 0,000 4,53 0,000 X 
LIPE 
lipase, hormone 
sensitive 
PPARg 1,46 0,000 1,19 0,032 1,14 0,100  
MOD1 
malic enzyme, 
supernatant 
PPARg 2,75 0,002 1,72 0,061 2,13 0,012 X 
FASN fatty acid synthase 
PPARg/ 
Srebp-1c 
1,56 0,032 1,18 0,400 1,65 0,018 X 
CD36 
CD36 antigen (fatty 
acid translocase) 
PPARg 1,37 0,049 1,53 0,010 1,29 0,098 X 
FABP4 
fatty acid binding 
protein 4 adipocyte 
PPARg 1,07 
0,290
6 
0,98 0,81 0,98 0,81 X 
DGAT1* 
diacylglycerol O-
acyltransferase 1 
PPARg 1,04 0,466 1,09 0,250 1,01 0,924 X 
Lipid metabolism, others 
LPIN1 lipin 1  0,08 0,000 0,39 0,033 0,27 0,005  
FABP5 
fatty acid binding 
protein 5, epidermal 
 0,20 0,000 0,08 0,000 0,37 0,015  
APOA4 apolipoprotein A4  0,22 0,007 0,44 0,115 0,10 0,000  
HDLBP (HDL binding protein  0,73 0,002 0,85 0,070 0,83 0,037  
DBI 
diazepam binding 
inhibitor 
 1,25 0,010 1,04 0,564 1,23 0,013  
APOC2 apolipoprotein C2  1,88 0,001 1,74 0,003 1,15 0,400  
FTO fatso  0,63 0,008 0,92 0,587 0,86 0,324  
LIPC lipase, hepatic  0,69 0,006 0,64 0,001 1,14 0,259  
ES esterase 31  0,33 0,004 0,30 0,002 0,17 0,000  
C/EBP 
CCAAT/enhancer 
binding protein, beta 
 2,00 
0,044
6 
1,51 
0,196
4 
0,56 0,13 X 
* = not statistically significant in Affymetrix analysis, included for completeness reasons 
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Loss of hepatic Stat5a/b increases HCC incidence and aggressiveness but abrogates 
negative side effects of GH overexpression in a murine inflammatory liver cancer model 
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Abstract 
Hepatic Stat5 transcription factors regulate postnatal body growth, sexual maturation, RNA 
biogenesis as well as metabolism and they have a protective effect on the liver. Important 
growth factors and cytokines such as growth hormone (GH), prolactin, and insulin are able to 
activate hepatic Stat5 proteins. Transcription of GH-stimulated target genes such as insulin-
like growth factor 1 (IGF-1) is mediated by Stat5, which is a direct downstream effector 
molecule of GH, and its cofactor, the glucocorticoid receptor (GR). In clinical studies and 
mouse models, both hyperactivation and deletion of Stat5b in hepatocytes have been shown to 
be involved in the development of hepatocellular carcinoma (HCC). Using growth hormone 
transgenic (GHtg) mice and conditional knockout mice lacking hepatic Stat5a/b (Stat5Δhep, 
AlfpCre), we analyzed the role of Stat5 in the development of inflammatory liver cancer 
caused by hyperactivated GH signaling. Interestingly, gigantism and premature mortality in 
GHtg mice was found to be dependent on Stat5. By contrast, the liver tumor phenotype seen in 
these mice was aggravated upon deletion of Stat5 and was accompanied by increased hepatic 
fat deposition (hepatosteatosis). Moreover, the polymorphonuclear shape and increased size 
of hepatocytes in GHtg mice were only found in the presence of Stat5. CONCLUSION: Our 
results suggest that hepatic Stat5 proteins prevent the formation of aggressive HCC and fatty 
liver disease via their hepatoprotective functions. At the same time, they are key factors in 
controlling organ and body size as well as systemic inflammation secondary to hyperactivated 
GH signaling. 
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Introduction 
 
Growth hormone (GH) is a single-chain polypeptide hormone that is synthesized, stored, and 
secreted into the circulation in a pulsatile manner by the anterior pituitary gland. Its secretion 
is strictly regulated on different levels 1-4. Binding of GH to the growth hormone receptor 
(GHR) and recruitment of tyrosine kinases, primarily Jak2, activate multiple signaling 
cascades which mediate a wide range of GH effects such as cellular proliferation, 
differentiation and migration, prevention of apoptosis, cytoskeletal reorganization, and 
regulation of metabolic pathways 5-7. 
Furthermore, GH also controls the physiology and pathophysiology of the liver. Its signals are 
conducted mainly by Stat5a and Stat5b proteins, two members of the family of signal 
transducers and activators of transcription 8-10. Both these transcription factors—just like Stat1 
and Stat3—are closely regulated by GH-GHR-JAK2 interactions. Well-known functions of 
Stat5 in the liver include regulation of genes associated with GH-dependent somatic growth, 
the most important of which is liver-derived insulin-like growth factor 1 (IGF-1), expression 
of sex-specific liver genes including activation of different key regulators of the cytochrome 
P-450 system. In addition, Stat5b has been shown to be involved in mediating metabolic 
effects of GH such as its lipolytic action on adipose tissue 11-13. Inactivation of the Stat5a/b 
locus in the murine liver has been demonstrated to result in GH resistance. 
In humans, GH insensitivity is typically associated with mutations in the gene for the GH 
receptor. Yet, there are also reports of patients with inactivating mutations in the gene that 
encodes Stat5b who present with a complex clinical phenotype of GH insensitivity and 
immune dysfunction 14-18. GH insensitivity and resistance are defined by high levels of 
circulating GH in association with low levels of IGF-1 and GH-binding protein. GH 
insensitivity has been reported in patients with cirrhotic and/or functionally impaired livers 19-
22. Although chronic liver damage, regardless of its etiology, carries an increased risk of 
developing hepatocellular carcinoma (HCC) 23-32, it has as yet not been determined whether 
elevated levels of serum GH contribute to this risk. 
Clinical use of recombinant GH, which was restricted to the treatment of GH-deficient 
children for many years, has been widened to various other clinical conditions 33. Compared 
to cancer mortality in the general population, patients treated with GH have been found to be 
at a significantly higher risk of dying from cancer 33,34. This is in line with an increasing body 
of literature suggesting that patients with acromegaly 35, adults with elevated concentrations 
of circulating IGF-1 36-41, and individuals of tall stature 42 are at increased risk of developing 
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epithelial cancers. Moreover, high serum levels of IGF-1 may contribute to the development 
of HCC in patients suffering from acromegaly or receiving recombinant growth hormone over 
a long period of time 43-46. 
HCC is the most common form of liver cancer and is the third leading cause of cancer death 
worldwide. Chronic hepatitis B and C virus infection associated with liver cirrhosis represent 
the major causes for HCC, being implicated in more than 70% of HCC cases. Among several 
other risk factors, obesity-induced hepatosteatosis and its more severe complication 
nonalcoholic steatohepatitis (NASH), which are classified as non-alcoholic fatty liver disease 
(NAFLD), are increasingly recognized as the most important causes of liver disease second 
only to hepatitis C in the number of patients going on to develop cirrhosis 47-52. Together, 
hepatic inflammation and NAFLD, which can both induce endoplasmic reticulum (ER) stress 
and accumulation of reactive oxygen species (ROS) within liver parenchymal cells and thus 
lead to chronic liver damage, can compound the risk for HCC 53-55. Although the natural 
history and pathologic characteristics of human HCC are well documented, the pathogenesis 
of HCC at the molecular level is still poorly understood. Detailed analyses in experimental 
animals and comparison of the results obtained from patients with HCC, however, have 
identified several genomic and molecular alterations contributing to HCC development 56,57. 
To be able to examine the effects of systemically high levels of GH on hepatocarcinogenesis, 
mice were engineered to express human, rat, and sheep growth hormone, respectively, from a 
transgene, thus mimicking long-term treatment with the cytokine 58-61. Several studies have 
shown that systemic overexpression of GH in transgenic mice induces the development of 
hepatocellular adenomas and carcinomas within 12 months 58,59,61-66. The liver pathology 
reported to precede hepatocarcinogenesis in GH transgenic mice is characterized by a 
sustained increase in both hepatocellular proliferation and apoptosis 64, chronic hepatic 
inflammation 58, proliferation of oval cells, and various degrees of necroinflammatory, 
cirrhotic, fibrotic and regenerative changes 63,67.  
Mice in which the Stat5a/b locus has been inactivated in hepatocytes develop hepatosteatosis, 
which is a hallmark of NAFLD. Moreover, activation of Stat5b in HCC patient samples was 
found to correlate with more aggressive tumors and poorer clinical outcome. This might be 
attributed to increased cell motility and tumor spread due to Stat5b-induced epithelial-
mesenchymal transition (EMT) 68. We, therefore, investigated whether Stat5 is an essential 
factor for the development of HCC in the inflammatory liver cancer model of GH transgenic 
mice. In the present study, transgenic mice overexpressing ovine GH (GHtg) were crossed 
with mice deficient in hepatic Stat5a/b using the hepatocyte- and cholangiocyte-specific 
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AlfpCre recombinase 69. In these compound mice, the roles of Stat5 in postnatal body growth 
and liver tumor formation were studied. Our results indicate that the alterations in liver 
morphology as well as the increased mortality observed in GH transgenic mice are Stat5-
dependent. Surprisingly, deletion of hepatic Stat5 proteins in GH transgenic mice was found 
to lead to enhanced tumor formation and a more aggressive form of HCC.  
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Materials and Methods 
 
Transgenic animals  
All mice were kept under standardized conditions at the Decentralized Biomedical Facilities 
of the Medical University of Vienna (MUW) and all animal experiments were performed 
according to an ethical animal license protocol approved by the MUW and the authorities of 
the Austrian government (BMBWK). The animals were maintained on a 12 h light-dark 
cycle. Mice harboring a hepatocyte-specific deletion of Stat5 were generated by crossing 
animals expressing the Cre recombinase under the control of the albumin promoter and alpha-
fetoprotein enhancer sequences (AlfpCre) 69 with mutants carrying a floxed Stat5a/b allele 
(Stat5AlfpCre) 70. Mice expressing ovine growth hormone under the control of a 
metallothionein promoter (GHtg) had been described earlier 64. Experimental mice were 
generated by intercrossing GHtg mice with Stat5AlfpCre animals. All animals were 
maintained on a mixed C57BL/6 and Sv129 background. Due to sex-related differences in 
predisposition to liver cancer and the influence of Stat5 deletion on differentially regulated 
sexual maturation genes, only male mice were used for analysis. The mice were analyzed for 
the development of liver tumors at the five time points indicated (Fig.2). Growth curves were 
generated from data obtained by weekly weight measurements over a period of 30 weeks after 
which the growth curves had reached a plateau. 
 
Blood sampling and assessment of serum parameters  
To determine the serum concentrations of biochemical parameters, cytokines, and growth 
factors, blood of CO2-euthanized mice was harvested by heart puncture at the indicated time 
points and collected in tubes precoated with EDTA. All blood samples were subsequently 
centrifuged at 5,000 rpm for 5 min at room temperature to remove insoluble cellular blood 
components. The serum (supernatant) was then shock frozen in liquid nitrogen and stored at -
80 °C for later use. The concentrations of important biochemical and metabolic serum 
parameters were determined using the test strip-based Reflotron Plus analyzer (Roche) 
according to the manufacturer’s protocols. Free fatty acid levels were determined 
photometrically at 550nm using the NEFA-HR(2) kit (Wako; ACS-ACOD - method). 
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Immunohistochemistry and transmission electron microscopy 
Immunohistochemistry was performed on sections prepared from paraffin-embedded 
formalin-fixed spleen, liver, and BM specimens using H&E staining.  
The stained sections and cytospins were analyzed by light microscopy. Images were captured 
with a PixeLINK camera and the corresponding acquisition software on a Zeiss Imager Z.1 
(magnification: ×100, ×200 or ×400) at a color temperature of 1300 Kelvin. For electron 
microscopy, mouse livers were cut into 1-2 mm slices and fixed overnight in 1.6 % 
glutaraldehyde. Images were taken at various magnifications (1,500 x – 4,000 x) using a 
standard transmission electron microscope (TEM). 
 
Immunoblotting and enzyme-linked immunosorbent assay (ELISA) 
Sample preparation and Western blotting were performed using standard techniques. Hybond 
nitrocellulose membranes were incubated with antibodies raised against the following 
proteins: pY-Stat5ab (#71-6900, Zymed), Stat5ab (N20, #836,  Santa Cruz), pY-Stat3 (#9131; 
Cell Signaling), Stat3 (H190, #7179 ; Santa Cruz), pY-Stat1 (#9171; Cell Signaling),  Stat1 
(#610115; BD), pY-Jak2 (#3771; Cell Signaling), Jak2 (#3230; Cell Signaling), phospho- 
pErk1/2 (#9106; Cell Signaling), pErk1/2 (#4695; Cell Signaling), pS-Akt (#3787; Cell 
Signaling), Akt1/2/3 (H136, #8312; Santa Cruz), pY-Src (#2113; Cell Signaling), Src (#2109; 
Cell Signaling), HSC70 (#7298, Santa Cruz, loading control). Serum IGF-1 levels were 
determined using a commercially available rat/mouse ELISA kit (novozymes, IDS Ltd).  
 
Quantitative real-time PCR 
RNA was isolated using Trizol reagent (Invitrogen). RNA integrity was checked on a 0.8% 
agarose gel; 0.8-1 µg of RNA was reverse transcribed using the Revert Aid cDNA synthesis 
kit (Fermentas). Real-time PCR was performed on an Eppendorf RealPlex cycler using 
5prime polymerase (Eppendorf) and SYBR Green (Roche Diagnostics). Intron-spanning 
primers were used to control for gene-specific amplification of mRNA transcripts. Expression 
levels are means of three independent measurements relative to the expression of GAPDH. 
Results were quantified using the “Δ C(T) method” (gene-specific expression level relative to 
that of an endogenous housekeeping gene [GAPDH]). Individual ΔCT values for all 
genotypes were calculated and compared to controls.  
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The following primer sequences were used for qPCR analysis: 
 
Pparγ      for: ACC CAA TGG TTG CTG ATT AC 
rev: CGG GAA GGA CTT TAT GTA TGA G 
Pparα     for: ATC GCG TAC GGC AAT GGC TTT A 
rev: GCC TCG GAG GTC CCT GAA CAG 
Cebpα    for: ATG GAG TAC AGC GGT GAG TAT TC 
rev: GTT GCC ACT GGA CAT CTC TTC 
Cebpβ      for: GGT GGA CAA GCT GAG CGA CGA GTA 
rev: AAC AAG TTC CGC AGG GTG CTG AG 
Igf-1     for: GATGCTCTTCAGTTCGTGTGTGG 
rev: TTCAGTGGGGCACAGTACATCTC 
Igf-2     for: GAGTTCAGAGAGGCCAAACG 
rev: CCTGCTCAAGAGGAGGTCAC 
Egfr     for: GCAGTGGAGGCCATGTTTCTTCG 
rev: GCAGGGGCTCCTGCAGCTTCTCC 
Hnf6     for: TCCAGCGCATGTCGGCGCTCCGC 
rev: TTTGTAATTCTTTGGACGGACGC 
Lifr     for: TGTGGGATTGATTATTGCCATCC 
rev: ATGTCTTAAGAGCATTGCTTCCC 
Prlr     for: ATACTGGAGTAGATGGGGCCAGG 
rev: AGAAGTGGGGGGAAAGTCTTGGC 
Tnf-α    for: TAGCCAGGAGGGAGAACAGA 
rev: TTTTCTGGAGGGAGATGTGG 
IL-6     for: TTCCATCCAGTTGCCTTCTTGG 
rev: TTCTCATTTCCACGATTTCCCAG 
 
Statistics 
All values are represented as means ± standard deviation if not indicated otherwise. Real-time 
quantifications and serum parameters were evaluated for significance using the two-tailed 
student test. A p-value below 0.05 was considered significant for all analyses. Differences 
between experimental groups were considered significant at * p < 0.05, ** p < 0.01 or *** p < 
0.005. In cases where the student t test did not show a significant difference, the variances 
were compared by means of an additional F test. Kaplan Meier plots were analyzed for 
significance using the logrank test. All calculations were performed using the GraphPad 
Prism 4 software. 
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Results 
 
Stat5 is essential for postnatal body growth 
Growth hormone (GH) is the major stimulator of somatic growth, cellular proliferation and 
regeneration. Overexpression of GH in mice leads to gigantism (Figs.1A and B), an increase 
in IGF-1 levels (Fig.1C), and reduced peripheral body fat (Table 1). Increased postnatal body 
growth is accompanied by an alteration of body proportions resulting in an acromegaly-like 
phenotype and differential enlargement of internal organs such as the liver (hepatomegaly) 
59,60,71. In order to assess the importance of hepatic Stat5 for postnatal growth, we used mice 
in which the entire Stat5 locus was flanked by loxP sites 69,70. Stat5 proteins were disrupted 
selectively in hepatocytes and cholangiocytes using a Cre-recombinase that is under the 
control of the albumin promoter and the albumin and α-fetoprotein enhancers (AlfpCre; 
Stat5Δhep). These mice were crossed with mice expressing the ovine GH (oGH) from a 
transgene (GHtg) to generate GHtgStat5Δhep mice. Postnatal body growth of GHtg, 
GHtgStat5Δhep, and Stat5Δhep mice was compared to that of wt mice (Fig.1B). Our data confirm 
that systemic GH overexpression leads to a 1.5-2-fold increase in the body weight of male 
mice (increase in body size of at least 40% compared to wt littermates) (Figs.1A and B). 
Contrary, abrogated GH signaling in the liver due to loss of hepatic Stat5 (Figs.1A and B) 
results in a reduction in body size of at least 40% (Fig.1B), which has also been observed 
following deletion of hepatic GR and hepatic Jak2 8. Additionally, metabolic defects manifest 
themselves in hepatosteatosis 9. It is of note that up to 8–9 weeks of age GHtgStat5Δhep mice 
showed growth curves identical to those of wt littermates. Thereafter deletion of Stat5 in GHtg 
mice resulted in growth retardation reducing the body weight to approximately 80% of that in 
wt mice (Fig.1B). Compared to Stat5Δhep mice, GHtgStat5Δhep mice were not significantly 
larger. As expected, GHtg mice displayed high levels of nuclear pY-Stat5, suggesting it is a 
main mediator of GH signaling. We were able to demonstrate that pY-Stat5 is completely 
absent in GHtgStat5Δhep and Stat5Δhep hepatocytes (Fig.1C). This was paralleled by reduced 
levels of IGF-1, a well-known Stat5 target. Both serum and mRNA expression levels were 
found to be significantly elevated in GHtg mice but barely detectable in GHtgStat5Δhep animals 
(Figs.1D and E, respectively). Similarly, IGF-2 expression was found to be significantly 
increased in GHtg mice, while animals lacking hepatic Stat5 showed reduced mRNA levels 
compared to wt littermates. Overall, systemic overexpression of GH with additional deletion 
of hepatic Stat5 demonstrated that Stat5 is essential for GH-stimulated body growth. 
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Reduced life-expectancy in GHtg mice is reversed by deletion of Stat5 
High serum levels of ovine GH also manifest themselves in reduced life expectancy (Fig.2A). 
This observation is in line with previous reports demonstrating progressive glomerulosclerosis 
associated with histopathological changes in the liver, heart, and other internal organs in GHtg 
mice 66,72. GH transgenic mice have been reported to have impaired cardiac function, 
hypertension 73, defective immune function 74, reduced reproductive potential 71, and 
functional alterations of the central nervous system. Strikingly, GHtgStat5Δhep animals had a 
life expectancy comparable to that of wt and Stat5Δhep littermates, which might be linked to 
their reduced levels of circulating IGF-1. Based on the survival curve (Fig.2A), five different 
time points were chosen for further analysis (Fig.2B). 
 
Dramatic increase in liver/body weight ratio in GHtgStat5Δhep mice due to increased fat 
deposition and higher tumor burden 
Compared to wt littermates, all mice expressing the GH transgene were found to display 
increased liver to body weight ratios (hepatomegaly) at all time points analyzed. However, the 
liver weights in GHtg mice never exceeded 12% of their body weights, whereas in 
GHtgStat5Δhep mice ratios up to 25% were observed at 28 and 40 weeks of age (Fig.3A). 
Compared to GHtg animals, their increase in liver/body weight ratio was significant at 28 and 
40 weeks but differences in ratio were detectable at the age of 12 weeks already (Fig.3A). 
Macroscopically, the dramatic increase in liver weight seen in GHtgStat5Δhep mice can be 
explained by increased fat deposition in the liver starting at a very early age (Fig.4B). Due to 
hepatosteatosis, the liver/body weight ratios in Stat5Δhep mice were also elevated compared to 
wt littermates. Yet, the ratios remained in the same range as those of GHtg controls over the 
whole period of analysis. High GH levels resulting from transgene expression and the deletion 
of hepatic Stat5 in GHtgStat5Δhep animals, however, led to massive lysis of peripheral fat and 
to the release of free fatty acids (FFA), which were deposited in the liver to a greater extent 
than in Stat5Δhep mice. This process, which was observed at a very young age already, was 
found to impair the metabolic competence of the liver and cause chronic damage to the 
hepatocytes as evident from elevated liver damage parameters (Fig.3C). Moreover, 
GHtgStat5Δhep mice showed a higher tumor burden at 28 and 40 weeks of age compared to 
GHtg animals (Fig.4B). 
The histologic findings were confirmed by the GOT (glutamate-oxalacetate-transaminase; 
also termed AST, aspartate-aminotransferase) and GPT (glutamate-pyruvate-transaminase; 
also termed ALT, alanine-aminotransferase) levels assessed at 4, 12, 28 and 40 weeks of age, 
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which demonstrated increased liver damage in GHtg and above all in GHtgStat5Δhep mice 
(Fig.3C). Stat5Δhep mice showed elevated GOT and GPT levels at 28 and 40 weeks, as lipids 
accumulated in the liver. In addition, serum triglyceride and cholesterol levels were found to 
be elevated in GHtgStat5Δhep mice, while their glucose levels were reduced at 4 weeks and 
slightly increased at 12 weeks of age (Fig.3D). 
 
Pathologic changes in GHtg hepatocytes are reversed by the deletion of Stat5 
To gain more insight into the cellular mechanisms contributing to increased hepatoycte 
damage and earlier tumor formation in GHtgStat5Δhep mice, the livers of all genotypes were 
subjected to thorough histopathologic analysis at all time points. In hepatocytes, high long-
term expression of GH resulted in strongly increased rates of hepatocellular apoptosis 
(Fig.4C), which, in turn, led to enhanced regenerative proliferation (Fig. 4C) and attracted 
immune cells to the sites of insult (Fig. 4C upper panel + Suppl.Fig.1A). These processes, 
which were observed to begin in GHtg mice in the first weeks after birth already, precede the 
onset of hepatic inflammation (Table 1), a key feature of liver pathology in these animals 58. 
In terms of morphology, hepatocytes of GHtg mice differed from those of wt animals in that 
they were abnormally large and had larger nuclei of polymorphic shape (Suppl.Figs.1A and 
2A). Additionally, irregular intranuclear inclusions and an increased number of mitochondria 
were detected in GHtg hepatocytes (Suppl.Fig.2A). Moreover, corticosterone levels in GH 
transgenic mice were markedly elevated, with the increase becoming more pronounced with 
age (Suppl.Fig.1B). At the same time, expression of the pro-inflammatory cytokines IL-6, 
tumor necrosis factor alpha (TNF-α) (Suppl.Fig.1C and D) and IL-1β (data not shown) was 
significantly increased only in GHtg mice, as was to be expected from their inflammatory 
phenotype. 
Oxidative phosphorylation is a key element of energy transduction and respiratory control 
(RC) in the electron transport system of mitochondria. Respiratory steady states 1-4 and 
respiratory control ratios have been defined to investigate mitochondrial respiratory control 75. 
Conventionally, ADP stimulation is expressed by the respiratory control ratio which is 
frequently used as an index of coupling for diagnosis of mitochondrial defects. Assessment of 
mitochondrial function by means of respiratory control ratios (= respiratory state 2/state 3 and 
respiratory state 3/state 4, respectively) revealed that these ratios were diminished in GHtg 
mice at 40 weeks of age, while Stat5Δhep mice displayed significantly increased values 
(Suppl.Fig.2B). 
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Upon deletion of Stat5 in GHtg mice, the increase in hepatocyte size, turnover, and sinusoidal 
cellularity, the irregular nuclear morphology as well as the corticosteroid and RC values were 
reversed and reached levels comparable to those of wt controls (Fig.4C and Suppl.Fig1A and 
2A). Unlike GHtg mice, which had a reduced life span, GHtgStat5Δhep mice showed a life 
expectancy comparable to that of wt and Stat5Δhep animals (Fig.2A). 
 
Loss of hepatic Stat5 promotes the development of HCC in GHtg mice 
Although the characteristic alterations seen in GHtg mice were reversed by the deletion of 
hepatic Stat5, earlier formation of more aggressive tumors was observed in GHtgStat5Δhep 
mice. GHtg mice first developed adenomas at 40 weeks and carcinomas at 52 weeks of age 
(Fig.4B). Contrary, GHtgStat5Δhep mice displayed dysplastic nodules (DN) and adenomas at 
28 weeks already. At this time point, their tumor sizes (large nodules > 9 mm in diameter; 
Fig.4A right panel) already exceeded those seen in GHtg mice at all time points analyzed 
(nodules of 1-2 mm in diameter, data not shown). At 40 weeks of age, all GHtgStat5Δhep mice 
had large steatotic tumors, which were classified as full-blown HCC by hepatopathologists. 
By comparison, the development of HCC in GHtg mice lagged behind that of GHtgStat5Δhep 
animals by about 12 weeks. It was only after the 40th week of age that HCC was found in 90% 
of the GHtg mice studied.  
 
Loss of hepatic Stat5 is associated with increased lipid synthesis in the liver 
To better understand the mechanisms responsible for the aggravated phenotype seen in 
GHtgStat5Δhep mice, we investigated the extensive steatosis seen in these mice at 4 weeks of 
age already. Hepatosteatosis is known to be caused by an imbalance of either fatty acid 
synthesis and oxidation or of lipid catabolism and transport out of hepatocytes. Real-time 
PCR analysis of the liver was performed to determine which of these mechanisms contributes 
to steatosis in GHtg mice lacking hepatic Stat5. Our results demonstrate that the expression of 
the lipogenic master regulators PPARγ (Fig.5A) and SREBP-1c (data not shown) was induced 
in GHtgStat5Δhep mice, which suggests that the fatty liver phenotype is likely to be caused by 
the induction of de novo lipid synthesis in the liver. Increased expression of these two genes 
was also observed in Stat5Δhep mice, which implies a role of Stat5 in the regulation of SREBP-
1c and PPARγ (Kornfeld/Mueller, unpublished data). 
 
GHtgStat5Δhep mice show decreased expression of hepatoprotective factors  
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Loss of Stat5 in mouse livers has been found to lead to a significant down-regulation of a 
group of genes that have been described to protect the liver from injury 76. Reduced 
expression of these hepatoprotective factors creates an environment for cells which facilitates 
damage-induced hepatocarcinogenesis. Potentially harmful events such as the accumulation 
of lipids within hepatocytes, are then more likely to result in mutations. Indeed, the mRNA 
levels of Egfr, Prlr, Hnf6, and Lifr, which are all considered to have a hepatoprotective 
function, were decreased to barely detectable levels in mice lacking Stat5 independent of GH 
overexpression (Fig.5B). Conversely, expression of all four genes was significantly increased 
in the livers of GHtg mice. 
 
Increased compensatory activation of Stat3 in the livers of GHtgStat5Δhep mice 
Using Western blot analysis, alternative pathways that can be activated by GH were 
investigated in 40-week-old mice to identify additional molecular mechanisms responsible for 
the development of HCC in GHtgStat5Δhep mice (Fig.5C). Apart from GH-induced pY-Jak2-
pY-Stat5, a number of signaling proteins and pathways are known to regulate the transcription 
of GH-responsive genes. In the absence of Stat5 proteins, these include in particular pY-Stat1 
and pY-Stat3 87, activation of Src kinase, mitogen-activated protein kinase (MAPK) pathway, 
which has a role in cellular growth and differentiation, and of the PI3K-Akt-mTOR pathway, 
which mediates survival and growth signals for the cells. Analysis of Src kinase revealed an 
upregulation of total Src protein in all animals expressing the GH transgene. However, pY-
Src was not increased in GHtgStat5Δhep mice as compared to wt mice, and was not detectable 
in GHtg mice.  
Enhanced AKT and ERK activation caused by high concentrations of circulating insulin and 
IGF-1 in overweight and obese individuals has been suggested to promote tumor formation 48. 
However, we found Akt1/2/3 levels to be only slightly increased in all mice expressing the 
GH transgene. Moreover, higher total ERK1/2 and phosphorylated ERK1/2 levels were 
detected exclusively in GHtg mice. These findings suggest that AKT and ERK activation is not 
the major cause for enhanced HCC development in GHtgStat5Δhep mice. 
As reported in earlier Stat5 deletion studies70,87, Stat1 protein levels were found to be 
significantly upregulated in GHtgStat5Δhep mice, while pY-Stat1 remained unchanged 
(Fig.5D). Moreover, pY-Jak2 levels were slightly downregulated in GHtgStat5Δhep and 
Stat5Δhep mice at 40 weeks of age, while the Jak2 protein levels were unaffected. Strikingly, 
loss of Stat5 in GH-transgenic mice resulted in enhanced GH-induced Stat3 activity (Fig.5D), 
which was not seen in any other genotype. Stat3 has been shown to stimulate proliferation and 
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progression of aberrant hepatocytes 77 and could thus be a potential molecular mediator 
contributing to tumor formation and progression in GHtgStat5Δhep animals as it has been 
suggested by others 87. Real-time PCR analysis was performed to investigate whether IL-6, a 
major Stat3 activator in the liver, is elevated in GHtgStat5Δhep mice. However, mRNA levels of 
IL-6 were elevated only in GHtg but significantly downregulated in GHtgStat5Δhep mice. We, 
therefore, concluded that IL-6 is not the cytokine activating Stat3 in these livers. As GH—in 
the absence of Stat5 proteins—is also a potent activator of Stat3, GH overexpression might be 
sufficient to cause aberrant Stat3 activation in GHtgStat5Δhep mice. 
 
 
Discussion 
Hepatocarcinogenesis in humans is known to be a multistep process which requires more than 
a decade to evolve from hepatic inflammation and cirrhosis to dysplastic nodules and HCC. It 
is the accumulation of different genetic alterations induced by chronic inflammation and 
oxidative DNA damage that finally leads to malignant transformation of hepatocytes. Single 
transformed cells constitute preneoplastic lesions, which may progress to HCC as a result of 
clonal selection of genetically altered cells. Transformation and the pathologic changes in the 
liver preceding the development of HCC in GH-transgenic mice are characterized by 
increased hepatocyte turnover, which manifests itself in increased apoptosis and 
compensatory mitotic activity 78-80 and eventually results in chronic inflammation. These 
pathologic mechanisms can also be observed in GHtg mice, which developed tumors at 52-60 
weeks of age that closely resembled human hepatocellular carcinomas histologically. 
Mice in which the Stat5a/b locus has been inactivated in hepatic epithelial cells display 
depleted bioactive IGF-1 factors, which results in dwarfism. Due to the lack of a negative 
feedback via IGF-1, this leads to reduced body growth and high endogenous GH levels (GH 
resistance). In patients, liver cirrhosis and hepatic dysfunction have been shown to be 
associated with severe impairment of the GH-IGF-1-insulin receptor axis resulting in low 
IGF-1 levels and reduced response to exogenous GH, which is clinically defined as acquired 
GH resistance 81. 
In the present study, wt, GHtg, GHtgStat5Δhep, and Stat5Δhep mice were analyzed for postnatal 
body growth and liver phenotypes. Our data suggest an essential role of hepatic Stat5 in the 
regulation of postnatal body growth. Moreover, histopathologic analysis of the liver showed 
that the increase in the size of hepatocytes and the number of mitochondria as well as the 
decrease in mitochondrial function observed in GHtg mice are dependent on Stat5.  
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However, HCC development in mice was found to be induced by overexpression of GH 
independent of Stat5. Compared to GHtg controls, GHtgStat5Δhep mice displayed even more 
progressed lesions. Most strikingly, they developed HCC four months earlier than GHtg 
controls, even though the Stat5 deficiency corrected the hepatocellular nuclear polymorphism, 
normalized the hepatocyte turnover, reduced the sinusoidal cellularity (i.e. inflammation), and 
reduced life expectancy. Therefore, it is most likely the massive fat deposition within 
hepatocytes which is the main pathogenic factor responsible for the development of HCC in 
GHtgStat5Δhep mice. 
Over the past few years, there has been increasing evidence that obesity, which is associated 
with hepatosteatosis and elevated liver enzymes, may predispose to liver disease and promote 
its progression 52. Moreover, patients with cirrhotic and/or functionally impaired livers have 
been shown to acquire GH insensitivity and resistance 19-22, a condition also observed in the 
GHtgStat5Δhep mouse model. In GHtgStat5Δhep mice, high GH levels resulting from both 
transgene expression and deletion of hepatic Stat5 therefore led to massive lipodystrophy and 
to the release of free fatty acids, which were deposited in the liver. In addition, Stat5 
deficiency resulted in uncontrolled lipid synthesis in the liver and an impaired glucose and 
insulin tolerance (Kornfeld/Mueller, unpublished data). It can be assumed that these complex 
mechanisms are chiefly responsible for the steatotic phenotype observed in GHtgStat5Δhep 
mice, which over time increasingly compromises the metabolic competence of the liver, 
chronically damages hepatocytes, and eventually induces hepatocarcinogenesis. Surprisingly, 
it was the hepatic GH-Stat5b axis which caused complex disease phenotypes and mortality in 
GHtg mice. Enhanced synthesis of growth factors such as IGF-1 and IGF-2 might contribute 
to this premature mortality in GHtg mice. 
Studies evaluating different signaling molecules implicated in HCC progression have revealed 
that AKT and ERK are frequently activated in both humans and mouse models 48. Both 
proteins, however, were not significantly activated and are therefore unlikely to be the 
molecular cause for enhanced HCC development in GHtgStat5Δhep mice. A more relevant 
player whose role needs to be investigated in future studies might be mTOR and survival 
proteins, which are influenced by Stat5 activation and contribute to cell and tumor growth 82.  
Increased activity of Stat3 has been reported in human HCC and mouse models as well, 
particularly in progressed HCC 56,77. Furthermore, expression of the pro-inflammatory 
cytokines TNF-alpha, IL-1beta, and IL-6—a potent activator of hepatic Stat3—was found to 
be elevated in patients with chronic liver disease, cirrhosis, and HCC 83-85. These cytokines 
were shown to play an important role in the pathogenesis of GH resistance in chronic liver 
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disease 86. There is an increasing body of evidence that, in the absence of Stat5, GH is able to 
cause aberrant activation of Stat1 and Stat3 and their downstream target genes 87. Indeed, loss 
of Stat5 resulted in enhanced GH-induced compensatory Stat3 activity in GHtgStat5Δhep mice. 
Rerouting of GH signaling may activate different downstream molecules, which also 
contributes to the physiologic alterations in Stat5-deficient GHtg mice. Moreover, Stat3 has 
been shown to stimulate proliferation and progression of aberrant hepatocytes 77 and thus 
could be a molecular mediator contributing to tumor induction and progression in 
GHtgStat5Δhep animals. This is in line with recent findings of Park and co-workers who have 
suggested that the elevated levels of circulating IL-6 and activated Stat3 increase the cancer 
risk in obese patients 83.  
In addition to the above-mentioned mechanisms, loss of the hepatoprotective factors EGFR, 
PRLR, LIFR, and HNF6 in Stat5-deficient animals promotes chronic hepatocyte damage 
secondary to lipid accumulation in the liver. At the same time, oncogenic signals from 
activated Stat3 stimulate proliferation and progression of damaged hepatocytes, which 
accelerates the development of steatotic HCC. 
Nevertheless, increased lipid synthesis, lipodystrophy, deregulated expression of 
hepatoprotective factors, and elevated Stat3 activation are unlikely to cause HCC independent 
of each other. It is most probably a combination of the above-mentioned mechanisms that 
increases the risk of neoplastic transformation and progression to HCC. Our data suggest that 
the HCC development observed in GHtg mice in the absence of Stat5 is due to two distinct 
molecular processes. Firstly, loss of hepatic Stat5 results in deregulation of the Stat5 target 
genes involved in growth regulation, protection of hepatocyte integrity, and lipid metabolism 
where Srebp1 is normally repressed by Stat5. Secondly, rerouting of GH signaling to other 
Stat proteins, which may partially compensate for the loss of Stat5, must activate signaling 
cascades that are distinct from Stat5a and Stat5b.  
The present study suggests that it is intrahepatic lipid accumulation with concomitant loss of 
protective factors and growth-stimulating signals rather than obesity that increases the risk of 
developing HCC. In addition, we were able to demonstrate that the loss of Stat5 function in 
the liver plays a key role in this process. These findings may have major clinical implications 
as more than 100,000 patients worldwide are estimated to have received growth-hormone 
therapy. Our data suggest that the risks and benefits of GH therapy should be reassessed in 
light of the prevalence of metabolic disorders in the Western world, particularly long-term 
treatment and the more controversial indications such as the use of GH as an “anti-aging” 
regimen. 
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Figure 1. Stat5 is essential for postnatal body growth. 
(A) Mice deficient for hepatic Stat5 were crossed with GHtg mice to generate GHtgStat5Δhep mice. 
Brown fur color was found to invariably correspond to the expression of the oGH transgene in the 
C57BL/6/Sv129 background.  All GHtg mice were larger than wt mice, while animals lacking hepatic 
Stat5 displayed reduced body size in the C57BL/6/Sv129 as well as the GHtg background. (B) 
Postnatal body growth of GHtg, GHtgStat5Δhep, and Stat5Δhep mice was compared to that of wt mice. In 
male mice, GH overexpression was associated with a 1.5-2 fold increase in body weight (increase in 
body size of at least 40% over that of wt littermates). GHtgStat5Δhep mice showed growth curves 
identical to those of wt littermates up to 8–9 weeks of age. Thereafter deletion of Stat5 in GHtg mice 
resulted in growth retardation reducing the body weight to approximately 80% of that in wt mice. 
Compared to Stat5Δhep mice, GHtgStat5Δhep mice were not significantly larger (n≥12). (C) H&E (upper 
panel) and pY-Stat5 (lower panel) staining of livers obtained from 28-week-old mice. (D) Assessment 
by ELISA revealed that overexpression of GH leads to an increase in IGF-1 levels in male mice (n≥6). 
In C57BL/6/Sv129 and GHtg mice, deletion of Stat5 resulted in reduced IGF-1 serum levels, which 
were barely detectable. (E) Similarly, reduced IGF-1 mRNA expression levels were found in 
GHtgStat5Δhep and Stat5Δhep mice at 40 weeks of age (n≥3). (F) On real-time PCR analysis, IGF-2 
expression was also significantly increased in GHtg mice, while mice lacking hepatic Stat5 showed 
reduced mRNA levels compared to wt littermates (n≥3). The data represent means of triplicate assays. 
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Figure 2. High serum levels of ovine GH reduce life expectancy. 
(A) Kaplan-Meier plot of all four genotypes over a period of 65 weeks. GHtgStat5Δhep mice were 
studied until 40 weeks of age, when all mice were used for histopathologic analysis. GH transgenic 
mice were found to have a reduced life span. By contrast, GHtgStat5Δhep animals had a life expectancy 
comparable to that of wt and Stat5Δhep littermates. (B) Based on the Kaplan Meier plot in (A), the 
following time points were chosen for further analysis: the first at 4 weeks, the second at 12 weeks 
when the hepatic inflammation in GHtg mice was already detectable, the third at 28 weeks when the 
GHtg mice started to die, and the fourth time point at 40 weeks of age, when first macroscopic tumors 
could be detected in GHtg mice. For the analysis of more progressed tumor stages in GHtg mice, 
animals that survived longer than 7-10 months were analyzed at the ages of 52-60 weeks and 
compared to wt littermates.  
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Figure 3. Dramatic increase in liver/body weight ratio of GHtgStat5Δhep mice due to increased fat 
deposition and higher tumor burden. 
(A) Compared to wt mice, all animals expressing the GH transgene displayed increased liver to body 
weight ratios at all time points analyzed (p<0.005). Compared to GHtg controls, there is a significant 
increase (p<0.0001) in liver/body weight ratio of GHtgStat5Δhep mice at 28 and 40 weeks (n≥8). (B) 
Free fatty acid (FFA) levels in the serum were determined using an enzymatic test. Levels were 
elevated in mice lacking Stat5at all time points analyzed (n≥4).  (C) Analysis of the transaminases 
GOT and GPT at 28 and 40 weeks of age indicated increased liver damage in GHtg and GHtgStat5Δhep 
mice. (D) In GHtgStat5Δhep mice, serum triglycerides and cholesterol were elevated, while glucose 
levels were decreased at 4 weeks and slightly increased at 12 weeks of age (n > 4).  
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Figure 4. Loss of hepatic Stat5 promotes HCC progression in GHtg mice. 
(A) Macroscopic appearance of representative livers of wt, GHtg, Stat5Δhep, and GHtgStat5Δhep mice at 
28 weeks of age. On H&E staining, GHtgStat5Δhep mice displayed large steatotic nodules (> 9 mm in 
diameter, right panel). (B) On histopathologic analysis, liver morphology of GHtg mice revealed 
increased sinusoidal cellularity and large dysplastic hepatocytes with large polymorphic nuclei. The 
latter was observed at 4 weeks of age already. At 40 weeks of age, GHtg mice first developed 
adenomas. By contrast, in GHtgStat5Δhep livers were comparable to those of wt mice in terms of cell 
size, inflammation, and nuclear shape. However, GHtgStat5Δhep mice showed massive lipid 
accumulation in the liver at 4 weeks of age already and first developed adenomas at 28, while 
carcinomas were detected at 40 weeks of age. (C) GHtg mice showed increased hepatocellular 
apoptosis and mitosis at the age of 12 weeks (upper panel; H&E, 200x, 400x, and 100x 
magnification). Mice overexpressing oGH did not develop carcinomas before 52 weeks of age (lower 
panel; three tumors in three different mice, 100x and 200x magnification, respectively). (D)  H&E 
staining of GHtgStat5Δhep livers revealed dysplastic nodules (DN) and adenomas at 28 weeks already. 
At 40 weeks of age, all GHtgStat5Δhep mice displayed large steatotic hepatocellular carcinomas.  
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Figure 5. Loss of hepatic Stat5 in GHtg mice is associated with increased lipid synthesis, 
decreased expression of hepatoprotective factors, and increased hepatic pY-Stat3. 
(A) Quantitative real-time PCR analysis of key lipogenic genes in the livers of 40-week-old animals. 
Compared to wt livers, mRNA expression of PPARγ was significantly increased in Stat5Δhep livers and 
to an even greater extent in GHtgStat5Δhep mice (n≥3).  PPARα, CEBPα, and CEBPβ were also found 
to be deregulated. All assays were performed in triplicate. (B) Loss of Stat5 in mouse livers results in a 
significant downregulation of the expression of the hepatoprotective factors Egfr, Prlr, Hnf6, and Lifr. 
On real-time PCR, the mRNA levels of all four factors were decreased to a barely detectable level in 
Stat5-deficient livers independent of GH overexpression. Conversely, expression of all four genes was 
significantly increased in the livers of GHtg mice (n≥3). The data represent means of triplicate assays. 
(C+D) Western blot analysis of the livers of 40-week-old animals most strikingly revealed a 
significant upregulation of pY-Stat3 in GHtgStat5Δhep mice. The results are representative of three 
independent experiments. 
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Table 1. Overview of phenotypical characteristics.  
Wt, GHtg, GHtgStat5Δhep as well as Stat5Δhep mice were analyzed for postnatal body growth and liver 
phenotypes. In GHtg mice, peripheral body fat was reduced, the liver was enlarged, and postnatal body 
growth was increased. Additionally, hepatocyte turnover was increased, which manifested itself in 
increased mitotic activity and apoptosis resulting in chronic inflammation. This in turn induced the 
development of tumors at 60 weeks of age, which histologically resembled human HCC. By contrast, 
loss of hepatic Stat5 which abrogates GH signaling in the liver resulted in a reduction in body size by 
at least 40% and additionally gave rise to metabolic defects (steatosis). Most strikingly, GHtgStat5Δhep 
mice developed HCC four months earlier than GHtg controls, although Stat5 deficiency reversed the 
nuclear polymorphism, normalized hepatocyte turnover, and reduced hepatic inflammation. 
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Supplementary Figure 1. Liver phenotypes resulting from GH overexpression.  
(A) When analyzed at 28 weeks, GHtg livers were characterized by increased cell size, nuclear 
polymorphism, and increased sinusoidal cellularity. Though it corrected the sinusoidal cellularity, 
hepatocellular polymorphism and increase in cell size, Stat5 deficiency led to extensive accumulation 
of fat. (B) In GH transgenic mice, corticosteroid levels were significantly increased, which became 
even more pronounced with age. Additional deletion of Stat5 brings the corticosteroids down to wt 
levels. (C) Expression of the pro-inflammatory cytokine TNF-α was assessed by means of real-time 
PCR. As was to be expected in an inflammatory phenotype, mRNA levels were significantly increased 
in GHtg mice, while all Stat5-deficient animals exhibited a slight increase only (n≥3). All assays were 
performed in triplicate. (D) IL-6 mRNA levels were analyzed by real-time PCR. Expression levels 
were elevated in GHtg but significantly downregulated in GHtgStat5Δhep mice (n≥3). All assays were 
performed in triplicate. 
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Supplementary Figure 2. Pathologic changes in GHtg hepatocytes are reversed by the deletion of 
Stat5.  
(A) On transmission electron microscopy (4000x magnification) of 28 week-old GHtg mice had 
abnormally large hepatocytes with an increased number of mitochondria (M) and large nuclei (N) with 
irregular contours (4000x magnification). In addition, irregular intranuclear inclusions were detected 
in. Upon deletion of Stat5 in GHtg mice, hepatocytes were found to have normally shaped nuclei but 
marked accumulation of lipid droplets (L) and glycogen (G). (B) Assessment of mitochondrial 
function by means of respiratory control ratios (RC1 = respiratory state 2/state 3 and RC2 =respiratory 
state 3/state 4) revealed that the ratios were diminished in GHtg mice at 40 weeks of age, while 
Stat5Δhep mice displayed significantly increased values. Upon deletion of Stat5 in GHtg mice, the RC 
values seen were corrected to be in the range of wt controls (n=4 per genotype).  
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Supplementary Figure 3. Schematic diagram modeling the development of phenotypes resulting 
from Stat5 deletion in GHtg mice. 
Loss of Stat5 in the liver results in depletion of the IGF-1 target gene, which—due to the lack of a 
negative feedback mechanism—leads to reduced body growth and high endogenous GH levels. 
Consequently, high GH levels due to transgene expression and the deletion of hepatic Stat5 cause 
extensive lysis of peripheral fat depots and release of free fatty acids, which are subsequently 
deposited in lipid droplets within hepatocytes. The lipids lead to impairment of their metabolic 
competence and thus chronically damage hepatocytes. Additionally, increased lipogenesis, 
compensatory Stat3 activation, and the loss of hepatoprotective factors (EGFR, PRLR, LIFR; HNF6) 
are responsible for severe tissue damage and the development of steatotic HCC. 
Moreover, the  
Systemically, the hepatic GH-Stat5b axis is responsible for the disease phenotype and high mortality 
seen in mice displaying hyperactivated GH signaling. This is most likely due to a systemic 
inflammatory reaction and increased growth of all cells mediated by IGF-1/insulin receptor signaling. 
Loss of hepatic Stat5 in GHtg animals precludes chronic inflammation. At the same time, depletion of 
serum IGF-1 in Stat5-deficient GHtg mice prevents histopathologic changes of internal organs, so that 
their life expectancy is comparable to that of wt and Stat5Δhep animals. 
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3.2 Review Article 
The different functions of Stat5 and chromatin alteration through Stat5 proteins 
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